BROAD-SPECTRUM DELTA-ENDOTOXINS

Abstract: Disclosed are novel synthetically-modified B. thuringiensis chimeric crystal proteins having improved insecticidal activity against coleopteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments encoding these novel peptides. Methods of making and using these genes and proteins are disclosed as well as methods for the recombinant expression, and transformation of suitable host cells. Transformed host cells and transgenic plants expressing the modified endotoxin are also aspects of the invention.

Description: DESCRIPTION BROAD-SPECTRUM DELTA-ENDOTOXINS 1.0 BACKGROUND OF THE INVENTION The present application is a continuation-in-part of U. S. Patent Application Serial Number 08/922,505, filed September 3, 1997, which is a continuation-in-part of U. S. Patent Application Serial Number 08/754,490, filed November 20, 1996, the entire contents of which are specifically incorporated herein by reference. 1.1 FIELD OF THE INVENTION The present invention provides new genes encoding Bacillus thuringiensis crystal proteins toxic to coleopteran, dipteran, and lepidopteran insects. Also provided are protein compositions comprising chimeric crystal proteins have enhanced insecticidal activity and increased insecticidal specificity. 1.2 DESCRIPTION OF RELATED ART 1.2.1 B. THURINGIENSIS CRYSTAL PROTEINS The Gram-positive soil bacterium B. thuringiensis is well known for its production of proteinaceous parasporal crystals, or δ-endotoxins, that are toxic to a variety of lepidopteran, coleopteran, and dipteran larvae. B. thuringiensis produces crystal proteins during sporulation which are specifically toxic to certain species of insects. Many different strains of B. thuringiensis have been shown to produce insecticidal crystal proteins, and compositions comprising B. thuringiensis strains which produce proteins having insecticidal activity have been used commercially as environmentally-acceptable insecticides because of their toxicity to the specific target insect, and non-toxicity to plants and other non-targeted organisms. Commercial formulations of naturally occurring B. thuringiensis isolates have long been used for the biological control of agricultural insect pests. In commercial production, the spores and crystals obtained from the fermentation process are concentrated and formulated for foliar application according to conventional agricultural practices. 1.2.2 NOMENCLATURE OF CRYSTAL PROTEINS A review by Hδfte et al, (1989) describes the general state of the art with respect to the majority of insecticidal B. thuringiensis strains that have been identified which are active against insects of the Order Lepidoptera, i.e., caterpillar insects. This treatise also describes B. thuringiensis strains having insecticidal activity against insects of the Orders Diptera (i. e. flies and mosquitoes) and Coleoptera (i.e. beetles). A number of genes encoding crystal proteins have been cloned from several strains of B. thuringiensis. Hδfte et al. (1989) discusses the genes and proteins that were identified in B. thuringiensis prior to 1990, and sets forth the nomenclature and classification scheme which has traditionally been applied to B. thuringiensis genes and proteins, cryl genes encode lepidopteran-toxic Cryl proteins, cryl genes encode Cry2 proteins that are toxic to both lepidopterans and dipterans. cry3 genes encode coleopteran-toxic Cry3 proteins, while cry4 genes encode dipteran-toxic Cry4 proteins, etc. Recently a new nomenclature has been proposed which systematically classifies the Cry proteins based upon amino acid sequence homology rather than upon insect target specificities. This classification scheme is summarized in Table 1. TABLE 1 REVISED B. THURINGIENSIS 6-ENDOTOXIN NOMENCLATURE A New Old GenBank Accession # CrylAa CryΙA(a) M11250 CrylAb CryΙA(b) M13898 Cryl Ac CryΙA(c) Ml 1068 Cryl Ad CryΙA(d) M73250 CrylAe CryΙA(e) M65252 CrylBa CrylB X06711 CrylBb ET5 L32020 Cryl Be PEG5 Z46442 CrylBd Cry El U70726 CrylCa CrylC X07518 CrylCb CryΙC(b) M97880 New Old GenBank Accession # Cryl Da CrylD X54160 CrylDb PrtB Z2251 1 CrylEa CrylE X53985 CrylEb CryΙE(b) M73253 Cryl Fa CrylF M63897 CrylFb PrtD Z22512 CrylGa PrtA Z22510 Cry 1Gb CryH2 U70725 Cryl Ha PrtC Z22513 CrylHb U35780 Cryl la CryV X62821 Cry lib CryV U07642 CrylJa ET4 L32019 CrylJb ET1 U31527 CrylK U28801 Cry2Aa CryllA M31738 Cry2Ab CryllB M23724 Cry2Ac CryllC X57252 Cry3A CrylllA M22472 Cry3Ba CrylllB X17123 Cry3Bb CryIIIB2 M89794 Cry3C CrylllD X59797 Cry4A CrylVA Y00423 Cry4B CrylVB X07423 Cry5Aa CryVA(a) L07025 Cry5Ab CryVA(b) L07026 Cry5B U19725 Cry6A Cry VIA L07022 Cry6B CryVIB L07024 Cry7Aa CrylllC M64478 New Old GenBank Accession # Cry7Ab CrylllCb U04367 Cry8A CrylllE U04364 Cry8B CrylllG U04365 Cry8C CrylllF U04366 Cry9A CrylG X58120 Cry9B CrylX X75019 Cry9C CrylH Z37527 Cryl 0 A CrylVC M12662 Cryl lA CrylVD M31737 Cryl lB Jeg80 X86902 Cryl2A CryVB L07027 Cryl3A CryVC L07023 Cryl4A CryVD U13955 Cryl5A 34kDa M76442 Cryl6A cbm71 X94146 Cryl7A cbm71 X99478 Cryl8A CryBPl X99049 Cryl9A Jeg65 Y08920 CytlAa CytA X03182 CytlAb CytM X98793 CytlB U37196 Cyt2A CytB Z14147 Cyt2B CytB U52043 a Adapted from: http://epunix.biols.susx.ac.uk/Home/Neil_Crickmore/Bt index.html 1.2.3 MODE OF CRYSTAL PROTEIN TOXICITY All δ-endotoxin crystals are toxic to insect larvae by ingestion. Solubilization of the crystal in the midgut ofthe insect releases the protoxin form of the δ-endotoxin which, in most instances, is subsequently processed to an active toxin by midgut protease. The activated toxins recognize and bind to the brush-border of the insect midgut epithelium through receptor proteins. Several putative crystal protein receptors have been isolated from certain insect larvae (Knight et al, 1995; Gill et al, 1995; Masson et al, 1995). The binding of active toxins is followed by intercalation and aggregation of toxin molecules to form pores within the midgut epithelium. This process leads to osmotic imbalance, swelling, lysis of the cells lining the midgut epithelium, and eventual larvae mortality. 1.2.4 MOLECULAR BIOLOGY OF 6-ENDOTOXINS With the advent of molecular genetic techniques, various δ-endotoxin genes have been isolated and their DNA sequences determined. These genes have been used to construct certain genetically engineered B. thuringiensis products that have been approved for commercial use. Recent developments have seen new δ-endotoxin delivery systems developed, including plants that contain and express genetically engineered δ-endotoxin genes. The cloning and sequencing of a number of δ-endotoxin genes from a variety of Bacillus thuringiensis strains have been described and are summarized by Hδfte and Whiteley, 1989. Plasmid shuttle vectors designed for the cloning and expression of δ-endotoxin genes in E. coli or B. thuringiensis are described by Gawron-Burke and Baum (1991). U. S. Patent No. 5,441,884 discloses a site-specific recombination system for constructing recombinant B. thuringiensis strains containing δ-endotoxin genes that are free of DNA not native to B. thuringiensis. The Cryl family of crystal proteins, which are primarily active against lepidopteran pests, are the best studied class of δ-endotoxins. The pro-toxin form of Cryl δ-endotoxins consist of two approximately equal sized segments. The carboxyl-half, or pro-toxin segment, is not toxic and is thought to be important for crystal formation (Arvidson et al, 1989). The amino-half of the protoxin comprises the active-toxin segment of the Cryl molecule and may be further divided into three structural domains as determined by the recently described crystallographic structure for the active toxin segment of the CrylAa δ-endotoxin (Grochulski et al, 1995). Domain 1 occupies the first third of the active toxin and is essential for channel formation (Thompson et al, 1995). Domain 2 and domain 3 occupy the middle and last third of the active toxin, respectively. Both domains 2 and 3 have been implicated in receptor binding and insect specificity, depending on the insect and δ-endotoxin being examined (Thompson et al. , 1995). 1.2.5 CHIMERIC CRYSTAL PROTEINS In recent years, researchers have focused effort on the construction of hybrid δ- endotoxins with the hope of producing proteins with enhanced activity or improved properties. Advances in the art of molecular genetics over the past decade have facilitated a logical and orderly approach to engineering proteins with improved properties. Site-specific and random mutagenesis methods, the advent of polymerase chain reaction (PCR™) methodologies, and the development of recombinant methods for generating gene fusions and constructing chimeric proteins have facilitated an assortment of methods for changing amino acid sequences of proteins, fusing portions of two or more proteins together in a single recombinant protein, and altering genetic sequences that encode proteins of commercial interest. Unfortunately, for crystal proteins, these techniques have only been exploited in limited fashion. The likelihood of arbitrarily creating a chimeric protein with enhanced properties from portions of the numerous native proteins which have been identified is remote given the complex nature of protein structure, folding, oligomerization, activation, and correct processing of the chimeric protoxin to an active moiety. Only by careful selection of specific target regions within each protein, and subsequent protein engineering can toxins be synthesized which have improved insecticidal activity. Some success in the area, however, has been reported in the literature. For example, the construction of a few hybrid δ-endotoxins is reported in the following related art: Intl. Pat. Appl. Publ. No. WO 95/30753 discloses the construction of hybrid B. thuringiensis δ-endotoxins for production in Pseudomonas fluorescens in which the non-toxic protoxin fragment of Cry IF has been replaced by the non-toxic protoxin fragment from the Cryl Ac/Cryl Ab that is disclosed in U. S. Patent 5,128,130. U. S. Patent 5,128,130 discloses the construction of hybrid B. thuringiensis δ-endotoxins for production in P. fluorescens in which a portion of the non-toxic protoxin segment of Cryl Ac is replaced with the corresponding non-toxic protoxin fragment of CrylAb. U. S. Patent 5,055,294 discloses the construction of a specific hybrid δ-endotoxin between Cryl Ac (amino acid residues 1-466) and CrylAb (amino acid residues 466-1155) for production in P. fluorescens. Although the aforementioned patent discloses the construction of a hybrid toxin within the active toxin segment, no specifics are presented in regard to the hybrid toxin's insecticidal activity. Intl. Pat. Appl. Publ. No. WO 95/30752 discloses the construction of hybrid B. thuringiensis δ-endotoxins for production in P. fluorescens in which the non-toxic protoxin segment of CrylC is replaced by the non-toxic protoxin segment from CrylAb. The aforementioned application further discloses that the activity against Spodoptera exigua for the hybrid δ-endotoxin is improved over that ofthe parent active toxin, CrylC. Intl. Pat. Appl. Publ. No. WO 95/06730 discloses the construction of a hybrid B. thuringiensis δ-endotoxin consisting of domains 1 and 2 of Cry IE coupled to domain 3 and the non-toxic protoxin segment of CrylC. Insect bioassays performed against Manduca sexta (sensitive to CrylC and CrylE), Spodoptera exigua (sensitive to CrylC), and Mamestra brassicae (sensitive to CrylC) show that the hybrid CrylE/CrylC hybrid toxin is active against M. sexta, S. exigua, and M. brassicae. The bioassay results were expressed as EC 50 values (toxin concentration giving a 50% growth reduction) rather than LC 50 values (toxin concentration giving 50% mortality). Although the δ-endotoxins used for bioassay were produced in B. thuringiensis, only artificially-generated active segments of the δ-endotoxins were used, not the naturally-produced crystals typically produced by B. thuringiensis that are present in commercial B. thuringiensis formulations. Bioassay results indicated that the LC 50 values for the hybrid CrylE/CrylC crystal against S. frugiperda were 1.5 to 1.7 fold lower (more active) than for native CrylC. This art also discloses the construction of a hybrid B. thuringiensis δ-endotoxin between CrylAb (domains 1 and 2) and CrylC (domain 3 and the non-toxic protoxin segment), although no data are given regarding the hybrid toxin's activity or usefulness. Lee et al. (1995) report the construction of hybrid B. thuringiensis δ-endotoxins between Cryl Ac and CrylAa within the active toxin segment. Artificially generated active segments of the hybrid toxins were used to examine protein interactions in susceptible insect brush border membranes vesicles (BBMV). The bioactivity of the hybrid toxins was not reported. Honee et al. (1991) report the construction of hybrid δ-endotoxins between CrylC (domain 1) and CrylAb (domains 2 and 3) and the reciprocal hybrid between CrylAb (domain 1) and CrylC (domains 2 and 3). These hybrids failed to show any significant increase in activity against susceptible insects. Furthermore, the CrylC (domain l)/CrylAb (domains 2 and 3) hybrid toxin was found to be hypersensitive to protease degradation. A report by Schnepf et al. (1990) discloses the construction of Cryl Ac hybrid toxin in which a small portion of domain 2 was replaced by the corresponding region of CrylAa, although no significant increase in activity against susceptible insect larvae was observed. 1.3 DEFICIENCIES IN THE PRIOR ART The limited successes in producing chimeric crystal proteins which have improved activity have negatively impacted the field by thwarting efforts to produce recombinantly- engineered crystal protein for commercial development, and to extend the toxic properties and host specificities of the known endotoxins. Therefore, what is lacking in the prior art are reliable methods and compositions comprising recombinantly-engineered crystal proteins which have improved insecticidal activity, broad-host-range specificities, and which are suitable for commercial production in B. thuringiensis. 2.0 SUMMARY OF THE INVENTION The present invention overcomes these and other limitations in the prior art by providing novel chimeric δ-endotoxins which have improved insecticidal properties, and broad-range specificities. Disclosed are methods for the construction of B. thuringiensis hybrid δ-endotoxins comprising amino acid sequences from native Cryl Ac and Cry IF crystal proteins. These hybrid proteins, in which all or a portion of Cryl Ac domain 2, all or a portion of Cryl Ac domain 3, and all or a portion of the Cryl Ac protoxin segment is replaced by the corresponding portions of Cry IF, possess not only the insecticidal characteristics of the parent δ-endotoxins, but also have the unexpected and remarkable properties of enhanced broad-range specificity which is not proficiently displayed by either of the native δ-endotoxins from which the chimeric proteins were engineered. Specifically, the present invention discloses and claims genetically-engineered hybrid δ-endotoxins which comprise a portion of a Cryl Ac crystal protein fused to a portion of a Cry IF crystal protein. These chimeric endotoxins have broad-range specificity for the insect pests described herein. In a further embodiment, the present invention also discloses and claims recombinant B. thuringiensis hybrid δ-endotoxins which comprise a portion of CrylAb, Cry IF, and Cryl Ac in which all or a portion of CrylAb domain 2 or all or a portion of CrylAb domain 3 is replaced by the corresponding portions of Cry IF and all or a portion of the CrylAb protoxin segment is replaced by the corresponding portions of Cryl Ac. Exemplary hybrid δ-endotoxins between CrylAb and CrylF are identified in SEQ ID NO:13 and SEQ ID NO: 14. One aspect of the present invention demonstrates the unexpected result that certain hybrid δ-endotoxins derived from Cryl Ac and CrylF proteins exhibit not only the insecticidal characteristics of the parent δ-endotoxins, but also possess insecticidal activity which is not proficiently displayed by either ofthe parent δ-endotoxins. Another aspect of the invention further demonstrates the unexpected result that certain chimeric CrylAb/CrylF proteins maintain not only the insecticidal characteristics of the parent δ-endotoxins, but also exhibit insecticidal activity which is not displayed by either the native CrylAb or CrylF endotoxins. The present invention also encompasses Cryl Ac/Cry IF and CrylAb/CrylF hybrid δ-endotoxins that maintain the desirable characteristics needed for commercial production in B. thuringiensis. Specifically, the hybrid δ-endotoxins identified in SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:34 can efficiently form proteinaceous parasporal inclusions in B. thuringiensis and have the favorable characteristics of solubility, protease susceptibility, and insecticidal activity ofthe parent δ-endotoxins. In a further embodiment, the present invention also discloses and claims recombinant B. thuringiensis hybrid δ-endotoxins which comprise a portion of Cryl Ac and CrylC in which all or a portion of Cryl Ac domain 3 is replaced by the corresponding portions of CrylC and all or a portion of the Cryl Ac protoxin segment is replaced by the corresponding portion of CrylC. Exemplary hybrid δ-endotoxins between Cryl Ac and CrylC are identified in SEQ ID NO:29 and SEQ ID NO:30. One aspect of the present invention demonstrates the unexpected result that, although neither Cryl Ac nor CrylC possess S. frugiperda activity, the Cryl Ac/Cry IC hybrid δ- endotoxin identified by SEQ ID NO:29 and SEQ ID NO:30 has significant activity against S. frugiperda. Furthermore, the Cryl Ac/Cry IC hybrid δ-endotoxin identified by SEQ ID NO:29 and SEQ ID NO:30 has significantly better activity against S. exigua than the CrylC parental δ-endotoxin. The impetus for constructing these and other hybrid δ-endotoxins is to create novel toxins with improved insecticidal activity, increased host-range specificity, and improved production characteristics. The DNA sequences listed in Table 8 define the exchange points for the hybrid δ-endotoxins pertinent to the present invention and as oligonucleotide primers, may be used to identify like or similar hybrid δ-endotoxins by Southern or colony hybridization under conditions of moderate to high stringency. Researchers skilled in the art will recognize the importance of the exchange site chosen between two or more δ-endotoxins can be achieved using a number of in vivo or in vitro molecular genetic techniques. Small variations in the exchange region between two or more δ-endotoxins may yield similar results or, as demonstrated for EG11062 and EG11063, adversely affect desirable traits. Similarly, large variations in the exchange region between two or more δ-endotoxins may have no effect on desired traits, as demonstrated by EG 11063 and EG 11074, or may adversely affect desirable traits, as demonstrated by EG11060 and EG 11063. Favorable traits with regard to improved insecticidal activity, increased host range, and improved production characteristics may be achieved by other such hybrid δ-endotoxins including, but not limited to, the cryl, cry 2, cry 3, cry 4, cry 5, cry 6, cryl, cry8, cry9, cry 10, cryll, cry 12, cryl 3, cry 14, cry 15 class of δ-endotoxin genes and the B. thuringiensis cytolytic cytl and cyt2 genes. Members of these classes of B. thuringiensis insecticidal proteins include, but are not limited to CrylAa, CrylAb, CrylAc, CrylAd, CrylAe, CrylBa, CrylBb, CrylCa, CrylCb, Cryl Da, CrylDb, CrylEa, CrylEb, Cryl Fa, CrylFb, CrylGa, Cryl Ha, Cry2a, Cry2b, CrylJa, CrylKa, Cryl lAa, Cryl lAb, Cryl2Aa, Cry3Ba, Cry3Bb, Cry3C, Cry4a, Cry4Ba, Cry5a, Cry5Ab, CryόAa, Cry6Ba, Cry7Aa, Cry7Ab, Cry8Aa, Cry8Ba, Cry8Ca, Cry9Aa, Cry9Ba, Cry9Ca, CrylOAa, Cryl lAa, Cryl2Aa, Cryl3Aa, Cryl4Aa, Cryl5Aa, CytlAa, and Cyt2Aa. Related hybrid δ-endotoxins would consist of the amino portion of one ofthe aforementioned δ-endotoxins, including all or part of domain 1 or domain 2, fused to all or part of domain 3 from another ofthe aforementioned δ-endotoxins. The non-active protoxin fragment of such hybrid δ-endotoxins may consist of the protoxin fragment from any of the aforementioned δ-endotoxins which may act to stabilize the hybrid δ-endotoxin as demonstrated by EG11087 and EG11091 (see e.g., Table 5). Hybrid δ-endotoxins possessing similar traits as those described in the present invention could be constructed by conservative, or "similar" replacements of amino acids within hybrid δ-endotoxins. Such substitutions would mimic the biochemical and biophysical properties of the native amino acid at any position in the protein. Amino acids considered similar include for example, but are not limited to: Ala, Ser, and Thr; Asp and Glu; Asn and Gin; Lys and Arg; He, Leu, Met, and Val; and Phe, Tyr, and Trp. Researchers skilled in the art will recognize that improved insecticidal activity, increased host range, and improved production characteristics imparted upon hybrid δ-endotoxins may be further improved by altering the genetic code for one or more amino acid positions in the hybrid δ-endotoxin such that the position, or positions, is replaced by any other amino acid. This may be accomplished by targeting a region or regions of the protein for mutagenesis by any number of established mutagenic techniques, including those procedures relevant to the present invention. Such techniques include site-specific mutagenesis (Kunkel, 1985; Kunkel et al, 1987), DNA shuffling (Stemmer, 1994), and PCR™ overlap extension (Horton et al, 1989). Since amino acids situated at or near the surface of a protein are likely responsible for its interaction with other proteinaceous or non-proteinaceous moieties, they may serve as "target" regions for mutagenesis. Such surface exposed regions may consist of, but not be limited to, surface exposed amino acid residues within the active toxin fragment of the protein and include the inter-α-helical or inter-β-strand "loop" -regions of δ-endotoxins that separate α-helices within domain 1 and β-strands within domain 2 and domain 3. Such procedures may favorably change the protein's biochemical and biophysical characteristics or its mode of action as outlined in the Section 1. These include, but are not limited to: 1) improved crystal formation, 2) improved protein stability or reduced protease degradation, 3) improved insect membrane receptor recognition and binding, 4) improved oligomerization or channel formation in the insect midgut endothelium, and 5) improved insecticidal activity or insecticidal specificity due to any or all ofthe reasons stated above. The present invention provides an isolated nucleic acid segment encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26 SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. Preferably the nucleic acid segment encodes a polypeptide having insecticidal activity against Spodoptera frugiperda, Spodoptera exigua, Heliothis virescens, Helicoverpazea or Ostrinia nubilalis. Such nucleic acid segments are isolatable from Bacillus thuringiensis NRRL B-21579, NRRL B-21580, NRRL B- 21581, NRRL B-21635,NRRL B-21636, NRRL B-21780, or NRRL B-21781 cells, respectively. In preferred embodiments, these nucleic acid segments specifically hybridize to a nucleic acid segment having the sequence of SEQ ID NO:9, SEQ ID NO:l l, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33, or a complement thereof, and in highly preferred embodiments these nucleic acid segments comprise the nucleic acid sequences which are disclosed in SEQ ID NO:9, SEQ ID NO:l l, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:33, respectively. Such a nucleic acid segment may be operably linked to a promoter to express the nucleic acid segment in a host cell. In such embodiments, the nucleic acid segment may be comprised within a recombinant vector such as a plasmid, cosmid, phage, phagemid, viral, baculovirus, bacterial artificial chromosome, or yeast artificial chromsome. Exemplary plasmid vectors include the vectors pEG1068, pEG1077, pEG11092, pEG1093, pEG365, pEG378, and pEG381. A further aspect of the invention involves the use of the nucleic acid segments described herein in the preparation of recombinant polypeptide compositions, in the generation of a vector for use in producing an transformed host cell, and the generation of an insect resistant transgenic plant. Host cells also represent an important aspect of the invention. Such host cells generally comprise one or more of the nucleic acid segments as described above. Preferred host cells include bacterial cells such as E. coli, B. thuringiensis, B. subtilis, B. megaterium, and Pseudomonas spp. cells, with B. thuringiensis EG11060, EG11062, EG11063, EG11071, EG11073, EG11074, EG11090, EG11091, EG11092, EG11735, EG11751, EG11768, NRRL B- 21579, NRRL B-21580, NRRL B-21581, NRRL B-21635, NRRL B-21636, NRRL B-21780, and NRRL B-21781 cells being particularly preferred. Preferred host cells may also include eukaryotic cells, such as plant and animal cells. Preferred plant cells include grain, tree, vegetable, fruit, berry, nut, grass, cactus, succulent, and ornamental plant cells, with commercial crops such as corn, rice, tobacco, potato, tomato, flax, canola, sunflower, cotton, wheat, oat, barley, and rye being particularly preferred. In one embodiment, the host cell may be comprised within a transgenic plant, or may be used in the preparation of a transgenic plant, or in the generation of pluripotent plant cells. Alternatively, the host cell may be used in the recombinant expression of a crystal protein, or in the preparation of an insecticidal polypeptide formulation comprising one or more of the toxins disclosed herein. Such a composition preferably comprises one or more isolated polypeptides habing the amino acid sequence of SEQ ID NO: 10, SEQ ID NOT2, SEQ ID NOT4, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. Such a composition has particular use in killing an insect cell, in the preparation of an insecticidal formulation, and in the formulation of a plant protective spray. The invention also provides a method for preparing a B. thuringiensis crystal protein. Such a method generally involves culturing a B. thuringiensis NRRL B-21579, NRRL B- 21580, NRRL B-21581, NRRL B-21635, NRRL B-21636, NRRL B-21780, NRRL B-21781, EG11768, EG11090, EG11063, EG11074, EG11092, EG11735, or EG11751 cell under conditions effective to produce a B. thuringiensis crystal protein, and then obtaining said B. thuringiensis crystal protein from the cell. Such methods are quite useful in recombinant production ofthe crystal proteins disclosed herein. The invention also discloses and claims a method of killing an insect cell. The method generally involves providing to an insect cell an insecticidally-effectiveamount of one or more of the insecticidal compositions disclosed herein. Such cells may be isolated cells, or alternatively, may be comprised within an insect itself. Typically the composition will be provided to the insect either by directly spraying the insects, or alternatively, by the insect ingesting the composition either directly, or by ingesting a plant which has been either coated with the composition, or alternatively, by ingesting part of a transgenic plant which expresses one or more ofthe insecticidal compositions. A further aspect of the invention is a purified antibody that specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. Such antibodies may be operatively attached to a detectable label, provided in an immunodetection kit or used in a method for detecting an insecticidal polypeptide in a biological sample by contacting a biological sample suspected of containing said insecticidal polypeptide with such an antibodyunder conditions effective to allow the formation of immunecomplexes, and then detecting the immunecomplexes which are formed. Another important aspect ofthe invention concerns a transgenic plant having incorporated into its genome a transgene that encodes a polypeptide comprising the amino sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. Preferably, such transgenic plants will comprise one or more of the nucleic acid sequences which are disclosed in SEQ ID NO:9, SEQ ID NO:l 1, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:33. Progeny and seeds from such transgenic plants and their offspring or descendants are also important aspects of the invention which are described in detail elsewhere herein. 2.1 CRYSTAL PROTEIN TRANSGENES AND TRANSGENIC PLANTS In yet another aspect, the present invention provides methods for producing a transgenic plant which expresses a nucleic acid segment encoding the novel chimeric crystal proteins of the present invention. The process of producing transgenic plants is well-known in the art. In general, the method comprises transforming a suitable host cell with a DNA segment which contains a promoter operatively linked to a coding region that encodes a B. thuringiensis Cryl Ac- IF or CrylAb- IF, CrylAc-lC, or a CrylAb-lAc-lF chimeric crystal protein. Such a coding region is generally operatively linked to a transcription-terminating region, whereby the promoter is capable of driving the transcription of the coding region in the cell, and hence providing the cell the ability to produce the recombinant protein in vivo. Alternatively, in instances where it is desirable to control, regulate, or decrease the amount of a particular recombinant crystal protein expressed in a particular transgenic cell, the invention also provides for the expression of crystal protein antisense mRNA. The use of antisense mRNA as a means of controlling or decreasing the amount of a given protein of interest in a cell is well-known in the art. Another aspect of the invention comprises a transgenic plant which express a gene or gene segment encoding one or more of the novel polypeptide compositions disclosed herein. As used herein, the term "transgenic plant" is intended to refer to a plant that has incoφorated DNA sequences, including but not limited to genes which are perhaps not normally present, DNA sequences not normally transcribed into RNA or translated into a protein ("expressed"), or any other genes or DNA sequences which one desires to introduce into the non-transformed plant, such as genes which may normally be present in the non-transformed plant but which one desires to either genetically engineer or to have altered expression. The construction and expression of synthetic B. thuringiensis genes in plants has been described in detail in U. S. Patents 5,500,365 and 5,380,831 (each specifically incoφorated herein by reference). It is contemplated that in some instances the genome of a transgenic plant ofthe present invention will have been augmented through the stable introduction of one or more crylAc-IF, crylAb-IF, crylAc-lC, or crylAb-lAc-lF transgenes, either native, synthetically-modified, or further mutated. In some instances, more than one transgene will be incoφorated into the genome of the transformed host plant cell. Such is the case when more than one crystal protein-encoding DNA segment is incoφorated into the genome of such a plant. In certain situations, it may be desirable to have one, two, three, four, or even more B. thuringiensis crystal proteins (either native or recombinantly-engineered) incoφorated and stably expressed in the transformed transgenic plant. A preferred gene, such as those disclosed in SEQ ID NO:9, SEQ ID NO: 11, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, and SEQ ID NO:33 which may be introduced includes, for example, a crystal protein-encoding a DNA sequence from bacterial origin, and particularly one or more of those described herein which are obtained from Bacillus spp. Highly preferred nucleic acid sequences are those obtained from B. thuringiensis, or any of those sequences which have been genetically engineered to decrease or increase the insecticidal activity ofthe crystal protein in such a transformed host cell. Means for transforming a plant cell and the preparation of a transgenic cell line are well-known in the art, and are discussed herein. Vectors, plasmids, cosmids, yeast artificial chromosomes (YACs) and nucleic acid segments for use in transforming such cells will, of course, generally comprise either the operons, genes, or gene-derived sequences of the present invention, either native, or synthetically-derived, and particularly those encoding the disclosed crystal proteins. These DNA constructs can further include structures such as promoters, enhancers, polylinkers, or even gene sequences which have positively- or negatively-regulating activity upon the particular genes of interest as desired. The DNA segment or gene may encode either a native or modified crystal protein, which will be expressed in the resultant recombinant cells, and/or which will impart an improved phenotype to the regenerated plant. Nucleic acid sequences optimized for expression in plants have been disclosed in Intl. Pat. Appl. Publ. No. WO 93/07278 (specifically incoφorated herein by reference). Such transgenic plants may be desirable for increasing the insecticidal resistance of a monocotyledonous or dicotyledonous plant, by incoφorating into such a plant, a transgenic DNA segment encoding Cryl Ac- IF and/or CrylAc-lC, and/or CrylAb- IF and/or CrylAb- lAc-lF crystal protein(s) which possess broad-insect specificity. Particularly preferred plants such as grains, including but not limited to corn, wheat, oats, rice, maize, and barley; cotton; soybeans and other legumes; trees, including but not limited to ornamentals, shrubs, fruits, nuts; vegetables, turf and pasture grasses, berries, citrus, and other crops of commercial interest; such as garden crops and or houseplants, succulents, cacti, and flowering species. In a related aspect, the present invention also encompasses a seed produced by the transformed plant, a progeny from such seed, and a seed produced by the progeny of the original transgenic plant, produced in accordance with the above process. Such progeny and seeds will have a stably crystal protein transgene stably incoφorated into its genome, and such progeny plants will inherit the traits afforded by the introduction of a stable transgene in Mendelian fashion. All such transgenic plants having incoφorated into their genome transgenic DNA segments encoding one or more chimeric crystal proteins or polypeptides are aspects of this invention. 2.2 CRYSTAL PROTEIN SCREENING AND IMMUNODETECTION KITS The present invention contemplates methods and kits for screening samples suspected of containing crystal protein polypeptides or crystal protein-related polypeptides, or cells producing such polypeptides. Exemplary proteins include those disclosed in SEQ ID NO: 10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, and SEQ ID NO:34. Said kit can contain a nucleic acid segment or an antibody of the present invention. The kit can contain reagents for detecting an interaction between a sample and a nucleic acid or antibody of the present invention. The provided reagent can be radio-, fluorescently- or enzymatically-labeled. The kit can contain a known radiolabeled agent capable of binding or interacting with a nucleic acid or antibody ofthe present invention. The reagent ofthe kit can be provided as a liquid solution, attached to a solid support or as a dried powder. Preferably, when the reagent is provided in a liquid solution, the liquid solution is an aqueous solution. Preferably, when the reagent provided is attached to a solid support, the solid support can be chromatograph media, a test plate having a plurality of wells, or a microscope slide. When the reagent provided is a dry powder, the powder can be reconstituted by the addition of a suitable solvent, that may be provided. In still further embodiments, the present invention concerns immunodetection methods and associated kits. It is proposed that the crystal proteins or peptides of the present invention may be employed to detect antibodies having reactivity therewith, or, alternatively, antibodies prepared in accordance with the present invention, may be employed to detect crystal proteins or crystal protein-related epitope-containing peptides. In general, these methods will include first obtaining a sample suspected of containing such a protein, peptide or antibody, contacting the sample with an antibody or peptide in accordance with the present invention, as the case may be, under conditions effective to allow the formation of an immunocomplex, and then detecting the presence ofthe immunocomplex. In general, the detection of immunocomplex formation is quite well known in the art and may be achieved through the application of numerous approaches. For example, the present invention contemplates the application of ELISA, RIA, immunoblot (e.g., dot blot), indirect immunofluorescence techniques and the like. Generally, immunocomplex formation will be detected through the use of a label, such as a radiolabel or an enzyme tag (such as alkaline phosphatase, horseradish peroxidase, or the like). Of course, one may find additional advantages through the use of a secondary binding ligand such as a second antibody or a biotin/avidin ligand binding arrangement, as is known in the art. For assaying puφoses, it is proposed that virtually any sample suspected of comprising either a crystal protein or peptide or a crystal protein-related peptide or antibody sought to be detected, as the case may be, may be employed. It is contemplated that such embodiments may have application in the titering of antigen or antibody samples, in the selection of hybridomas, and the like. In related embodiments, the present invention contemplates the preparation of kits that may be employed to detect the presence of crystal proteins or related peptides and/or antibodies in a sample. Samples may include cells, cell supernatants, cell suspensions, cell extracts, enzyme fractions, protein extracts, or other cell-free compositions suspected of containing crystal proteins or peptides. Generally speaking, kits in accordance with the present invention will include a suitable crystal protein, peptide or an antibody directed against such a protein or peptide, together with an immunodetection reagent and a means for containing the antibody or antigen and reagent. The immunodetection reagent will typically comprise a label associated with the antibody or antigen, or associated with a secondary binding ligand. Exemplary ligands might include a secondary antibody directed against the first antibody or antigen or a biotin or avidin (or streptavidin) ligand having an associated label. Of course, as noted above, a number of exemplary labels are known in the art and all such labels may be employed in connection with the present invention. The container will generally include a vial into which the antibody, antigen or detection reagent may be placed, and preferably suitably aliquotted. The kits of the present invention will also typically include a means for containing the antibody, antigen, and reagent containers in close confinement for commercial sale. Such containers may include injection or blow- molded plastic containers into which the desired vials are retained. 2.3 ELISAs AND IMMUNOPRECIPITATION ELISAs may be used in conjunction with the invention. In an ELISA assay, proteins or peptides incoφorating crystal protein antigen sequences are immobilized onto a selected surface, preferably a surface exhibiting a protein affinity such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed material, it is desirable to bind or coat the assay plate wells with a nonspecific protein that is known to be antigenically neutral with regard to the test antisera such as bovine serum albumin (BSA), casein or solutions of milk powder. This allows for blocking of nonspecific adsoφtion sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface. After binding of antigenic material to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the antisera or clinical or biological extract to be tested in a manner conducive to immune complex (antigen antibody) formation. Such conditions preferably include diluting the antisera with diluents such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween\ These added agents also tend to assist in the reduction of nonspecific background. The layered antisera is then allowed to incubate for from about 2 to about 4 hours, at temperatures preferably on the order of about 25° to about 27°C. Following incubation, the antisera-contacted surface is washed so as to remove non-immunocomplexed material. A preferred washing procedure includes washing with a solution such as PBS/Tween " , or borate buffer. Following formation of specific immunocomplexes between the test sample and the bound antigen, and subsequent washing, the occurrence and even amount of immunocomplex formation may be determined by subjecting same to a second antibody having specificity for the first. To provide a detecting means, the second antibody will preferably have an associated enzyme that will generate a color development upon incubating with an appropriate chromogenic substrate. Thus, for example, one will desire to contact and incubate the antisera- bound surface with a urease or peroxidase-conjugated anti-human IgG for a period of time and under conditions which favor the development of immunocomplex formation (e.g., incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween ). After incubation with the second enzyme-tagged antibody, and subsequent to washing to remove unbound material, the amount of label is quantified by incubation with a chromogenic substrate such as urea and bromocresol puφle or 2, 2'-azino-di-(3-ethyl- benzthiazoline)-6-sulfonic acid (ABTS) and H 2 O 2 , in the case of peroxidase as the enzyme label. Quantitation is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer. The anti-crystal protein antibodies of the present invention are particularly useful for the isolation of other crystal protein antigens by immunoprecipitation. Immunoprecipitation involves the separation ofthe target antigen component from a complex mixture, and is used to discriminate or isolate minute amounts of protein. For the isolation of membrane proteins cells must be solubilized into detergent micelles. Nonionic salts are preferred, since other agents such as bile salts, precipitate at acid pH or in the presence of bivalent cations. In an alternative embodiment the antibodies of the present invention are useful for the close juxtaposition of two antigens. This is particularly useful for increasing the localized concentration of antigens, e.g. enzyme-substrate pairs. 2.4 WESTERN BLOTS The compositions ofthe present invention will find great use in immunoblot or western blot analysis. The anti-peptide antibodies may be used as high-affinity primary reagents for the identification of proteins immobilized onto a solid support matrix, such as nitrocellulose, nylon or combinations thereof. In conjunction with immunoprecipitation, followed by gel electrophoresis, these may be used as a single step reagent for use in detecting antigens against which secondary reagents used in the detection of the antigen cause an adverse background. This is especially useful when the antigens studied are immunoglobulins (precluding the use of immunoglobulins binding bacterial cell wall components), the antigens studied cross-react with the detecting agent, or they migrate at the same relative molecular weight as a cross-reacting signal. Immunologically-based detection methods for use in conjunction with Western blotting include enzymatically-, radiolabel-, or fluorescently-tagged secondary antibodies against the toxin moiety are considered to be of particular use in this regard. 2.5 EPITOPIC CORE SEQUENCES The present invention is also directed to protein or peptide compositions, free from total cells and other peptides, which comprise a purified protein or peptide which incoφorates an epitope that is immunologically cross-reactive with one or more anti-crystal protein antibodies. In particular, the invention concerns epitopic core sequences derived from Cry proteins or peptides. As used herein, the term "incoφorating an epitope(s) that is immunologically cross- reactive with one or more anti-crystal protein antibodies" is intended to refer to a peptide or protein antigen which includes a primary, secondary or tertiary structure similar to an epitope located within a crystal protein or polypeptide. The level of similarity will generally be to such a degree that monoclonal or polyclonal antibodies directed against the crystal protein or polypeptide will also bind to, react with, or otherwise recognize, the cross-reactive peptide or protein antigen. Various immunoassay methods may be employed in conjunction with such antibodies, such as, for example, Western blotting, ELISA, RIA, and the like, all of which are known to those of skill in the art. The identification of Cry immunodominant epitopes, and/or their functional equivalents, suitable for use in vaccines is a relatively straightforward matter. For example, one may employ the methods of Hopp, as taught in U. S. Patent 4,554,101, incoφorated herein by reference, which teaches the identification and preparation of epitopes from amino acid sequences on the basis of hydrophilicity. The methods described in several other papers, and software programs based thereon, can also be used to identify epitopic core sequences (see, for example, Jameson and Wolf, 1988; Wolf et al, 1988; U. S. Patent. 4,554,101). The amino acid sequence of these "epitopic core sequences" may then be readily incoφorated into peptides, either through the application of peptide synthesis or recombinant technology. Preferred peptides for use in accordance with the present invention will generally be on the order of about 8 to about 20 amino acids in length, and more preferably about 8 to about 15 amino acids in length. It is proposed that shorter antigenic crystal protein-derived peptides will provide advantages in certain circumstances, for example, in the preparation of immunologic detection assays. Exemplary advantages include the ease of preparation and purification, the relatively low cost and improved reproducibility of production, and advantageous biodistribution. It is proposed that particular advantages of the present invention may be realized through the preparation of synthetic peptides which include modified and/or extended epitopic/immunogenic core sequences which result in a "universal" epitopic peptide directed to crystal proteins, and in particular Cry and Cry-related sequences. These epitopic core sequences are identified herein in particular aspects as hydrophilic regions of the particular polypeptide antigen. It is proposed that these regions represent those which are most likely to promote T-cell or B-cell stimulation, and, hence, elicit specific antibody production. An epitopic core sequence, as used herein, is a relatively short stretch of amino acids that is "complementary" to, and therefore will bind, antigen binding sites on the crystal protein- directed antibodies disclosed herein. Additionally or alternatively, an epitopic core sequence is one that will elicit antibodies that are cross-reactive with antibodies directed against the peptide compositions of the present invention. It will be understood that in the context of the present disclosure, the term "complementary" refers to amino acids or peptides that exhibit an attractive force towards each other. Thus, certain epitope core sequences of the present invention may be operationally defined in terms of their ability to compete with or perhaps displace the binding of the desired protein antigen with the corresponding protein-directed antisera. In general, the size of the polypeptide antigen is not believed to be particularly crucial, so long as it is at least large enough to carry the identified core sequence or sequences. The smallest useful core sequence anticipated by the present disclosure would generally be on the order of about 8 amino acids in length, with sequences on the order of 10 to 20 being more preferred. Thus, this size will generally correspond to the smallest peptide antigens prepared in accordance with the invention. However, the size of the antigen may be larger where desired, so long as it contains a basic epitopic core sequence. The identification of epitopic core sequences is known to those of skill in the art, for example, as described in U. S. Patent 4,554,101, incoφorated herein by reference, which teaches the identification and preparation of epitopes from amino acid sequences on the basis of hydrophilicity. Moreover, numerous computer programs are available for use in predicting antigenic portions of proteins (see e.g., Jameson and Wolf, 1988; Wolf et al, 1988). Computerized peptide sequence analysis programs (e.g., DNAStar software, DNAStar, Inc., Madison, WI) may also be useful in designing synthetic peptides in accordance with the present disclosure. Syntheses of epitopic sequences, or peptides which include an antigenic epitope within their sequence, are readily achieved using conventional synthetic techniques such as the solid phase method (e.g., through the use of commercially available peptide synthesizer such as an Applied Biosystems Model 43 OA Peptide Synthesizer). Peptide antigens synthesized in this manner may then be aliquotted in predetermined amounts and stored in conventional manners, such as in aqueous solutions or, even more preferably, in a powder or lyophilized state pending use. In general, due to the relative stability of peptides, they may be readily stored in aqueous solutions for fairly long periods of time if desired, e.g., up to six months or more, in virtually any aqueous solution without appreciable degradation or loss of antigenic activity. However, where extended aqueous storage is contemplated it will generally be desirable to include agents including buffers such as Tris or phosphate buffers to maintain a pH of about 7.0 to about 7.5. Moreover, it may be desirable to include agents which will inhibit microbial growth, such as sodium azide or Merthiolate. For extended storage in an aqueous state it will be desirable to store the solutions at about 4°C, or more preferably, frozen. Of course, where the peptides are stored in a lyophilized or powdered state, they may be stored virtually indefinitely, e.g., in metered aliquots that may be rehydrated with a predetermined amount of water (preferably distilled) or buffer prior to use. 2.6 NUCLEIC ACID SEGMENTS ENCODING CRYSTAL PROTEIN CHIMERAS The present invention also concerns DNA segments, both native, synthetic, and mutagenized, that can be synthesized, or isolated from virtually any source, that are free from total genomic DNA and that encode the novel chimeric peptides disclosed herein. DNA segments encoding these peptide species may prove to encode proteins, polypeptides, subunits, functional domains, and the like of crystal protein-related or other non-related gene products. In addition these DNA segments may be synthesized entirely in vitro using methods that are well-known to those of skill in the art. As used herein, the term "DNA segment" refers to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a crystal protein or peptide refers to a DNA segment that contains crystal protein coding sequences yet is isolated away from, or purified free from, total genomic DNA of the species from which the DNA segment is obtained, which in the instant case is the genome of the Gram-positive bacterial genus, Bacillus, and in particular, the species of Bacillus known as B. thuringiensis. Included within the term "DNA segment", are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phagemids, phage, viruses, and the like. Similarly, a DNA segment comprising an isolated or purified crystal protein-encoding gene refers to a DNA segment which may include in addition to peptide encoding sequences, certain other elements such as, regulatory sequences, isolated substantially away from other naturally occurring genes or protein-encoding sequences. In this respect, the term "gene" is used for simplicity to refer to a functional protein-, polypeptide- or peptide-encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences, operon sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides or peptides. "Isolated substantially away from other coding sequences" means that the gene of interest, in this case, a gene encoding a bacterial crystal protein, forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally-occurring coding DNA, such as large chromosomal fragments or other functional genes or operon coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes, recombinant genes, synthetic linkers, or coding regions later added to the segment by the hand of man. In particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incoφorating DNA sequences that encode a Cry peptide species that includes within its amino acid sequence an amino acid sequence essentially as set forth in SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:34. The term "a sequence essentially as set forth in SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34" means that the sequence substantially corresponds to a portion of the sequence of either SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34 and has relatively few amino acids that are not identical to, or a biologically functional equivalent of, the amino acids of any of these sequences. The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein (e.g., see Illustrative Embodiments). Accordingly, sequences that have between about 70% and about 80%, or more preferably between about 81% and about 90%, or even more preferably between about 91% and about 99% amino acid sequence identity or functional equivalence to the amino acids of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34 will be sequences that are "essentially as set forth in SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34." It will also be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which are known to occur within genes. The nucleic acid segments of the present invention, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, nucleic acid fragments may be prepared that include a short contiguous stretch encoding either of the peptide sequences disclosed in SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34, or that are identical to or complementary to DNA sequences which encode any of the peptides disclosed in SEQ ID NO: 10, SEQ ID NO: 12 SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34, and particularly those DNA segments disclosed in SEQ ID NO:9, SEQ ID NO:l 1, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33. For example, DNA sequences such as about 14 nucleotides, and that are up to about 10,000, about 5,000, about 3,000, about 2,000, about 1,000, about 500, about 200, about 100, about 50, and about 14 base pairs in length (including all intermediate lengths) are also contemplated to be useful. It will be readily understood that "intermediate lengths", in these contexts, means any length between the quoted ranges, such as 14, 15, 16, 17, 18, 19, 20, etc.; 21, 22, 23, etc. ; 30, 31, 32, etc.; 50, 51, 52, 53, etc. ; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through the 200-500; 500-1,000; 1,000-2,000; 2,000-3,000; 3,000-5,000; and up to and including sequences of about 10,000 nucleotides and the like. It will also be understood that this invention is not limited to the particular nucleic acid sequences which encode peptides of the present invention, or which encode the amino acid sequences of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34, including those DNA sequences which are particularly disclosed in SEQ ID NO:9, SEQ ID NO:l l SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33. Recombinant vectors and isolated DNA segments may therefore variously include the peptide-coding regions themselves, coding regions bearing selected alterations or modifications in the basic coding region, or they may encode larger polypeptides that nevertheless include these peptide-coding regions or may encode biologically functional equivalent proteins or peptides that have variant amino acids sequences. The DNA segments of the present invention encompass biologically-functional, equivalent peptides. Such sequences may arise as a consequence of codon redundancy and functional equivalency that are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally-equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations ofthe properties ofthe amino acids being exchanged. Changes designed by man may be introduced through the application of site- directed mutagenesis techniques, e.g., to introduce improvements to the antigenicity of the protein or to test mutants in order to examine activity at the molecular level. If desired, one may also prepare fusion proteins and peptides, e.g., where the peptide- coding regions are aligned within the same expression unit with other proteins or peptides having desired functions, such as for purification or immunodetection puφoses (e.g., proteins that may be purified by affinity chromatography and enzyme label coding regions, respectively). Recombinant vectors form further aspects of the present invention. Particularly useful vectors are contemplated to be those vectors in which the coding portion of the DNA segment, whether encoding a full length protein or smaller peptide, is positioned under the control of a promoter. The promoter may be in the form of the promoter that is naturally associated with a gene encoding peptides of the present invention, as may be obtained by isolating the 5' non- coding sequences located upstream of the coding segment or exon, for example, using recombinant cloning and or PCR™ technology, in connection with the compositions disclosed herein. 2.7 RECOMBINANT VECTORS AND PROTEIN EXPRESSION In other embodiments, it is contemplated that certain advantages will be gained by positioning the coding DNA segment under the control of a recombinant, or heterologous, promoter. As used herein, a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a DNA segment encoding a crystal protein or peptide in its natural environment. Such promoters may include promoters normally associated with other genes, and/or promoters isolated from any bacterial, viral, eukaryotic, or plant cell. Naturally, it will be important to employ a promoter that effectively directs the expression of the DNA segment in the cell type, organism, or even animal, chosen for expression. The use of promoter and cell type combinations for protein expression is generally known to those of skill in the art of molecular biology, for example, see Sambrook et al, 1989. The promoters employed may be constitutive, or inducible, and can be used under the appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins or peptides. Appropriate promoter systems contemplated for use in high-level expression include, but are not limited to, the Pichia expression vector system (Pharmacia LKB Biotechnology). In connection with expression embodiments to prepare recombinant proteins and peptides, it is contemplated that longer DNA segments will most often be used, with DNA segments encoding the entire peptide sequence being most preferred. However, it will be appreciated that the use of shorter DNA segments to direct the expression of crystal peptides or epitopic core regions, such as may be used to generate anti-crystal protein antibodies, also falls within the scope of the invention. DNA segments that encode peptide antigens from about 8 to about 50 amino acids in length, or more preferably, from about 8 to about 30 amino acids in length, or even more preferably, from about 8 to about 20 amino acids in length are contemplated to be particularly useful. Such peptide epitopes may be amino acid sequences which comprise contiguous amino acid sequences from SEQ ID NO: 10, SEQ ID NO: 12 SEQ ID NO: 14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34; or any peptide epitope encoded by the nucleic acid sequences of SEQ ID NO:9, SEQ ID NO: 11, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:33. Methods for the recombinant expression of crystal proteins and vectors useful in the expression of DNA constructs encoding crystal proteins are described in Intl. Pat. Appl. Publ. No. WO 95/02058, specifically incoφorated herein by reference. 2.8 RECOMBINANT HOST CELLS The recombinant host cells of the present invention which have been deposited under the terms ofthe Budapest Treaty are listed in Table 2. TABLE 2 STRAINS DEPOSITED WITH THE NRRL UNDER THE BUDAPEST TREATY STRAIN PLASMID ACCESSION NUMBER DEPOSIT DATE EG 11063 pEG1068 NRRL B-21579 June 26, 1996 EG 11074 pEG1077 NRRL B-21580 June 26, 1996 EG11091 pEG1092 NRRL B-21780 May 21, 1997 EG 11092 pEG1093 NRRL B-21635 November 14, 1996 EG11735 pEG365 NRRL B-21581 June 26, 1996 EG11751 pEG378 NRRL B-21636 November 14, 1996 EG11768 pEG381 NRRL B-21781 May 21, 1997 2.9 DNA SEGMENTS AS HYBRIDIZATION PROBES AND PRIMERS In addition to their use in directing the expression of crystal proteins or peptides of the present invention, the nucleic acid sequences contemplated herein also have a variety of other uses. For example, they also have utility as probes or primers in nucleic acid hybridization embodiments. As such, it is contemplated that nucleic acid segments that comprise a sequence region that consists of at least a 14 nucleotide long contiguous sequence that has the same sequence as, or is complementary to, a 14 nucleotide long contiguous DNA segment of SEQ ID NO:9, SEQ ID NO:l l, SEQ ID NO: 13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 will find particular utility. Also, nucleic acid segments which encode at least a 6 amino acid contiguous sequence from SEQ ID NO: 10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34, are also preferred. Longer contiguous identical or complementary sequences, e.g., those of about 20, 30, 40, 50, 100, 200, 500, 1000, 2000, 5000, 10000 etc. (including all intermediate lengths and up to and including full-length sequences will also be of use in certain embodiments. The ability of such nucleic acid probes to specifically hybridize to crystal protein- encoding sequences will enable them to be of use in detecting the presence of complementary sequences in a given sample. However, other uses are envisioned, including the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions. Nucleic acid molecules having sequence regions consisting of contiguous nucleotide stretches of 10-14, 15-20, 30, 50, or even of 100-200 nucleotides or so, identical or complementary to DNA sequences of SEQ ID NO:9, SEQ ID NO:l l, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33, are particularly contemplated as hybridization probes for use in, e.g., Southern and Northern blotting. Smaller fragments will generally find use in hybridization embodiments, wherein the length of the contiguous complementary region may be varied, such as between about 10-14 and about 100 or 200 nucleotides, but larger contiguous complementarity stretches may be used, according to the length complementary sequences one wishes to detect. Of course, fragments may also be obtained by other techniques such as, e.g., by mechanical shearing or by restriction enzyme digestion. Small nucleic acid segments or fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, as is commonly practiced using an automated oligonucleotide synthesizer. Also, fragments may be obtained by application of nucleic acid reproduction technology, such as the PCR™ technology of U. S. Patents 4,683,195 and 4,683,202 (each specifically incoφorated herein by reference), by introducing selected sequences into recombinant vectors for recombinant production, and by other recombinant DNA techniques generally known to those of skill in the art of molecular biology. Accordingly, the nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of DNA fragments. Depending on the application envisioned, one will desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids, e.g., one will select relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.15 M NaCl at temperatures of about 50°C to about 70°C. Such selective conditions tolerate little, if any, mismatch between the probe and the template or target strand, and would be particularly suitable for isolating crystal protein-encoding DNA segments. Detection of DNA segments via hybridization is well- known to those of skill in the art, and the teachings of U. S. Patents 4,965,188 and 5,176,995 (each specifically incoφorated herein by reference) are exemplary of the methods of hybridization analyses. Teachings such as those found in the texts of Maloy et al, 1994; Segal 1976; Prokop, 1991 ; and Kuby, 1994, are particularly relevant. Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template or where one seeks to isolate crystal protein-encoding sequences from related species, functional equivalents, or the like, less stringent hybridization conditions will typically be needed in order to allow formation of the heteroduplex. In these circumstances, one may desire to employ conditions such as about 0.15 M to about 0.9 M salt, at temperatures ranging from about 20°C to about 55°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results. In certain embodiments, it will be advantageous to employ nucleic acid sequences of the present invention in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detectable signal. In preferred embodiments, one will likely desire to employ a fluorescent label or an enzyme tag, such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmental undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known that can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples. In general, it is envisioned that the hybridization probes described herein will be useful both as reagents in solution hybridization as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired conditions. The selected conditions will depend on the particular circumstances based on the particular criteria required (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridized surface so as to remove nonspecifically bound probe molecules, specific hybridization is detected, or even quantitated, by means ofthe label. 2.10 BIOLOGICAL FUNCTIONAL EQUIVALENTS Modification and changes may be made in the structure of the peptides of the present invention and DNA segments which encode them and still obtain a functional molecule that encodes a protein or peptide with desirable characteristics. The following is a discussion based upon changing the amino acids of a protein to create an equivalent, or even an improved, second-generation molecule. In particular embodiments of the invention, mutated crystal proteins are contemplated to be useful for increasing the insecticidal activity ofthe protein, and consequently increasing the insecticidal activity and/or expression of the recombinant transgene in a plant cell. The amino acid changes may be achieved by changing the codons of the DNA sequence, according to the codons given in Table 3. TABLE 3 Amino Acid Codons Alanine Ala A GCA GCC GCG GCU Cysteine Cys C UGC UGU Aspartic acid Asp D GAC GAU Glutamic acid Glu E GAA GAG Phenylalanine Phe F UUC uuu Glycine Gly G GGA GGC GGG GGU Histidine His H CAC CAU Isoleucine He I AUA AUC AUU Lysine Lys K AAA AAG Leucine Leu L UUA UUG CUA CUC CUG CUU Methionine Met M AUG Asparagine Asn N AAC AAU Proline Pro P CCA ccc CCG CCU Glutamine Gin Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG CGU Serine Ser S AGC AGU UCA UCC UCG ucu Threonine Thr T ACA ACC ACG ACU Valine Val V GUA GUC GUG GUU Tryptophan Tφ w UGG Tyrosine Tyr Y UAC UAU For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated by the inventors that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity. In making such changes, the hydropathic index of amino acids may be considered. The importance ofthe hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incoφorate herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics (Kyte and Doolittle, 1982), these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (- 3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5). It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i. e. , still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within ±2 is preferred, those which are within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U. S. Patent 4,554,101, incoφorated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property ofthe protein. As detailed in U. S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ± 1); glutamate .. s& (+3.0 ± 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5 + 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (- 1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those which are within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred. As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine. 2.11 SITE-SPECIFIC MUTAGENESIS Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, for example, incoφorating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction ofthe sequence being altered. In general, the technique of site-specific mutagenesis is well known in the art, as exemplified by various publications. As will be appreciated, the technique typically employs a phage vector which exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the Ml 3 phage. These phage are readily commercially available and their use is generally well known to those skilled in the art. Double stranded plasmids are also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage. In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart of two strands of a double stranded vector which includes within its sequence a DNA sequence which encodes the desired peptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically. This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as E. coli polymerase I Klenow fragment, in order to complete the synthesis ofthe mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as E. coli cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement. The preparation of sequence variants of the selected peptide-encoding DNA segments using site-directed mutagenesis is provided as a means of producing potentially useful species and is not meant to be limiting as there are other ways in which sequence variants of peptides and the DNA sequences encoding them may be obtained. For example, recombinant vectors encoding the desired peptide sequence may be treated with mutagenic agents, such as hydroxylamine, to obtain sequence variants. 2.12 CRYSTAL PROTEIN COMPOSITIONS As INSECTICIDES AND METHODS OF USE The inventors contemplate that the chimeric crystal protein compositions disclosed herein will find particular utility as insecticides for topical and/or systemic application to field crops, grasses, fruits and vegetables, and ornamental plants. In a preferred embodiment, the bioinsecticide composition comprises an oil flowable suspension of bacterial cells which expresses a novel crystal protein disclosed herein. Preferably the cells are B. thuringiensis cells, however, any such bacterial host cell expressing the novel nucleic acid segments disclosed herein and producing a crystal protein is contemplated to be useful, such as B. megaterium, B. subtilis, E. coli, or Pseudomonas spp. In another important embodiment, the bioinsecticide composition comprises a water dispersible granule. This granule comprises bacterial cells which expresses a novel crystal protein disclosed herein. Preferred bacterial cells are B. thuringiensis cells, however, bacteria such as B. megaterium, B. subtilis, E. coli, or Pseudomonas spp. cells transformed with a DNA segment disclosed herein and expressing the crystal protein are also contemplated to be useful. In a third important embodiment, the bioinsecticide composition comprises a wettable powder, dust, pellet, or collodial concentrate. This powder comprises bacterial cells which expresses a novel crystal protein disclosed herein. Preferred bacterial cells are B. thuringiensis cells, however, bacteria such as B. megaterium, B. subtilis, E. coli, or Pseudomonas spp. cells transformed with a DNA segment disclosed herein and expressing the crystal protein are also contemplated to be useful. Such dry forms of the insecticidal compositions may be formulated to dissolve immediately upon wetting, or alternatively, dissolve in a controlled-release, sustained-release, or other time-dependent manner. In a fourth important embodiment, the bioinsecticide composition comprises an aqueous suspension of bacterial cells such as those described above which express the crystal protein. Such aqueous suspensions may be provided as a concentrated stock solution which is diluted prior to application, or alternatively, as a diluted solution ready-to-apply. For these methods involving application of bacterial cells, the cellular host containing the crystal protein gene(s) may be grown in any convenient nutrient medium, where the DNA construct provides a selective advantage, providing for a selective medium so that substantially all or all of the cells retain the B. thuringiensis gene. These cells may then be harvested in accordance with conventional ways. Alternatively, the cells can be treated prior to harvesting. When the insecticidal compositions comprise intact B. thuringiensis cells expressing the protein of interest, such bacteria may be formulated in a variety of ways. They may be employed as wettable powders, granules or dusts, by mixing with various inert materials, such as inorganic minerals (phyllosilicates, carbonates, sulfates, phosphates, and the like) or botanical materials (powdered corncobs, rice hulls, walnut shells, and the like). The formulations may include spreader-sticker adjuvants, stabilizing agents, other pesticidal additives, or surfactants. Liquid formulations may be aqueous-based or non-aqueous and employed as foams, suspensions, emulsifiable concentrates, or the like. The ingredients may include rheological agents, surfactants, emulsifiers, dispersants, or polymers. Alternatively, the novel chimeric Cry proteins may be prepared by recombinant bacterial expression systems in vitro and isolated for subsequent field application. Such protein may be either in crude cell lysates, suspensions, colloids, etc., or alternatively may be purified, refined, buffered, and/or further processed, before formulating in an active biocidal formulation. Likewise, under certain circumstances, it may be desirable to isolate crystals and/or spores from bacterial cultures expressing the crystal protein and apply solutions, suspensions, or collodial preparations of such crystals and/or spores as the active bioinsecticidal composition. Regardless of the method of application, the amount of the active component(s) are applied at an insecticidally-effective amount, which will vary depending on such factors as, for example, the specific coleopteran insects to be controlled, the specific plant or crop to be treated, the environmental conditions, and the method, rate, and quantity of application of the insecticidally-active composition. The insecticide compositions described may be made by formulating either the bacterial cell, crystal and/or spore suspension, or isolated protein component with the desired agriculturally-acceptable carrier. The compositions may be formulated prior to administration in an appropriate means such as lyophilized, freeze-dried, dessicated, or in an aqueous carrier, medium or suitable diluent, such as saline or other buffer. The formulated compositions may be in the form of a dust or granular material, or a suspension in oil (vegetable or mineral), or water or oil/water emulsions, or as a wettable powder, or in combination with any other carrier material suitable for agricultural application. Suitable agricultural carriers can be solid or liquid and are well known in the art. The term "agriculturally-acceptable carrier" covers all adjuvants, e.g., inert components, dispersants, surfactants, tackifiers, binders, etc. that are ordinarily used in insecticide formulation technology; these are well known to those skilled in insecticide formulation. The formulations may be mixed with one or more solid or liquid adjuvants and prepared by various means, e.g., by homogeneously mixing, blending and/or grinding the insecticidal composition with suitable adjuvants using conventional formulation techniques. The insecticidal compositions of this invention are applied to the environment of the target coleopteran insect, typically onto the foliage of the plant or crop to be protected, by conventional methods, preferably by spraying. The strength and duration of insecticidal application will be set with regard to conditions specific to the particular pest(s), crop(s) to be treated and particular environmental conditions. The proportional ratio of active ingredient to carrier will naturally depend on the chemical nature, solubility, and stability of the insecticidal composition, as well as the particular formulation contemplated. Other application techniques, e.g., dusting, sprinkling, soaking, soil injection, seed coating, seedling coating, spraying, aerating, misting, atomizing, and the like, are also feasible and may be required under certain circumstances such as e.g., insects that cause root or stalk infestation, or for application to delicate vegetation or ornamental plants. These application procedures are also well-known to those of skill in the art. The insecticidal composition of the invention may be employed in the method of the invention singly or in combination with other compounds, including and not limited to other pesticides. The method of the invention may also be used in conjunction with other treatments such as surfactants, detergents, polymers or time-release formulations. The insecticidal compositions ofthe present invention may be formulated for either systemic or topical use. The concentration of insecticidal composition which is used for environmental, systemic, or foliar application will vary widely depending upon the nature of the particular formulation, means of application, environmental conditions, and degree of biocidal activity. Typically, the bioinsecticidal composition will be present in the applied formulation at a concentration of at least about 0.5% by weight and may be up to and including about 99% by weight. Dry formulations of the compositions may be from about 0.5% to about 99% or more by weight of the composition, while liquid formulations may generally comprise from about 0.5% to about 99%o or more of the active ingredient by weight. Formulations which comprise intact bacterial cells will generally contain from about 10 to about 10 cells/mg. The insecticidal formulation may be administered to a particular plant or target area in one or more applications as needed, with a typical field application rate per hectare ranging on the order of from about 50 g to about 500 g of active ingredient, or of from about 500 g to about 1000 g, or of from about 1000 g to about 5000 g or more of active ingredient. 2.13 ANTIBODY COMPOSITIONS AND METHODS FOR PRODUCING In particular embodiments, the inventors contemplate the use of antibodies, either monoclonal or polyclonal which bind to the crystal proteins disclosed herein. Means for preparing and characterizing antibodies are well known in the art (See, e.g., Harlow and Lane, 1988; incorporated herein by reference). The methods for generating monoclonal antibodies (mAbs) generally begin along the same lines as those for preparing polyclonal antibodies. Briefly, a polyclonal antibody is prepared by immunizing an animal with an immunogenic composition in accordance with the present invention and collecting antisera from that immunized animal. A wide range of animal species can be used for the production of antisera. Typically the animal used for production of anti-antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a goat. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies. As is well known in the art, a given composition may vary in its immunogenicity. It is often necessary therefore to boost the host immune system, as may be achieved by coupling a peptide or polypeptide immunogen to a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers. Means for conjugating a polypeptide to a carrier protein are well known in the art and include glutaraldehyde, w-maleimidobencoyl-N-hydroxysuccinimide ester, carbodiimide and bis- biazotized benzidine. As is also well known in the art, the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund's adjuvants and aluminum hydroxide adjuvant. The amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen (subcutaneous, intramuscular, intradermal, intravenous and intraperitoneal). The production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization. A second, booster, injection may also be given. The process of boosting and titering is repeated until a suitable titer is achieved. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate mAbs. mAbs may be readily prepared through use of well-known techniques, such as those exemplified in U. S. Patent 4,196,265 (specifically incoφorated herein by reference). Typically, this technique involves immunizing a suitable animal with a selected immunogen composition, e.g., a purified or partially purified crystal protein, polypeptide or peptide. The immunizing composition is administered in a manner effective to stimulate antibody producing cells. Rodents such as mice and rats are preferred animals, however, the use of rabbit, sheep frog cells is also possible. The use of rats may provide certain advantages (Goding, 1986, pp. 60-61), but mice are preferred, with the BALB/c mouse being most preferred as this is most routinely used and generally gives a higher percentage of stable fusions. Following immunization, somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the mAb generating protocol. These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible. Often, a panel of animals will have been immunized and the spleen of animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5 x 10 7 to 2 x 10 lymphocytes. The antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized. Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render then incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas). Any one of a number of myeloma cells may be used, as are known to those of skill in the art (Goding, pp. 65-66, 1986; Campbell, pp. 75-83, 1984). For example, where the immunized animal is a mouse, one may use P3-X63/Ag8, X63-Ag8.653, NSl/l.Ag 4 1, Sp210-Agl4, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bui; for rats, one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions. One preferred murine myeloma cell is the NS-1 myeloma cell line (also termed P3-NS- 1-Ag4-1), which is readily available from the NIGMS Human Genetic Mutant Cell Repository by requesting cell line repository number GM3573. Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line. Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 ratio, though the ratio may vary from about 20:1 to about 1 :1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes. Fusion methods using Sendai virus have been described (Kohler and Milstein, 1975; 1976), and those using polyethylene glycol (PEG), such as 37% (vol./vol.) PEG, (Gefter et al, 1977). The use of electrically induced fusion methods is also appropriate (Goding, 1986, pp. 71-74). Fusion procedures usually produce viable hybrids at low frequencies, about 1 x 10 " to 1 x 10 " . However, this does not pose a problem, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that would normally continue to divide indefinitely) by culturing in a selective medium. The selective medium is generally one that contains an agent that blocks the de novo synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block de novo synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium). Where azaserine is used, the media is supplemented with hypoxanthine. The preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium. The myeloma cells are defective in key enzymes of the salvage pathway, e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive. The B-cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B-cells. This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single- clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity. The assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like. The selected hybridomas would then be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide mAbs. The cell lines may be exploited for mAb production in two basic ways. A sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal ofthe type that was used to provide the somatic and myeloma cells for the original fusion. The injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid. The body fluids of the animal, such as serum or ascites fluid, can then be tapped to provide mAbs in high concentration. The individual cell lines could also be cultured in vitro, where the mAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations. mAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography. 3.0 BRIEF DESCRIPTION OF THE DRAWINGS The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. FIG. 1. The wild-type δ-endotoxins and the relevant restriction sites that were used to construct the hybrid δ-endotoxins pertinent to the invention are diagrammed in FIG. 1A. Only the DNA encoding the δ-endotoxin that is contained on the indicated plasmid (identified by the "pEG" prefix) is shown. The B. thuringiensis strains containing the indicated plasmids are identified by the "EG" prefix. The hybrid δ-endotoxins described in the invention are diagrammed in FIG. IB and are aligned with the wild-type δ-endotoxins in FIG. 1 A. FIG. 2. An equal amount of each washed sporulated B. thuringiensis culture was analyzed by SDS-PAGE. Lane a: control CrylAc producing B. thuringiensis strain EG11070, b: EGl 1060, c: EGl 1062, d: EGl 1063, e: EGl 1065, f: EGl 1067, g: EGl 1071, h: EGl 1073, i: EGl 1074, j: EGl 1088, k: EGl 1090, and 1: EGl 1091. FIG. 3. Solubilized hybrid δ-endotoxins were exposed to trypsin for 0, 15, 30, 60, and 120 minutes. The resulting material was analyzed by SDS-PAGE. The amount of active δ-endotoxin fragment remaining was quantitated by scanning densitometry using a Molecular Dynamics model 300 A densitometer. The percent active toxin remaining was plotted versus time. Wild-type Cryl Ac δ-endotoxin (open box) served as the control. FIG. 4. Schematic diagrams of the wild-type toxins and the relevant restriction sites that were used to construct the hybrid δ-endotoxin encoded by pEG381 and expressed in EGl 1768. Only the DNA encoding the δ-endotoxin that is contained on the indicated plasmid (identified by the "pEG" prefix) is shown. 4.0 BRIEF DESCRIPTION OF THE SEQUENCE IDENTIFIERS SEQ ID NO:l is oligonucleotide primer A. SEQ ID NO:2 is oligonucleotide primer B. SEQ ID NO:3 is oligonucleotide primer C. SEQ ID NO:4 is oligonucleotide primer D. SEQ ID NO: 5 is oligonucleotide primer E. SEQ ID NO: 6 is oligonucleotide primer F. SEQ ID NO:7 is oligonucleotide primer G. SEQ ID NO:8 is oligonucleotide primer H. SEQ ID NO:9 is the nucleotide and deduced amino acid sequences of the EGl 1063 hybrid δ-endotoxin. SEQ ID NO: 10 denotes in the three-letter abbreviation form, the amino acid sequence for the hybrid δ-endotoxin specified in SEQ ID NO:9. SEQ ID NO: 11 is the nucleotide and deduced amino acid sequences of the EGl 1074 hybrid δ-endotoxin. SEQ ID NO: 12 denotes in the three-letter abbreviation form, the amino acid sequence for the hybrid δ-endotoxin specified in SEQ ID NO: 11. SEQ ID NO: 13 is the nucleotide and deduced amino acid sequences of the EGl 1735 hybrid δ-endotoxin. SEQ ID NO: 14 denotes in the three-letter abbreviation form, the amino acid sequence for the hybrid δ-endotoxin specified in SEQ ID NO: 13. SEQ ID NO:15 is the 5' exchange site for pEG1065, pEG1070, and pEG1074. SEQ ID NO: 16 is the 5' exchange site for pEG1067, pEG1072, and pEG1076. SEQ ID NO:17 is the 5' exchange site for pEG1068, pEG1077, and pEG365. SEQ ID NO: 18 is the 5' exchange site for pEG1088 and pEG1092. SEQ ID NO: 19 is the 5' exchange site for pEG1089 and the 3' exchange site for pEG1070 and pEG1072. SEQ ID NO:20 is the 5' exchange site for pEG1091. SEQ ID NO:21 is the 3' exchange site for pEG1065, pEG1067, pEG1068, pEG1093, pEG378, and pEG 365. SEQ ID NO:22 is the 3' exchange site for pEG1088. SEQ ID NO:23 is oligonucleotide Primer I. SEQ ID NO:24 is oligonucleotide Primer J. SEQ ID NO:25 is the nucleic acid sequence and deduced amino acid sequence of the hybrid crystal protein-encoding gene of EGl 1092. SEQ ID NO:26 is the three-letter abbreviation form of the amino acid sequence of the hybrid crystal protein produced by strain EGl 1092 encoded by SEQ ID NO:25. SEQ ID NO:27 is the nucleic acid sequence and the deduced amino acid sequence of the hybrid crystal protein-encoding gene of EGl 1751. SEQ ID NO:28 is the three-letter abbreviation form of the amino acid sequence of the hybrid crystal protein produced by strain EGl 1751 encoded by SEQ ID NO:27. SEQ ID NO:29 is the nucleic acid sequence and the deduced amino acid sequence of the hybrid crystal protein-encoding gene of EGl 1091. SEQ ID NO:30 is the three-letter abbreviation form of the amino acid sequence of the hybrid crystal protein produced by strain EGl 1091 encoded by SEQ ID NO:29. SEQ ID NO:31 is oligonucleotide primer K. SEQ ID NO:32 is the 5' exchange site for pEG378 and pEG381. SEQ ID NO:33 is the nucleic acid sequence and the deduced amino acid sequence of the hybrid crystal protein-encoding gene of EGl 1768. SEQ ID NO: 34 denotes in the three-letter abbreviation form, the amino acid sequence ofthe hybrid crystal protein produced by strain EGl 1768 encoded by SEQ ID NO:33. SEQ ID NO:35 is the 3' exchange site for pEG1074, pEG1076, pEG1077 and pEG381. 5.0 DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS 5.1 METHODS FOR CULTURING B. THURINGIENSIS TO PRODUCE CRY PROTEINS The B. thuringiensis strains described herein may be cultured using standard known media and fermentation techniques. Upon completion of the fermentation cycle, the bacteria may be harvested by first separating the B. thuringiensis spores and crystals from the fermentation broth by means well known in the art. The recovered B. thuringiensis spores and crystals can be formulated into a wettable powder, a liquid concentrate, granules or other formulations by the addition of surfactants, dispersants, inert carriers and other components to facilitate handling and application for particular target pests. The formulation and application procedures are all well known in the art and are used with commercial strains of B. thuringiensis (HD-1) active against Lepidoptera, e.g., cateφillars. 5.2 RECOMBINANT HOST CELLS FOR EXPRESSION OF CRY GENES The nucleotide sequences of the subject invention can be introduced into a wide variety of microbial hosts. Expression of the toxin gene results, directly or indirectly, in the intracellular production and maintenance of the pesticide. With suitable hosts, e.g., Pseudomonas, the microbes can be applied to the sites of lepidopteran insects where they will proliferate and be ingested by the insects. The results is a control of the unwanted insects. Alternatively, the microbe hosting the toxin gene can be treated under conditions that prolong the activity of the toxin produced in the cell. The treated cell then can be applied to the environment of target pest(s). The resulting product retains the toxicity of the B. thuringiensis toxin. Suitable host cells, where the pesticide-containing cells will be treated to prolong the activity ofthe toxin in the cell when the then treated cell is applied to the environment of target pest(s), may include either prokaryotes or eukaryotes, normally being limited to those cells which do not produce substances toxic to higher organisms, such as mammals. However, organisms which produce substances toxic to higher organisms could be used, where the toxin is unstable or the level of application sufficiently low as to avoid any possibility or toxicity to a mammalian host. As hosts, of particular interest will be the prokaryotes and the lower eukaryotes, such as fungi. Illustrative prokaryotes, both Gram-negative and Gram-positive, include Enter obacteriaceae, such as Escherichia, Erwinia, Shigella, Salmonella, and Proteus; Bacillaceae; Rhizobiceae, such as Rhizobium; Spirillaceae, such as photobacterium, Zymomonas, Serratia, Aeromonas, Vibrio, Desulfovibrio, Spirillum; Lactobacillaceae; Pseudomonadaceae, such as Pseudomonas and Acetobacter; Azotobacteraceae, Actinomycetales, and Nitrobacteraceae. Among eukaryotes are fungi, such as Phycomycetes and Ascomycetes, which includes yeast, such as Saccharomyces and Schizosaccharomyces; and Basidiomycetes yeast, such as Rhodotorula, Aureobasidium, Sporobolomyces, and the like. Characteristics of particular interest in selecting a host cell for puφoses of production include ease of introducing the B. thuringiensis gene into the host, availability of expression systems, efficiency of expression, stability of the pesticide in the host, and the presence of auxiliary genetic capabilities. Characteristics of interest for use as a pesticide microcapsule include protective qualities for the pesticide, such as thick cell walls, pigmentation, and intracellular packaging or formation of inclusion bodies; leaf affinity; lack of mammalian toxicity; attractiveness to pests for ingestion; ease of killing and fixing without damage to the toxin; and the like. Other considerations include ease of formulation and handling, economics, storage stability, and the like. Host organisms of particular interest include yeast, such as Rhodotorula sp., Aureobasidium sp., Saccharomyces sp., and Sporobolomyces sp.; phylloplane organisms such as Pseudomonas sp., Erwinia sp. and Flavobacterium sp.; or such other organisms as Escherichia, Lactobacillus sp., Bacillus sp., Streptomyces sp., and the like. Specific organisms include Pseudomonas aeruginosa, P. fluorescens, Saccharomyces cerevisiae, B. thuringiensis, B. subtilis, E. coli, Streptomyces lividans and the like. Treatment of the microbial cell, e.g., a microbe containing the B. thuringiensis toxin gene, can be by chemical or physical means, or by a combination of chemical and/or physical means, so long as the technique does not deleteriously affect the properties of the toxin, nor diminish the cellular capability in protecting the toxin. Examples of chemical reagents are halogenating agents, particularly halogens of atomic no. 17-80. More particularly, iodine can be used under mild conditions and for sufficient time to achieve the desired results. Other suitable techniques include treatment with aldehydes, such as formaldehyde and glutaraldehye; anti-infectives, such as zephiran chloride and cetylpyridinium chloride; alcohols, such as isopropyl and ethanol; various histologic fixatives, such as Lugol's iodine, Bouin's fixative, and Helly's fixatives, (see e.g., Humason, 1967); or a combination of physical (heat) and chemical agents that preserve and prolong the activity of the toxin produced in the cell when the cell is administered to a suitable host. Examples of physical means are short wavelength radiation such as γ-radiation and X-radiation, freezing, UV irradiation, lyophilization, and the like. The cells employed will usually be intact and be substantially in the proliferative form when treated, rather than in a spore form, although in some instances spores may be employed. Where the B. thuringiensis toxin gene is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, it is essential that certain host microbes be used. Microorganism hosts are selected which are known to occupy the "phytosphere" (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest. These microorganisms are selected so as to be capable of successfully competing in the particular environment (crop and other insect habitats) with the wild-type microorganisms, provide for stable maintenance and expression of the gene expressing the polypeptide pesticide, and, desirably, provide for improved protection of the pesticide from environmental degradation and inactivation. A large number of microorganisms are known to inhabit the phylloplane (the surface of the plant leaves) and/or the rhizosphere (the soil surrounding plant roots) of a wide variety of important crops. These microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., genera Bacillus, Pseudomonas, Erwinia, Serratia, Klebsiella, Zanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylophilius, Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc, and Alcaligenes; fungi, particularly yeast, e.g., genera Saccharomyces, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula, and Aureobasidium. Of particular interest are such phytosphere bacterial species as Pseudomonas syringae, Pseudomonas fluorescens, Serratia marcescens, Acetobacter xylinum, Agrobacterium tumefaciens, Rhodobacter sphaeroides, Xanthomonas campestris, Rhizobium melioti, Alcaligenes eutrophus, and Azotobacter vinlandii; and phytosphere yeast species such as Rhodotorula rubra, R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C. diffluens, C laurentii, Saccharomyces rosei, S. pretoriensis, S. cerevisiae, Sporobolomyces roseus, S. odorus, Kluyveromyces veronae, and Aureobasidium pollulans. 5.3 DEFINITIONS The following words and phrases have the meanings set forth below. Broad-Spectrum: refers to a wide range of insect species. Broad-Spectrum Insecticidal Activity: toxicity towards a wide range of insect species. Expression: The combination of intracellular processes, including transcription and translation undergone by a coding DNA molecule such as a structural gene to produce a polypeptide. Insecticidal Activity: toxicity towards insects. Insecticidal Specificity: the toxicity exhibited by a crystal protein towards multiple insect species. Intraorder Specificity: the toxicity of a particular crystal protein towards insect species within an Order of insects (e.g., Order Lepidoptera). Interorder Specificity: the toxicity of a particular crystal protein towards insect species of different Orders (e.g., Orders Lepidoptera and Diptera). LC 50 : the lethal concentration of crystal protein that causes 50% mortality of the insects treated. LC 95 : the lethal concentration of crystal protein that causes 95% mortality of the insects treated. Promoter: A recognition site on a DNA sequence or group of DNA sequences that provide an expression control element for a structural gene and to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene. Regeneration: The process of growing a plant from a plant cell (e.g., plant protoplast or explant). Structural Gene: A gene that is expressed to produce a polypeptide. Transformation: A process of introducing an exogenous DNA sequence (e.g., a vector, a recombinant DNA molecule) into a cell or protoplast in which that exogenous DNA is incoφorated into a chromosome or is capable of autonomous replication. Transformed Cell: A cell whose DNA has been altered by the introduction of an exogenous DNA molecule into that cell. Transgene: An exogenous gene which when introduced into the genome of a host cell through a process such as transformation, electroporation, particle bombardment, and the like, is expressed by the host cell and integrated into the cells genome such that the trait or traits produced by the expression ofthe transgene is inherited by the progeny ofthe transformed cell. Transgenic Cell: Any cell derived or regenerated from a transformed cell or derived from a transgenic cell. Exemplary transgenic cells include plant calli derived from a transformed plant cell and particular cells such as leaf, root, stem, e.g., somatic cells, or reproductive (germ) cells obtained from a transgenic plant. Transgenic Plant: A plant or progeny thereof derived from a transformed plant cell or protoplast, wherein the plant DNA contains an introduced exogenous DNA molecule not originally present in a native, non-transgenic plant of the same strain. The terms "transgenic plant" and "transformed plant" have sometimes been used in the art as synonymous terms to define a plant whose DNA contains an exogenous DNA molecule. However, it is thought more scientifically correct to refer to a regenerated plant or callus obtained from a transformed plant cell or protoplast as being a transgenic plant, and that usage will be followed herein. Vector: A DNA molecule capable of replication in a host cell and/or to which another DNA segment can be operatively linked so as to bring about replication of the attached segment. A plasmid is an exemplary vector. 5.4 PROBES AND PRIMERS In another aspect, DNA sequence information provided by the invention allows for the preparation of relatively short DNA (or RNA) sequences having the ability to specifically hybridize to gene sequences of the selected polynucleotides disclosed herein. In these aspects, nucleic acid probes of an appropriate length are prepared based on a consideration of a selected crystal protein gene sequence, e.g., a sequence such as that shown in SEQ ID NO:9, SEQ ID NO:l l, SEQ ID NO: 13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33. The ability of such nucleic acid probes to specifically hybridize to a crystal protein-encoding gene sequence lends them particular utility in a variety of embodiments. Most importantly, the probes may be used in a variety of assays for detecting the presence of complementary sequences in a given sample. In certain embodiments, it is advantageous to use oligonucleotide primers. The sequence of such primers is designed using a polynucleotide of the present invention for use in detecting, amplifying or mutating a defined segment of a crystal protein gene from B. thuringiensis using PCR™ technology. Segments of related crystal protein genes from other species may also be amplified by PCR™ using such primers. To provide certain of the advantages in accordance with the present invention, a preferred nucleic acid sequence employed for hybridization studies or assays includes sequences that are complementary to at least a 14 to 30 or so long nucleotide stretch of a crystal protein-encoding sequence, such as that shown in SEQ ID NO:9, SEQ ID NO: 11, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33. A size of at least 14 nucleotides in length helps to ensure that the fragment will be of sufficient length to form a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 14 bases in length are generally preferred, though, in order to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 14 to 20 nucleotides, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR™ technology of U. S. Patents 4,683,195, and 4,683,202 (each specifically incoφorated herein by reference), or by excising selected DNA fragments from recombinant plasmids containing appropriate inserts and suitable restriction sites. 5.5 EXPRESSION VECTORS The present invention contemplates an expression vector comprising a polynucleotide of the present invention. Thus, in one embodiment an expression vector is an isolated and purified DNA molecule comprising a promoter operatively linked to an coding region that encodes a polypeptide of the present invention, which coding region is operatively linked to a transcription-terminating region, whereby the promoter drives the transcription of the coding region. As used herein, the term "operatively linked" means that a promoter is connected to an coding region in such a way that the transcription of that coding region is controlled and regulated by that promoter. Means for operatively linking a promoter to a coding region are well known in the art. Promoters that function in bacteria are well known in the art. Exemplary and preferred promoters for the Bacillus ciystal proteins include the sigA, sigE, and sigK gene promoters. Alternatively, the native, mutagenized, or recombinant crystal protein-encoding gene promoters themselves can be used. Where an expression vector ofthe present invention is to be used to transform a plant, a promoter is selected that has the ability to drive expression in plants. Promoters that function in plants are also well known in the art. Useful in expressing the polypeptide in plants are promoters that are inducible, viral, synthetic, constitutive as described (Poszkowski et al, 1989; Odell et al, 1985), and temporally regulated, spatially regulated, and spatio-temporally regulated (Chau et al, 1989). A promoter is also selected for its ability to direct the transformed plant cell's or transgenic plant's transcriptional activity to the coding region. Structural genes can be driven by a variety of promoters in plant tissues. Promoters can be near-constitutive, such as the CaMV 35S promoter, or tissue-specific or developmentally specific promoters affecting dicots or monocots. Where the promoter is a near-constitutive promoter such as CaMV 35S, increases in polypeptide expression are found in a variety of transformed plant tissues (e.g., callus, leaf, seed and root). Alternatively, the effects of transformation can be directed to specific plant tissues by using plant integrating vectors containing a tissue-specific promoter. An exemplary tissue-specific promoter is the lectin promoter, which is specific for seed tissue. The Lectin protein in soybean seeds is encoded by a single gene (Lei) that is only expressed during seed maturation and accounts for about 2 to about 5% of total seed mRNA. The lectin gene and seed-specific promoter have been fully characterized and used to direct seed specific expression in transgenic tobacco plants (Vodkin et al, 1983; Lindstrom et al, 1990.) An expression vector containing a coding region that encodes a polypeptide of interest is engineered to be under control of the lectin promoter and that vector is introduced into plants using, for example, a protoplast transformation method (Dhir et al, 1991). The expression of the polypeptide is directed specifically to the seeds ofthe transgenic plant. A transgenic plant of the present invention produced from a plant cell transformed with a tissue specific promoter can be crossed with a second transgenic plant developed from a plant cell transformed with a different tissue specific promoter to produce a hybrid transgenic plant that shows the effects of transformation in more than one specific tissue. Exemplary tissue-specific promoters are corn sucrose synthetase 1 (Yang et al. , 1990), corn alcohol dehydrogenase 1 (Vogel et al, 1989), corn light harvesting complex (Simpson, 1986), corn heat shock protein (Odell et al, 1985), pea small subunit RuBP carboxylase (Poulsen et al, 1986; Cashmore et al, 1983), Ti plasmid mannopine synthase (Langridge et al, 1989), Ti plasmid nopaline synthase (Langridge et al, 1989), petunia chalcone isomerase (Van Tunen et al, 1988), bean glycine rich protein 1 (Keller et al, 1989), CaMV 35s transcript (Odell et al, 1985) and Potato patatin (Wenzler et al, 1989). Preferred promoters are the cauliflower mosaic virus (CaMV 35S) promoter and the S-E9 small subunit RuBP carboxylase promoter. The choice of which expression vector and ultimately to which promoter a polypeptide coding region is operatively linked depends directly on the functional properties desired, e.g., the location and timing of protein expression, and the host cell to be transformed. These are well known limitations inherent in the art of constructing recombinant DNA molecules. However, a vector useful in practicing the present invention is capable of directing the expression ofthe polypeptide coding region to which it is operatively linked. Typical vectors useful for expression of genes in higher plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of Agrobacterium tumefaciens described (Rogers et al, 1987). However, several other plant integrating vector systems are known to function in plants including pCaMVCN transfer control vector described (Fromm et al, 1985). pCaMVCN (available from Pharmacia, Piscataway, NJ) includes the cauliflower mosaic virus CaMV 35 S promoter. In preferred embodiments, the vector used to express the polypeptide includes a selection marker that is effective in a plant cell, preferably a drug resistance selection marker. One preferred drug resistance marker is the gene whose expression results in kanamycin resistance; i.e., the chimeric gene containing the nopaline synthase promoter, Tni neomycin phosphotransferase II (nptll) and nopaline synthase 3' non-translated region described (Rogers et al, 1988). RNA polymerase transcribes a coding DNA sequence through a site where polyadenylation occurs. Typically, DNA sequences located a few hundred base pairs downstream of the polyadenylation site serve to terminate transcription. Those DNA sequences are referred to herein as transcription-termination regions. Those regions are required for efficient polyadenylation of transcribed messenger RNA (mRNA). Means for preparing expression vectors are well known in the art. Expression (transformation vectors) used to transform plants and methods of making those vectors are described in U. S. Patents 4,971,908, 4,940,835, 4,769,061 and 4,757,011 (each of which is specifically incorporated herein by reference). Those vectors can be modified to include a coding sequence in accordance with the present invention. A variety of methods has been developed to operatively link DNA to vectors via complementary cohesive termini or blunt ends. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted and to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules. A coding region that encodes a polypeptide having the ability to confer insecticidal activity to a cell is preferably a chimeric B. thuringiensis crystal protein-encoding gene. In preferred embodiments, such a polypeptide has the amino acid residue sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34; or a functional equivalent of one or more of those sequences. In accordance with such embodiments, a coding region comprising the DNA sequence of SEQ ID NO:9, SEQ ID NO: 11, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 is also preferred. 5.6 TRANSFORMED OR TRANSGENIC PLANT CELLS A bacterium, a yeast cell, or a plant cell or a plant transformed with an expression vector of the present invention is also contemplated. A transgenic bacterium, yeast cell, plant cell or plant derived from such a transformed or transgenic cell is also contemplated. Means for transforming bacteria and yeast cells are well known in the art. Typically, means of transformation are similar to those well known means used to transform other bacteria or yeast such as E. coli or S. cerevisiae. Methods for DNA transformation of plant cells include Agrobacterium-mediated plant transformation, protoplast transformation, gene transfer into pollen, injection into reproductive organs, injection into immature embryos and particle bombardment. Each of these methods has distinct advantages and disadvantages. Thus, one particular method of introducing genes into a particular plant strain may not necessarily be the most effective for another plant strain, but it is well known which methods are useful for a particular plant strain. There are many methods for introducing transforming DNA segments into cells, but not all are suitable for delivering DNA to plant cells. Suitable methods are believed to include virtually any method by which DNA can be introduced into a cell, such as infection by A. tumefαciens and related Agrobacterium, direct delivery of DNA such as, for example, by PEG- mediated transformation of protoplasts (Omirulleh et al, 1993), by desiccation/inhibition- mediated DNA uptake, by electroporation, by agitation with silicon carbide fibers, by acceleration of DNA coated particles, etc. In certain embodiments, acceleration methods are preferred and include, for example, microprojectile bombardment and the like. Technology for introduction of DNA into cells is well-known to those of skill in the art. Four general methods for delivering a gene into cells have been described: (1) chemical methods (Graham and van der Eb, 1973); (2) physical methods such as microinjection (Capecchi, 1980), electroporation (Wong and Neumann, 1982; From et al, 1985) and the gene gun (Johnston and Tang, 1994; Fynan et al, 1993); (3) viral vectors (Clapp, 1993; Lu et al, 1993; Eglitis and Anderson, 1988a; 1988b); and (4) receptor-mediated mechanisms (Curiel et al, 1991; 1992; Wagner et al, 1992). 5.6.1 ELECTROPORATION The application of brief, high-voltage electric pulses to a variety of animal and plant cells leads to the formation of nanometer-sized pores in the plasma membrane. DNA is taken directly into the cell cytoplasm either through these pores or as a consequence of the redistribution of membrane components that accompanies closure of the pores. Electroporation can be extremely efficient and can be used both for transient expression of clones genes and for establishment of cell lines that carry integrated copies of the gene of interest. Electroporation, in contrast to calcium phosphate-mediated transfection and protoplast fusion, frequently gives rise to cell lines that carry one, or at most a few, integrated copies ofthe foreign DNA. The introduction of DNA by means of electroporation, is well-known to those of skill in the art. In this method, certain cell wall-degrading enzymes, such as pectin-degrading enzymes, are employed to render the target recipient cells more susceptible to transformation by electroporation than untreated cells. Alternatively, recipient cells are made more susceptible to transformation, by mechanical wounding. To effect transformation by electroporation one may employ either friable tissues such as a suspension culture of cells, or embryogenic callus, or alternatively, one may transform immature embryos or other organized tissues directly. One would partially degrade the cell walls of the chosen cells by exposing them to pectin-degrading enzymes (pectolyases) or mechanically wounding in a controlled manner. Such cells would then be recipient to DNA transfer by electroporation, which may be carried out at this stage, and transformed cells then identified by a suitable selection or screening protocol dependent on the nature ofthe newly incoφorated DNA. 5.6.2 MICROPROJECTILE BOMBARDMENT A further advantageous method for delivering transforming DNA segments to plant cells is microprojectile bombardment. In this method, particles may be coated with nucleic acids and delivered into cells by a propelling force. Exemplary particles include those comprised of tungsten, gold, platinum, and the like. An advantage of microprojectile bombardment, in addition to it being an effective means of reproducibly stably transforming monocots, is that neither the isolation of protoplasts (Cristou et al, 1988) nor the susceptibility to Agrobacterium infection is required. An illustrative embodiment of a method for delivering DNA into maize cells by acceleration is a Biolistics Particle Delivery System, which can be used to propel particles coated with DNA or cells through a screen, such as a stainless steel or Nytex screen, onto a filter surface covered with corn cells cultured in suspension. The screen disperses the particles so that they are not delivered to the recipient cells in large aggregates. It is believed that a screen intervening between the projectile apparatus and the cells to be bombarded reduces the size of projectiles aggregate and may contribute to a higher frequency of transformation by reducing damage inflicted on the recipient cells by projectiles that are too large. For the bombardment, cells in suspension are preferably concentrated on filters or solid culture medium. Alternatively, immature embryos or other target cells may be arranged on solid culture medium. The cells to be bombarded are positioned at an appropriate distance below the macroprojectile stopping plate. If desired, one or more screens are also positioned between the acceleration device and the cells to be bombarded. Through the use of techniques set forth herein one may obtain up to 1000 or more foci of cells transiently expressing a marker gene. The number of cells in a focus which express the exogenous gene product 48 hours post- bombardment often range from 1 to 10 and average 1 to 3. In bombardment transformation, one may optimize the prebombardment culturing conditions and the bombardment parameters to yield the maximum numbers of stable transformants. Both the physical and biological parameters for bombardment are important in this technology. Physical factors are those that involve manipulating the DNA/microprojectile precipitate or those that affect the flight and velocity of either the macro- or microprojectiles. Biological factors include all steps involved in manipulation of cells before and immediately after bombardment, the osmotic adjustment of target cells to help alleviate the trauma associated with bombardment, and also the nature of the transforming DNA, such as linearized DNA or intact supercoiled plasmids. It is believed that pre-bombardment manipulations are especially important for successful transformation of immature embryos. Accordingly, it is contemplated that one may wish to adjust various of the bombardment parameters in small scale studies to fully optimize the conditions. One may particularly wish to adjust physical parameters such as gap distance, flight distance, tissue distance, and helium pressure. One may also minimize the trauma reduction factors (TRFs) by modifying conditions which influence the physiological state of the recipient cells and which may therefore influence transformation and integration efficiencies. For example, the osmotic state, tissue hydration and the subculture stage or cell cycle of the recipient cells may be adjusted for optimum transformation. The execution of other routine adjustments will be known to those of skill in the art in light ofthe present disclosure. The methods of particle-mediated transformation is well-known to those of skill in the art. U. S. Patent 5,015,580 (specifically incorporated herein by reference) describes the transformation of soybeans using such a technique. 5.6.3 AGROBACTERIUM-MEΌIAΎEΌ TRANSFER Agrobacterium-mεdiated transfer is a widely applicable system for introducing genes into plant cells because the DNA can be introduced into whole plant tissues, thereby bypassing the need for regeneration of an intact plant from a protoplast. The use of Agrobαcterium- mediated plant integrating vectors to introduce DNA into plant cells is well known in the art. See, for example, the methods described (Fraley et α , 1985; Rogers et αl, 1987). The genetic engineering of cotton plants using Agrobαcterium-mediated transfer is described in U. S. Patent 5,004,863 (specifically incoφorated herein by reference), while the transformation of lettuce plants is described in U. S. Patent 5,349,124 (specifically incoφorated herein by reference). Further, the integration of the Ti-DNA is a relatively precise process resulting in few rearrangements. The region of DNA to be transferred is defined by the border sequences, and intervening DNA is usually inserted into the plant genome as described (Spielmann et αl. , 1986; Jorgensen et αl., 1987). Modern Agrobacterium transformation vectors are capable of replication in E. coli as well as Agrobacterium, allowing for convenient manipulations as described (Klee et al, 1985). Moreover, recent technological advances in vectors for Agrobacterium-m diated gene transfer have improved the arrangement of genes and restriction sites in the vectors to facilitate construction of vectors capable of expressing various polypeptide coding genes. The vectors described (Rogers et αl., 1987), have convenient multi-linker regions flanked by a promoter and a polyadenylation site for direct expression of inserted polypeptide coding genes and are suitable for present puφoses. In addition, Agrobacterium containing both armed and disarmed Ti genes can be used for the transformations. In those plant strains where Agrobacterium- mediated transformation is efficient, it is the method of choice because of the facile and defined nature ofthe gene transfer. Agrobacterium-nxQdxatQd transformation of leaf disks and other tissues such as cotyledons and hypocotyls appears to be limited to plants that Agrobacterium naturally infects. Agrobacterium-mediated transformation is most efficient in dicotyledonous plants. Few monocots appear to be natural hosts for Agrobacterium, although transgenic plants have been produced in asparagus using Agrobacterium vectors as described (Bytebier et al, 1987). Therefore, commercially important cereal grains such as rice, corn, and wheat must usually be transformed using alternative methods. However, as mentioned above, the transformation of asparagus using Agrobacterium can also be achieved (see, e.g., Bytebier et al, 1987). A transgenic plant formed using Agrobacterium transformation methods typically contains a single gene on one chromosome. Such transgenic plants can be referred to as being heterozygous for the added gene. However, inasmuch as use of the word "heterozygous" usually implies the presence of a complementary gene at the same locus of the second chromosome of a pair of chromosomes, and there is no such gene in a plant containing one added gene as here, it is believed that a more accurate name for such a plant is an independent segregant, because the added, exogenous gene segregates independently during mitosis and meiosis. More preferred is a transgenic plant that is homozygous for the added structural gene; i.e., a transgenic plant that contains two added genes, one gene at the same locus on each chromosome of a chromosome pair. A homozygous transgenic plant can be obtained by sexually mating (selfing) an independent segregant transgenic plant that contains a single added gene, germinating some of the seed produced and analyzing the resulting plants produced for enhanced carboxylase activity relative to a control (native, non-transgenic) or an independent segregant transgenic plant. It is to be understood that two different transgenic plants can also be mated to produce offspring that contain two independently segregating added, exogenous genes. Selfing of appropriate progeny can produce plants that are homozygous for both added, exogenous genes that encode a polypeptide of interest. Back-crossing to a parental plant and out-crossing with a non-transgenic plant are also contemplated. Transformation of plant protoplasts can be achieved using methods based on calcium phosphate precipitation, polyethylene glycol treatment, electroporation, and combinations of these treatments (see, e.g., Potrykus et al, 1985; Lorz et al, 1985; Fromm et al, 1985; Uchimiya et al, 1986; Callis et al, 1987; Marcotte et al, 1988). Application of these systems to different plant strains depends upon the ability to regenerate that particular plant strain from protoplasts. Illustrative methods for the regeneration of cereals from protoplasts are described (see, e.g. , Fujimura et al, 1985; Toriyama t α/., 1986; Yamada et al, 1986; Abdullah et al, 1986). To transform plant strains that cannot be successfully regenerated from protoplasts, other ways to introduce DNA into intact cells or tissues can be utilized. For example, regeneration of cereals from immature embryos or explants can be effected as described (Vasil, 1988). In addition, "particle gun" or high-velocity microprojectile technology can be utilized (Vasil, 1992). Using that latter technology, DNA is carried through the cell wall and into the cytoplasm on the surface of small metal particles as described (Klein et al, 1987; Klein et al, 1988; McCabe et al, 1988). The metal particles penetrate through several layers of cells and thus allow the transformation of cells within tissue explants. 5.6.4 GENE EXPRESSION IN PLANTS The fact that plant codon usage more closely resembles that of humans and other higher organisms than unicellular organisms, such as bacteria, unmodified bacterial genes are often poorly expressed in transgenic plant cells. The apparent overall preference for GC content in codon position three has been described in detail by Murray et al. (1990). The 207 plant genes described in this work permitted the compilation of codon preferences for amino acids in plants. These authors describe the difference between codon usage in monocots and dicots, as well as differences between chloroplast encoded genes and those which are nuclear encoded. Utilizing the codon frequency tables provided, those of skill in the art can engineer such a bacterial sequence for expression in plants by modifying the DNA sequences to provide a codon bias for G or C in the third position. The work by Diehn et al. (1996) details the modification of prokaryot-derived gene sequence to permit expression in plants. lannacone et al. (1997) describe the transformation of egg plant with a genetically engineered B. thuringiensis gene encoding a cry3 class endotoxin. Utilizing sequences which avoid polyadenylation sequences, ATTA sequences, and splicing sites a synthetic gene was constructed which permitted expression of the encoded toxin in planta. Expression of jellyfish green fluorescent protein, in transgenic tobacco has been described by Rouwendal et al. (1997). Using a synthetic gene, the third position codon bias for C+G was created to permit expression ofthe heterologous gene in planta. Fϋtterer and Hohn (1996) describe the effects of mRNA sequence, leader sequences, polycistronic messages, and internal ribosome binding site motis, on expression in plants. Modification of such sequences by construction of synthetic genes permitted expression of viral mRNAs in transgenic plant cells. Although great progress has been made in recent years with respect to preparation of transgenic plants which express bacterial proteins such as B. thuringiensis crystal proteins, the results of expressing native bacterial genes in plants are often disappointing. Unlike microbial genetics, little was known by early plant geneticists about the factors which affected heterologous expression of foreign genes in plants. In recent years, however, several potential factors have been implicated as responsible in varying degrees for the level of protein expression from a particular coding sequence. For example, scientists now know that maintaining a significant level of a particular mRNA in the cell is indeed a critical factor. Unfortunately, the causes for low steady state levels of mRNA encoding foreign proteins are many. First, full length RNA synthesis may not occur at a high frequency. This could, for example, be caused by the premature termination of RNA during transcription or due to unexpected mRNA processing during transcription. Second, full length RNA may be produced in the plant cell, but then processed (splicing, polyA addition) in the nucleus in a fashion that creates a nonfunctional mRNA. If the RNA is not properly synthesized, terminated and polyadenylated, it cannot move to the cytoplasm for translation. Similarly, in the cytoplasm, if mRNAs have reduced half lives (which are determined by their primary or secondary sequence) inisufficient protein product will be produced. In addition, there is an effect, whose magnitude is uncertain, of translational efficiency on mRNA half-life. In addition, every RNA molecule folds into a particular structure, or perhaps family of structures, which is determined by its sequence. The particular structure of any RNA might lead to greater or lesser stability in the cytoplasm. Structure per se is probably also a determinant of mRNA processing in the nucleus. Unfortunately, it is impossible to predict, and nearly impossible to determine, the structure of any RNA (except for tRNA) in vitro or in vivo. However, it is likely that dramatically changing the sequence of an RNA will have a large effect on its folded structure It is likely that structure per se or particular structural features also have a role in determining RNA stability. To overcome these limitations in foreign gene expression, researchers have identified particular sequences and signals in RNAs that have the potential for having a specific effect on RNA stability. In certain embodiments of the invention, therefore, there is a desire to optimize expression of the disclosed nucleic acid segments in planta. One particular method of doing so, is by alteration of the bacterial gene to remove sequences or motifs which decrease expression in a transformed plant cell. The process of engineering a coding sequence for optimal expression in planta is often referred to as "plantizing" a DNA sequence. Particularly problematic sequences are those which are A+T rich. Unfortunately, since B. thuringiensis has an A+T rich genome, native crystal protein gene sequences must often be modified for optimal expression in a plant. The sequence motif ATTTA (or AUUU A as it appears in RNA) has been implicated as a destabilizing sequence in mammalian cell mRNA (Shaw and Kamen, 1986). Many short lived mRNAs have A+T rich 3' untranslated regions, and these regions often have the ATTTA sequence, sometimes present in multiple copies or as multimers (e.g., ATTTATTTA...). Shaw and Kamen showed that the transfer of the 3' end of an unstable mRNA to a stable RNA (globin or VA1) decreased the stable RNA's half life dramatically. They further showed that a pentamer of ATTTA had a profound destabilizing effect on a stable message, and that this signal could exert its effect whether it was located at the 3' end or within the coding sequence. However, the number of ATTTA sequences and/or the sequence context in which they occur also appear to be important in determining whether they function as destabilizing sequences. Shaw and Kamen showed that a trimer of ATTTA had much less effect than a pentamer on mRNA stability and a dimer or a monomer had no effect on stability (Shaw and Kamen, 1987). Note that multimers of ATTTA such as a pentamer automatically create an A+T rich region. This was shown to be a cytoplasmic effect, not nuclear. In other unstable mRNAs, the ATTTA sequence may be present in only a single copy, but it is often contained in an A+T rich region. From the animal cell data collected to date, it appears that ATTTA at least in some contexts is important in stability, but it is not yet possible to predict which occurrences of ATTTA are destabiling elements or whether any of these effects are likely to be seen in plants. Some studies on mRNA degradation in animal cells also indicate that RNA degradation may begin in some cases with nucleolytic attack in A+T rich regions. It is not clear if these cleavages occur at ATTTA sequences. There are also examples of mRNAs that have differential stability depending on the cell type in which they are expressed or on the stage within the cell cycle at which they are expressed. For example, histone mRNAs are stable during DNA synthesis but unstable if DNA synthesis is disrupted. The 3' end of some histone mRNAs seems to be responsible for this effect (Pandey and Marzluff, 1987). It does not appear to be mediated by ATTTA, nor is it clear what controls the differential stability of this mRNA. Another example is the differential stability of IgG mRNA in B lymphocytes during B cell maturation (Genovese and Milcarek, 1988). A final example is the instability of a mutant β-thallesemic globin mRNA. In bone marrow cells, where this gene is normally expressed, the mutant mRNA is unstable, while the wild-type mRNA is stable. When the mutant gene is expressed in HeLa or L cells in vitro, the mutant mRNA shows no instability (Lim et al, 1988). These examples all provide evidence that mRNA stability can be mediated by cell type or cell cycle specific factors. Furthermore this type of instability is not yet associated with specific sequences. Given these uncertainties, it is not possible to predict which RNAs are likely to be unstable in a given cell. In addition, even the ATTTA motif may act differentially depending on the nature of the cell in which the RNA is present. Shaw and Kamen (1987) have reported that activation of protein kinase C can block degradation mediated by ATTTA. The addition of a polyadenylate string to the 3' end is common to most eukaryotic mRNAs, both plant and animal. The currently accepted view of polyA addition is that the nascent transcript extends beyond the mature 3' terminus. Contained within this transcript are signals for polyadenylation and proper 3' end formation. This processing at the 3' end involves cleavage ofthe mRNA and addition of polyA to the mature 3' end. By searching for consensus sequences near the polyA tract in both plant and animal mRNAs, it has been possible to identify consensus sequences that apparently are involved in polyA addition and 3' end cleavage. The same consensus sequences seem to be important to both of these processes. These signals are typically a variation on the sequence AATAAA. In animal cells, some variants of this sequence that are functional have been identified; in plant cells there seems to be an extended range of functional sequences (Wickens and Stephenson, 1984; Dean et al, 1986). Because all of these consensus sequences are variations on AATAAA, they all are A+T rich sequences. This sequence is typically found 15 to 20 bp before the polyA tract in a mature mRNA. Studies in animal cells indicate that this sequence is involved in both polyA addition and 3' maturation. Site directed mutations in this sequence can disrupt these functions (Conway and Wickens, 1988; Wickens et al, 1987). However, it has also been observed that sequences up to 50 to 100 bp 3' to the putative polyA signal are also required; i.e., a gene that has a normal AATAAA but has been replaced or disrupted downstream does not get properly polyadenylated (Gil and Proudfoot, 1984; Sadofsky and Alwine, 1984; McDevitt et al, 1984). That is, the polyA signal itself is not sufficient for complete and proper processing. It is not yet known what specific downstream sequences are required in addition to the polyA signal, or if there is a specific sequence that has this function. Therefore, sequence analysis can only identify potential polyA signals. In naturally occurring mRNAs that are normally polyadenylated, it has been observed that disruption of this process, either by altering the polyA signal or other sequences in the mRNA, profound effects can be obtained in the level of functional mRNA. This has been observed in several naturally occurring mRNAs, with results that are gene-specific so far. It has been shown that in natural mRNAs proper polyadenylation is important in mRNA accumulation, and that disruption of this process can effect mRNA levels significantly. However, insufficient knowledge exists to predict the effect of changes in a normal gene. In a heterologous gene, it is even harder to predict the consequences. However, it is possible that the putative sites identified are dysfunctional. That is, these sites may not act as proper polyA sites, but instead function as aberrant sites that give rise to unstable mRNAs. In animal cell systems, AATAAA is by far the most common signal identified in mRNAs upstream of the polyA, but at least four variants have also been found (Wickens and Stephenson, 1984). In plants, not nearly so much analysis has been done, but it is clear that multiple sequences similar to AATAAA can be used. The plant sites in Table 4 called major or minor refer only to the study of Dean et al. (1986) which analyzed only three types of plant gene. The designation of polyadenylation sites as major or minor refers only to the frequency of their occurrence as functional sites in naturally occurring genes that have been analyzed. In the case of plants this is a very limited database. It is hard to predict with any certainty that a site designated major or minor is more or less likely to function partially or completely when found in a heterologous gene such as those encoding the crystal proteins of the present invention. TABLE 4 POLYADENYLATION SITES IN PLANT GENES PA AATAAA Major consensus site P1A AATAAT Major plant site P2A AACCAA Minor plant site P3A ATATAA P4A AATCAA P5A ATACTA P6A ATAAAA P7A ATGAAA P8A AAGCAT P9A ATTAAT P10A ATACAT P11A AAAATA P12A ATTAAA Minor animal site P13A AATTAA P14A AATACA P15A CATAAA The present invention provides a method for preparing synthetic plant genes which genes express their protein product at levels significantly higher than the wild-type genes which were commonly employed in plant transformation heretofore. In another aspect, the present invention also provides novel synthetic plant genes which encode non-plant proteins. As described above, the expression of native B. thuringiensis genes in plants is often problematic. The nature of the coding sequences of B. thuringiensis genes distinguishes them from plant genes as well as many other heterologous genes expressed in plants. In particular, B. thuringiensis genes are very rich (-62%) in adenine (A) and thymine (T) while plant genes and most other bacterial genes which have been expressed in plants are on the order of 45-55% A+T. Due to the degeneracy of the genetic code and the limited number of codon choices for any amino acid, most of the "excess" A+T of the structural coding sequences of some Bacillus species are found in the third position of the codons. That is, genes of some Bacillus species have A or T as the third nucleotide in many codons. Thus A+T content in part can determine codon usage bias. In addition, it is clear that genes evolve for maximum function in the organism in which they evolve. This means that particular nucleotide sequences found in a gene from one organism, where they may play no role except to code for a particular stretch of amino acids, have the potential to be recognized as gene control elements in another organism (such as transcriptional promoters or terminators, polyA addition sites, intron splice sites, or specific mRNA degradation signals). It is perhaps suφrising that such misread signals are not a more common feature of heterologous gene expression, but this can be explained in part by the relatively homogeneous A+T content (~50%) of many organisms. This A+T content plus the nature of the genetic code put clear constraints on the likelihood of occurrence of any particular oligonucleotide sequence. Thus, a gene from E. coli with a 50% A+T content is much less likely to contain any particular A+T rich segment than a gene from B. thuringiensis. Typically, to obtain high-level expression of the δ-endotoxin genes in plants, existing structural coding sequence ("structural gene") which codes for the δ-endotoxin are modified by removal of ATTTA sequences and putative polyadenylation signals by site directed mutagenesis of the DNA comprising the structural gene. It is most preferred that substantially all the polyadenylation signals and ATTTA sequences are removed although enhanced expression levels are observed with only partial removal of either of the above identified sequences. Alternately if a synthetic gene is prepared which codes for the expression of the subject protein, codons are selected to avoid the ATTTA sequence and putative polyadenylation signals. For pmposes of the present invention putative polyadenylation signals include, but are not necessarily limited to, AATAAA, AATAAT, AACCAA, ATATAA, AATCAA, ATACTA, ATAAAA, ATGAAA, AAGCAT, ATTAAT, ATACAT, AAAATA, ATTAAA, AATTAA, AATACA and CATAAA. In replacing the ATTTA sequences and polyadenylation signals, codons are preferably utilized which avoid the codons which are rarely found in plant genomes. The selected DNA sequence is scanned to identify regions with greater than four consecutive adenine (A) or thymine (T) nucleotides. The A+T regions are scanned for potential plant polyadenylation signals. Although the absence of five or more consecutive A or T nucleotides eliminates most plant polyadenylation signals, if there are more than one of the minor polyadenylation signals identified within ten nucleotides of each other, then the nucleotide sequence of this region is preferably altered to remove these signals while maintaining the original encoded amino acid sequence. The second step is to consider the about 15 to about 30 or so nucleotide residues surrounding the A+T rich region identified in step one. If the A+T content of the surrounding region is less than 80%, the region should be examined for polyadenylation signals. Alteration of the region based on polyadenylation signals is dependent upon (1) the number of polyadenylation signals present and (2) presence of a major plant polyadenylation signal. The extended region is examined for the presence of plant polyadenylation signals. The polyadenylation signals are removed by site-directed mutagenesis of the DNA sequence. The extended region is also examined for multiple copies of the ATTTA sequence which are also removed by mutagenesis. It is also preferred that regions comprising many consecutive A+T bases or G+C bases are disrupted since these regions are predicted to have a higher likelihood to form haiφin structure due to self-complementarity. Therefore, insertion of heterogeneous base pairs would reduce the likelihood of self-complementary secondary structure formation which are known to inhibit transcription and/or translation in some organisms. In most cases, the adverse effects may be minimized by using sequences which do not contain more than five consecutive A+T or G+C. 5.7 PRODUCTION OF INSECT-RESISTANT TRANSGENIC PLANTS Thus, the amount of a gene coding for a polypeptide of interest (i.e., a bacterial crystal protein or polypeptide having insecticidal activity against one or more insect species) can be increased in plant such as com by transforming those plants using particle bombardment methods (Maddock et αl, 1991). By way of example, an expression vector containing a coding region for a B. thuringiensis crystal protein and an appropriate selectable marker is transformed into a suspension of embryonic maize (com) cells using a particle gun to deliver the DNA coated on microprojectiles. Transgenic plants are regenerated from transformed embryonic calli that express the disclosed insecticidal crystal proteins. Particle bombardment has been used to successfully transform wheat (Vasil et αl. , 1992). DNA can also be introduced into plants by direct DNA transfer into pollen as described (Zhou et al, 1983; Hess, 1987; Luo et al, 1988). Expression of polypeptide coding genes can be obtained by injection of the DNA into reproductive organs of a plant as described (Pena et al, 1987). DNA can also be injected directly into the cells of immature embryos and the rehydration of desiccated embryos as described (Neuhaus et al, 1987; Benbrook et al, 1986). The development or regeneration of plants from either single plant protoplasts or various explants is well known in the art (Weissbach and Weissbach, 1988). This regeneration and growth process typically includes the steps of selection of transformed cells, culturing those individualized cells through the usual stages of embryonic development through the rooted plantlet stage. Transgenic embryos and seeds are similarly regenerated. The resulting transgenic rooted shoots are thereafter planted in an appropriate plant growth medium such as soil. The development or regeneration of plants containing the foreign, exogenous gene that encodes a polypeptide of interest introduced by Agrobacterium from leaf explants can be achieved by methods well known in the art such as described (Horsch et al, 1985). In this procedure, transformants are cultured in the presence of a selection agent and in a medium that induces the regeneration of shoots in the plant strain being transformed as described (Fraley et al, 1983). In particular, U. S. Patent 5,349,124 (specification incoφorated herein by reference) details the creation of genetically transformed lettuce cells and plants resulting therefrom which express hybrid crystal proteins conferring insecticidal activity against Lepidopteran larvae to such plants. This procedure typically produces shoots within two to four months and those shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth. Shoots that rooted in the presence of the selective agent to form plantlets are then transplanted to soil or other media to allow the production of roots. These procedures vary depending upon the particular plant strain employed, such variations being well known in the art. Preferably, the regenerated plants are self-pollinated to provide homozygous transgenic plants, as discussed before. Otherwise, pollen obtained from the regenerated plants is crossed to seed-grown plants of agronomically important, preferably inbred lines. Conversely, pollen from plants of those important lines is used to pollinate regenerated plants. A transgenic plant of the present invention containing a desired polypeptide is cultivated using methods well known to one skilled in the art. A transgenic plant of this invention thus has an increased amount of a coding region (e.g., a cry gene) that encodes one or more of the Chimeric Cry polypeptides disclosed herein. A preferred transgenic plant is an independent segregant and can transmit that gene and its activity to its progeny. A more preferred transgenic plant is homozygous for that gene, and transmits that gene to all of its offspring on sexual mating. Seed from a transgenic plant may be grown in the field or greenhouse, and resulting sexually mature transgenic plants are self- pollinated to generate true breeding plants. The progeny from these plants become true breeding lines that are evaluated for, by way of example, increased insecticidal capacity against Coleopteran insects, preferably in the field, under a range of environmental conditions. The inventors contemplate that the present invention will find particular utility in the creation of transgenic corn, soybeans, cotton, tobacco, tomato, potato, flax, rye, barley, canola, wheat, oats, rice, other grains, vegetables, fruits, fruit trees, berries, turf grass, ornamentals, shrubs and trees. 5.8 RIBOZYMES Ribozymes are enzymatic RNA molecules which cleave particular mRNA species. In certain embodiments, the inventors contemplate the selection and utilization of ribozymes capable of cleaving the RNA segments ofthe present invention, and their use to reduce activity of target mRNAs in particular cell types or tissues. Six basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds in trans (and thus can cleave other RNA molecules) under physiological conditions. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets. The enzymatic nature of a ribozyme is advantageous over many technologies, such as antisense technology (where a nucleic acid molecule simply binds to a nucleic acid target to block its translation) since the concentration of ribozyme necessary to affect a therapeutic treatment is lower than that of an antisense oligonucleotide. This advantage reflects the ability ofthe ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base- substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme. Similar mismatches in antisense molecules do not prevent their action (Woolf et al, 1992). Thus, the specificity of action of a ribozyme is greater than that of an antisense oligonucleotide binding the same RNA site. The enzymatic nucleic acid molecule may be formed in a hammerhead, haiφin, a hepatitis δ virus, group I intron or RNaseP RNA (in association with an RNA guide sequence) or Neurospora VS RNA motif. Examples of hammerhead motifs are described by Rossi et al. (1992); examples of haiφin motifs are described by Hampel et al. (Eur. Pat. EP 0360257), Hampel and Tritz (1989), Hampel et al. (1990) and Cech et al. (U. S. Patent 5,631,359; an example of the hepatitis δ vims motif is described by Perrotta and Been (1992); an example of the RNaseP motif is described by Guerrier-Takada et al. (1983); Neurospora VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990; Saville and Collins, 1991; Collins and Olive, 1993); and an example of the Group I intron is described by Cech et al. (U.S. Patent 4,987,071). All that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule. Thus the ribozyme constmcts need not be limited to specific motifs mentioned herein. The invention provides a method for producing a class of enzymatic cleaving agents which exhibit a high degree of specificity for the RNA of a desired target. The enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of a target mRNA such that specific treatment of a disease or condition can be provided with either one or several enzymatic nucleic acids. Such enzymatic nucleic acid molecules can be delivered exogenously to specific cells as required. Alternatively, the ribozymes can be expressed from DNA or RNA vectors that are delivered to specific cells. Small enzymatic nucleic acid motifs (e.g., of the hammerhead or the haiφin structure) may be used for exogenous delivery. The simple structure of these molecules increases the ability of the enzymatic nucleic acid to invade targeted regions of the mRNA structure. Alternatively, catalytic RNA molecules can be expressed within cells from eukaryotic promoters (e.g., Scanlon et al, 1991 ; Kashani-Sabet et al, 1992; Dropulic et al, 1992; Weerasinghe et al, 1991; Ojwang et al, 1992; Chen et al, 1992; Sarver et al, 1990). Those skilled in the art realize that any ribozyme can be expressed in eukaryotic cells from the appropriate DNA vector. The activity of such ribozymes can be augmented by their release from the primary transcript by a second ribozyme (Draper et al, Int. Pat. Appl. Publ. No. WO 93/23569, and Sullivan et al, Int. Pat. Appl. Publ. No. WO 94/02595, both hereby incoφorated in their totality by reference herein; Ohkawa et al, 1992; Taira et al, 1991; Ventura et al, 1993). Ribozymes may be added directly, or can be complexed with cationic lipids, lipid complexes, packaged within liposomes, or otherwise delivered to target cells. The RNA or RNA complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, aerosol inhalation, infusion pump or stent, with or without their incoφoration in biopolymers. Ribozymes may be designed as described in Draper et al. (Int. Pat. Appl. Publ. No. WO 93/23569), or Sullivan et al, (Int. Pat. Appl. Publ. No. WO 94/02595) and synthesized to be tested in vitro and in vivo, as described. Such ribozymes can also be optimized for delivery. While specific examples are provided, those in the art will recognize that equivalent RNA targets in other species can be utilized when necessary. Hammerhead or haiφin ribozymes may be individually analyzed by computer folding (Jaeger et al, 1989) to assess whether the ribozyme sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular interactions between the binding arms and the catalytic core are eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity. Generally, at least 5 bases on each arm are able to bind to, or otherwise interact with, the target RNA. Ribozymes of the hammerhead or hairpin motif may be designed to anneal to various sites in the mRNA message, and can be chemically synthesized. The method of synthesis used follows the procedure for normal RNA synthesis as described in Usman et al. (1987) and in Scaringe et al. (1990) and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. Average stepwise coupling yields are typically >98%. Haiφin ribozymes may be synthesized in two parts and annealed to reconstruct an active ribozyme (Chowrira and Burke, 1992). Ribozymes may be modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-flouro, 2'-o-methyl, 2'-H (for a review s Usman and Cedergren, 1992). Ribozymes may be purified by gel electrophoresis using general methods or by high pressure liquid chromatography and resuspended in water. Ribozyme activity can be optimized by altering the length of the ribozyme binding arms, or chemically synthesizing ribozymes with modifications that prevent their degradation by serum ribonucleases (see e.g., Int. Pat. Appl. Publ. No. WO 92/07065; Perrault et al, 1990; Pieken et al, 1991 ; Usman and Cedergren, 1992; Int. Pat. Appl. Publ. No. WO 93/15187; Int. Pat. Appl. Publ. No. WO 91/03162; U.S. Patent 5,334,711 ; and Int. Pat. Appl. Publ. No. WO 94/13688, which describe various chemical modifications that can be made to the sugar moieties of enzymatic RNA molecules), modifications which enhance their efficacy in cells, and removal of stem II bases to shorten RNA synthesis times and reduce chemical requirements. Sullivan et al. (Int. Pat. Appl. Publ. No. WO 94/02595) describes the general methods for delivery of enzymatic RNA molecules. Ribozymes may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incoφoration into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, ribozymes may be directly delivered ex vivo to cells or tissues with or without the aforementioned vehicles. Alternatively, the RNA/vehicle combination may be locally delivered by direct inhalation, by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of ribozyme delivery and administration are provided in Sullivan et al. (Int. Pat. Appl. Publ. No. WO 94/02595) and Draper et al. (Int. Pat. Appl. Publ. No. WO 93/23569) which have been incoφorated by reference herein. Another means of accumulating high concentrations of a ribozyme(s) within cells is to incoφorate the ribozyme-encoding sequences into a DNA expression vector. Transcription of the ribozyme sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters may also be used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990; Gao and Huang, 1993; Lieber et al, 1993; Zhou et al, 1990). Ribozymes expressed from such promoters can function in mammalian cells (e.g. Kashani- Saber et al, 1992; Ojwang et al, 1992; Chen et al, 1992; Yu et al, 1993; LΗuillier et al, 1992; Lisziewicz et al, 1993). Such transcription units can be incoφorated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated vectors), or viral RNA vectors (such as retroviral, semliki forest vims, sindbis vims vectors). Ribozymes of this invention may be used as diagnostic tools to examine genetic drift and mutations within cell lines or cell types. They can also be used to assess levels of the target RNA molecule. The close relationship between ribozyme activity and the stmcture of the target RNA allows the detection of mutations in any region ofthe molecule which alters the base-pairing and three-dimensional stmcture of the target RNA. By using multiple ribozymes described in this invention, one may map nucleotide changes which are important to RNA stmcture and function in vitro, as well as in cells and tissues. Cleavage of target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in particular cells or cell types. 5.9 ISOLATING HOMOLOGOUS GENE AND GENE FRAGMENTS The genes and δ-endotoxins according to the subject invention include not only the full length sequences disclosed herein but also fragments of these sequences, or fusion proteins, which retain the characteristic insecticidal activity of the sequences specifically exemplified herein. It should be apparent to a person skill in this art that insecticidal δ-endotoxins can be identified and obtained through several means. The specific genes, or portions thereof, may be obtained from a culture depository, or constmcted synthetically, for example, by use of a gene machine. Variations of these genes may be readily constructed using standard techniques for making point mutations. Also, fragments of these genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as BaB or site-directed mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Also, genes which code for active fragments may be obtained using a variety of other restriction enzymes. Proteases may be used to directly obtain active fragments of these δ-endotoxins. Equivalent δ-endotoxins and/or genes encoding these equivalent δ-endotoxins can also be isolated from Bacillus strains and/or DNA libraries using the teachings provided herein. For example, antibodies to the δ-endotoxins disclosed and claimed herein can be used to identify and isolate other δ-endotoxins from a mixture of proteins. Specifically, antibodies may be raised to the portions ofthe δ-endotoxins which are most constant and most distinct from other B. thuringiensis δ-endotoxins. These antibodies can then be used to specifically identify equivalent δ-endotoxins with the characteristic insecticidal activity by immunoprecipitation, enzyme linked immunoassay (ELISA), or Western blotting. A further method for identifying the δ-endotoxins and genes of the subject invention is through the use of oligonucleotide probes. These probes are nucleotide sequences having a detectable label. As is well known in the art, if the probe molecule and nucleic acid sample hybridize by forming a strong bond between the two molecules, it can be reasonably assumed that the probe and sample are essentially identical. The probe's detectable label provides a means for determining in a known manner whether hybridization has occurred. Such a probe analysis provides a rapid method for identifying formicidal δ-endotoxin genes of the subject invention. The nucleotide segments which are used as probes according to the invention can be synthesized by use of DNA synthesizers using standard procedures. In the use of the nucleotide segments as probes, the particular probe is labeled with any suitable label known to those skilled in the art, including radioactive and non-radioactive labels. Typical radioactive labels include P, I, 5 S, or the like. A probe labeled with a radioactive isotope can be constructed from a nucleotide sequence complementary to the DNA sample by a conventional nick translation reaction, using a DNase and DNA polymerase. The probe and sample can then be combined in a hybridization buffer solution and held at an appropriate temperature until annealing occurs. Thereafter, the membrane is washed free of extraneous materials, leaving the sample and bound probe molecules typically detected and quantified by autoradiography and/or liquid scintillation counting. Non-radioactive labels include, for example, ligands such as biotin or thyroxine, as well as enzymes such as hydrolases or peroxidases, or the various chemiluminescers such as luciferin, or fluorescent compounds like fluorescein and its derivatives. The probe may also be labeled at both ends with different types of labels for ease of separation, as, for example, by using an isotopic label at the end mentioned above and a biotin label at the other end. Duplex formation and stability depend on substantial complementarity between the two strands of a hybrid, and, as noted above, a certain degree of mismatch can be tolerated. Therefore, the probes of the subject invention include mutations (both single and multiple), deletions, insertions of the described sequences, and combinations thereof, wherein said mutations, insertions and deletions permit formation of stable hybrids with the target polynucleotide of interest. Mutations, insertions, and deletions can be produced in a given polynucleotide sequence in many ways, by methods currently known to an ordinarily skilled artisan, and perhaps by other methods which may become known in the future. The potential variations in the probes listed is due, in part, to the redundancy of the genetic code. Because of the redundancy of the genetic code, i.e., more than one coding nucleotide triplet (codon) can be used for most of the amino acids used to make proteins. Therefore different nucleotide sequences can code for a particular amino acid. Thus, the amino acid sequences of the B. thuringiensis δ-endotoxins and peptides can be prepared by equivalent nucleotide sequences encoding the same amino acid sequence of the protein or peptide. Accordingly, the subject invention includes such equivalent nucleotide sequences. Also, inverse or complement sequences are an aspect ofthe subject invention and can be readily used by a person skilled in this art. In addition it has been shown that proteins of identified structure and function may be constructed by changing the amino acid sequence if such changes do not alter the protein secondary structure (Kaiser and Kezdy, 1984). Thus, the subject invention includes mutants of the amino acid sequence depicted herein which do not alter the protein secondary stmcture, or if the structure is altered, the biological activity is substantially retained. Further, the invention also includes mutants of organisms hosting all or part of a δ-endotoxin encoding a gene of the invention. Such mutants can be made by techniques well known to persons skilled in the art. For example, UV irradiation can be used to prepare mutants of host organisms. Likewise, such mutants may include asporogenous host cells which also can be prepared by procedures well known in the art. 6.0 EXAMPLES The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope ofthe invention. 6.1 EXAMPLE 1 ~ CONSTRUCTION OF HYBRID B. THURINGIENSIS δ-ENDθτoxiNS The B. thuringiensis shuttle vectors pEG853, pEG854, and pEG857 which are used in the present invention have been described (Baum et al, 1990). pEG857 contains the Cryl Ac gene cloned into pEG853 as an Sphl-BamHl DNA fragment. pEG1064 was constructed in such a way that the Kpnl site within the cryl Ac gene was preserved and the Kpnl site in the pEG857 multiple cloning site (MCS) was eliminated. This was accomplished by sequentially subjecting pEG857 DNA to limited Kpnl digestion so that only one Kpnl site is cut, filling in the Kpnl 5' overhang by Klenow fragment of DNA polymerase I to create blunt DNA ends, and joining the blunt ends of DNA by T4 DNA ligase. pEG318 contains the cry IF gene (Chambers et al, 1991) cloned into the Xhol site of pEG854 as an Xhol-Sa . DNA fragment. pEG315 contains the crylC gene from strain EG6346 (Chambers et al, 1991) cloned into the Xhol-BamEl sites of pEG854 as a Sall-BamHl DNA fragment. FIG. 1A shows a schematic representation of the DNA encoding the complete cryl Ac, crylAb, crylC, and crylF genes contained on pEG854/pEG1064, pEG20, pEG315, and pEG318, respectively. Unique restriction sites that were used in constmcting certain hybrid genes are also shown. FIG. IB shows a schematic representation of hybrid genes pertaining to the present invention. In some cases standard PCR™ amplification with mutagenic oligonucleotide primers were used to incoφorate appropriate restrictions sites into DNA fragments used for hybrid gene construction. Certain hybrid gene constmctions could not be accomplished by restriction fragment subcloning. In those instances, PCR™ overlap extension (POE) was used to constmct the desired hybrid gene (Horton et al, 1989). The following oligonucleotide primers (purchased from Integrated DNA Technologies Inc., Coralville, IA) were used: Primer A 5'-GGATAGCACTCATCAAAGGTACC-3' (SEQ ID NO:l) Primer B 5'-GAAGATATCCAATTCGAACAGTTTCCC-3' (SEQ ID NO:2) Primer C 5'-CATATTCTGCCTCGAGTGTTGCAGTAAC-3' (SEQ ID NO : 3 ) Primer D 5'-CCCGATCGGCCGCATGC-3' (SEQ ID NO: 4) Primer E 5'-CATTGGAGCTCTCCATG-3' (SEQ ID NO: 5) Primer F 5'-GCACTACGATGTATCC-3' (SEQ ID NO: 6) Primer G 5'-CATCGTAGTGCAACTCTTAC-3' (SEQ ID NO: 7) Primer H 5'-CCAAGAAAATACTAGAGCTCTTGTTAAAAAAGGTGTTCC-3' (SEQ ID NO: Primer I 5'-ATTTGAGTAATACTATCC-3' (SEQ ID NO:23) Primer J 5'-ATTACTCAAATACCATTGG-3' (SEQ ID NO: 24) Primer K 5'-TCGTTGCTCTGTTCCCG-3' (SEQ ID NO: 31) The plasmids described in FIG. IB containing the hybrid δ-endotoxin genes pertinent to this invention are described below. Isolation or purification of DNA fragments generated by restriction of plasmid DNA, PCR™ amplification, or POE refers to the sequential application of agarose-TAE gel electrophoresis and use of the Geneclean Kit (Bio 101) following the manufacturer's recommendation. pEG1065 was constmcted by PCR™ amplification of the cry IF DNA fragment using primer pair A and B and pEG318 as the DNA template. The resulting PCR™ product was isolated, cut with Asull and Kpnl, and used to replace the corresponding Asull-Kpnl DNA fragment in pEG857. Plasmid pEG1067 was constructed using POE and DNA fragments Saul-Kpnl of crylF and Asull-Clal of cryl Ac that were isolated from pEG318 and pEG857, respectively. The resulting POE product was PCR™ amplified with primer pair A and B, cut with Asull and Kpnl, and used to replace the corresponding Asull-Kpnl fragment in pEG857. pEG1068 was constmcted by replacing the Sacl-Kpnl DNA fragment of crylAc isolated from pEG857 with the corresponding Sacl-Kpnl DNA fragment isolated from crylF (pEG318). pEG1070 was constmcted by replacing the Sacl-Kpnl DNA fragment isolated from pEG1065 with the corresponding Sacl-Kpnl DNA fragment isolated from cryl Ac (pEG857). pEG1072 was constmcted by replacing the Sacl-Kpnl DNA fragment isolated from pEG1067 with the corresponding Sacl-Kpnl DNA fragment isolated from cryl Ac (pEG857). pEG1074, pEG1076, and pEG1077 were constmcted by replacing the Sphl-Xhol DNA fragment from pEG1064 with the PCR™ amplified Sphl-Xhol DNA fragment from pEG1065, pEG1067, pEG1068, respectively, using primer pairs C and D. pEG1089 was constmcted by replacing the Sphl-Sacl DNA fragment of pEG1064 with the isolated and Sphl and Sad cut PCR™ product of cry IF that was generated using primer pair D and E and the template pEG318. pEG1091 was constmcted by replacing the Sphl-Sacl DNA fragment of pEG1064 with the isolated and Sphl and Sad cut PCR™ product of crylC that was generated using primer pair D and H and the template pEG315. pEG1088 was constmcted by POE using a cryl Ac DNA fragment generated using primer pair B and F and a crylC DNA fragment generated using primer pair A and G. The Sacl-Kpnl fragment was isolated from the resulting POE product and used to replace the corresponding Sacl-Kpnl fragment in pEG1064. pEG365 was constmcted by first replacing the Sph -Kpn DNA fragment from pEG1065 with the corresponding crylAb DNA fragment isolated from pEG20 to give pEG364. The Sacl-Kpnl DNA fragment from pEG364 was then replaced with the corresponding cry IF DNA fragment isolated from pEG318. pEG1092 was constmcted by replacing the Kpnl-BamRl DNA fragment from pEG1088 with the corresponding DNA fragment isolated from pEG315. pEG1092 is distinct from the crylAb/crylC hybrid δ-endotoxin gene disclosed in Intl. Pat. Appl. Publ. No. WO 95/06730. pEG1093 was constmcted by replacing the Sphl-Asull DNA fragment from pEG1068 with the corresponding Sphl-Asull DNA fragment isolated from pEG20. pEG378 was constructed by POE using a cryl Ac DNA fragment generated using primer pair B and I using pEG857 as the template and a cry IF DNA fragment generated using primer pair A and J using pEG318 as the template. The resulting POE product was cut with Asull and Kpnl and the resulting isolated DNA fragment used to replace the corresponding Asull-Kpnl DNA fragment in pEG1064. pEG381 was constmcted by replacing the Asull-Xhol DNA fragment in pEG1064 with the corresponding Asull-Xhol DNA fragment isolated from the PCR™ amplification of pEG378 using primer pair C and K. 6.2 EXAMPLE 2 ~ PRODUCTION OF THE HYBRID TOXINS IN B. THURINGIENSIS The plasmids encoding the hybrid toxins described in Example 1 were transformed into B. thuringiensis as described (Mettus and Macaluso, 1990). The resulting B. thuringiensis strains were grown in 50 ml of C-2 medium until the culture was fully sporulated and lysed (approximately 48 hr.). Since crystal formation is a prerequisite for efficient commercial production of δ-endotoxins in B. thuringiensis, microscopic analysis was used to identify crystals in the sporulated cultures (Table 5). TABLE 5 CRYSTAL FORMATION BY THE HYBRID O-ENDOTOXINS Strain Plasmid Parent δ-Endotoxins Crystal Formation EGl 1060 pEG1065 CrylAc + CrylF + EGl 1062 pEG1067 CrylAc + CrylF + EGl 1063 pEG1068 CrylAc + CrylF + EGl 1065 pEG1070 CrylAc + CrylF - EGl 1067 pEG1072 CrylAc + CrylF - EGl 1071 pEG1074 CrylAc + CrylF + EGl 1073 pEG1076 CrylAc + CrylF + EGl 1074 pEG1077 CrylAc + CrylF + EGl 1087 pEG1088 CrylAc + CrylC - EGl 1088 pEG1089 CrylF + Cryl Ac - EGl 1090 pEG1091 CrylC + CrylAc - EGl 1091 pEG1092 CrylAc + CrylC + EGl 1092 pEG1093 CrylAb + CrylAc + CrylF + EGl 1735 pEG365 CrylAb + CrylF + Cryl Ac + EG11751 pEG378 CrylAc + CrylF + EGl 1768 pEG381 — CrylAc + CrylF + The δ-endotoxin production for some ofthe B. thuringiensis strains specified in Table 5 was examined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described by Baum et al, 1990. Equal volume cultures of each B. thuringiensis strain were grown in C-2 medium until fully spomlated and lysed. The cultures were centrifuged and the spore/crystal pellet was washed twice with equal volumes of distilled deionized water. The final pellet was suspended in half the culture volume of 0.005%> Triton X-100 ® . An equal volume of each washed culture was analyzed by SDS-PAGE as shown in FIG. 2. The majority of hybrids involving Cryl Ac and CrylF formed stable crystals in B. thuringiensis A notable exception is EGl 1088 in which the active toxin fragment would be the reciprocal exchange of EGl 1063. Two of the three hybrids involving CrylAc and CrylC, EGl 1087 and EGl 1090, failed to produce crystal in B. thuringiensis even though these reciprocal hybrids mimic the activated toxin fragments of crystal-forming EGl 1063 and EGl 1074. Every strain that was examined by SDS-PAGE produced some level of δ-endotoxin. As expected, however, those cultures identified as crystal negative produced very little protein (e.g., lane e: EGl 1065, lane f: EGl 1067, lane j: EGl 1088, and lane k: EGl 1090). For reference, typical yields from a crystal forming δ-endotoxin is shown for Cryl Ac (lane a). Several hybrid δ-endotoxins produce comparable levels of protein including EGl 1060 (lane b), EGl 1062 (lane c), EGl 1063 (lane d; SEQ ID NO: 10), and EGl 1074 (lane i; SEQ ID NO: 12). The data clearly show that efficient hybrid δ-endotoxin production in B. thuringiensis is unpredictable and varies depending on the parent δ-endotoxins used to construct the hybrid. 6.3 EXAMPLE 3 — PROTEOLYTIC PROCESSING OF THE HYBRID O-ENDOTOXINS Proteolytic degradation of the protoxin form of the δ-endotoxin to a stable active toxin occurs once δ-endotoxin crystals are solubilized in the larval midgut. One measure of the potential activity of δ-endotoxins is the stability of the active δ-endotoxin in a proteolytic environment. To test the proteolytic sensitivity of the hybrid δ-endotoxins, solubilized toxin was subjected to trypsin digestion. The δ-endotoxins were purified from spomlated B. thuringiensis cultures and quantified as described (Chambers et al, 1991). Exactly 250 μg of each hybrid δ-endotoxin crystal was solubilized in 30 mM NaHCO 3 , 10 mM DTT (total volume 0.5 ml). Trypsin was added to the solubilized toxin at a 1:10 ratio. At appropriate time points 50 μl aliquots were removed to 50 μl Laemmli buffer, heated to 100°C for 3 min., and frozen in a dry-ice ethanol bath for subsequent analysis. The trypsin digests of the solubilized toxins were analyzed by SDS-PAGE and the amount of active δ-endotoxin at each time point was quantified by densitometry. A graphic representation of the results from these studies are shown in FIG. 3. The wild-type Cryl Ac is rapidly processed to the active δ-endotoxin fragment that is stable for the duration of the study. The hybrid δ-endotoxins from EGl 1063 and EGl 1074 are also processed to active δ-endotoxin fragments which are stable for the duration of the study. The processing of the EGl 1063 δ-endotoxin occurs at a slower rate and a higher percentage of this active δ-endotoxin fragment remains at each time point. Although the hybrid δ-endotoxins from EGl 1060 and EGl 1062 are process to active δ-endotoxin fragments, these fragments are more susceptible to further cleavage and degrade at various rates during the course of the study. The 5' exchange points between crylAc and crylF for the EGl 1062 and EGl 1063 δ-endotoxins result in toxins that differ by only 21 amino acid residues (see FIG. 1). However, the importance of maintaining CrylAc sequences at these positions is evident by the more rapid degradation of the EG 11062 δ-endotoxin. These data demonstrate that different hybrid δ-endotoxins constructed using the same parental δ-endotoxins can vary significantly in biochemical characteristics such as proteotytic stability. 6.4 EXAMPLE 4 ~ BIOACTIVITY OF THE HYBRID O-ENDOTOXINS B. thuringiensis cultures expressing the desired δ-endotoxin were grown until fully spomlated and lysed and washed as described in Example 2. The δ-endotoxin levels for each culture were quantified by SDS-PAGE as described (Baum et al, 1990). In the case of bioassay screens, a single appropriate concentration of each washed δ-endotoxin culture was topically applied to 32 wells containing 1.0 ml artificial diet per well (surface area of 175 mm ). A single neonate larvae was placed in each of the treated wells and the tray covered by a clear perforated mylar sheet. Larvae mortality was scored after 7 days of feeding and percent mortality expressed as the ratio of the number of dead larvae to the total number of larvae treated, 32. In the case of LC 50 determinations (δ-endotoxin concentration giving 50% mortality), δ-endotoxins were purified from the B. thuringiensis cultures and quantified as described by Chambers et al. (1991). Eight concentrations of the δ-endotoxins were prepared by serial dilution in 0.005% Triton X-100 and each concentration was topically applied to wells containing 1.0 ml of artificial diet. Larvae mortality was scored after 7 days of feeding (32 larvae for each δ-endotoxin concentration). In all cases the diluent served as the control. A comparison ofthe Cryl A/Cry IF hybrid toxins by bioassay screens is shown in Table 6. The hybrid δ-endotoxins from strains EGl 1063 and EGl 1074 maintain the activities of the parental CrylAc and CrylF δ-endotoxins. Furthermore, the hybrid δ-endotoxin from EGl 1735 maintains the activity of its parental CrylAb and CrylF δ-endotoxins. The δ-endotoxins produce by strains EGl 1061, EGl 1062, EGl 1071, and EGl 1073 have no insecticidal activity on the insect larvae tested despite 1) being comprised of at least one parental δ-endotoxin that is active against the indicated larvae and 2) forming stable, well-defined crystals in B. thuringiensis These results demonstrate the unpredictable nature of hybrid toxin constructions. For the data in Table 6. All strains were tested as washed spomlated cultures. For each insect tested, equivalent amounts of δ-endotoxins were used and insecticidal activity was based on the strain showing the highest percent mortality (++++). TABLE 6 BIOASSAY SCREENS OF HYBRID CRYIA/CRYIF 6-ENDOTOXINS Strain S. frugiperda S. exigua H. virescens H. zea O. nubilalis CrylAc - - ++++ ++++ +++ CrylF ++ ++ ++ ++ CrylAb ++ + +++ ++ +++ EGl 1060 - - - - - EGl 1062 - - - - - EGl 1063 ++++ +++ +++ EGl 1071 - - - - - EGl 1073 - - - - - EGl 1074 ++++ +++ +++ ++++ EGl 1090 - +++ - - - EGl 1091 1 1 1 1 - - N.D. EGl 1092 ++++ ++++ +++ +++ N.D. EGl 1735 ++++ +++ +++ N.D. EGl 1751 N.D. a N.D. ++++ N.D. "N.D. = not determined. The δ-endotoxins described in FIG. 1 and that demonstrated insecticidal activity in bioassay screens were tested as purified crystals to determine their LC 50 (see Table 7). The δ-endotoxins purified from strains EGl 1063, EGl 1074, EGl 1091, and EGl 1735 all show increased armyworm (S. frugiperda and S. exigua) activity compared to any of the wild-type δ-endotoxins tested. The EGl 1063 and EGl 1074 δ-endotoxins would yield identical active toxin fragments (FIG. IB) which is evident by their similar LC50 values on the insects examined. An unexpected result evident from these data is that a hybrid δ-endotoxin such as EGl 1063, EGl 1092, EGl 1074, EGl 1735, or EGl 1751 can retain the activity of their respective parental δ-endotoxins, and, against certain insects such as S. exigua, can have activity far better than either parental δ-endotoxin. This broad range of insecticidal activity at doses close to or lower than the parental δ-endotoxins, along with the wild-type level of toxin production (Example 2), make these proteins particularly suitable for production in B. thuringiensis. Although the EGl 1091 derived δ-endotoxin has better activity against S. frugiperda and 5". exigua than its parental δ-endotoxins, it has lost the H virescens and H zea activity attributable to its CrylAc parent. This restricted host range along with lower toxin yield observed for the EGl 1091 δ-endotoxin (Example 2) make it less amenable to production in B. thuringiensis. TABLE 7 LC '™50 VALUES FOR THE PURIFIED HYBRID 6-ENDOTOXIN A Toxin S. frugiperda S. exigua H. virescens H zea O. nubilalis CrylAc >10000 > 10000 9 100 23 CrylAb 1435 4740 118 400 17 CrylC >10000 490 >10000 > 10000 >10000 CrylF 1027 3233 54 800 51 EGl 1063 550 114 33 80 7 (Cryl Ac/1 F) EGl 1074 468 77 25 76 9 (CrylAc/lF) EGl 1091 21 21 219 >10000 N.D. a (CrylAc/lC) "N.D^not determined. In Table 7, the LC 50 values are expressed in nanograms of purified δ-endotoxin per well (175 mm 2 ) and are the composite values for 2 to 6 replications, nd = not determined. TABLE 8 DNA EXCHANGE SITES FOR CRYI HYBRID δ-ENDθτoxiNS Plasmid SEQ ID NO: 5' Exchange Site SEQ ID NO: 3' Exchange Site pEG1065 15 TATCCAATTCGAACGTCATC 21 ACTACCAGGTACCTTTGATG pEG1067 16 TTTAGTCATCGATTAAATCA 21 ACTACCAGGTACCTTTGATG pEG1068 17 ATAATAAGAGCTCCAATGTT 21 ACTACCAGGTACCTTTGATG pEG1070 15 TATCCAATTCGAACGTCATC 19 TCATGGAGAGCTCCTATGTT pEG1072 16 TTTAGTCATCGATTAAATCA 19 TCATGGAGAGCTCCTATGTT pEG1074 15 TATCCAATTCGAACGTCATC 35 TGCAACACTCGAGGCTGAAT pEG1076 16 TTTAGTCATCGATTAAATCA 35 TGCAACACTCGAGGCTGAAT pEG1077 17 ATAATAAGAGCTCCAATGTT 35 TGCAACACTCGAGGCTGAAT pEG1088 18 TACATCGTAGTGCAACTCTT 22 ACTACCGGGTACCTTTGATA pEG1089 19 TCATGGAGAGCTCCTATGTT - NA pEG1091 20 TTAACAAGAGCTCCTATGTT - NA pEG1092 18 TACATCGTAGTGCAACTCTT - NA pEG1093 - ND b 21 ACTACCAGGTACCTTTGATG pEG365 17 ATAATAAGAGCTCCAATGTT 21 ACTACCAGGTACCTTTGATG pEG378 32 TCAAATACCATTGGTAAAAG 21 ACTACCAGGTACCTTTGATG pEG381 32 TCAAATACCATTGGTAAAAG 35 TGCAACACTCGAGGCTGAAT NA= Not Applicable. These hybrid toxins contain only one exchange site as shown in FIG. 1. TSfD = Not Distinguishable. The exchange site for these hybrid proteins are identified by DNA sequences that are not distinguishable from either ofthe parent toxins. 8,1 Table 8 describes the DNA surrounding the 5' and 3' exchange points for the hybrid δ-endotoxins which are pertinent to the present invention. As evident by the SEQ ID NO, certain hybrid δ-endotoxins share exchange sites. To examine the effect of other small changes in the exchange site chosen for hybrid endotoxin construction, the activity of EGl 1751 and EGl 1063 on S. exigua and H zea were compared (Table 9). The data clearly show that hybrid δ-endotoxin improvements can be made by altering the exchange site between the two parental δ-endotoxins. In this example, the exchange site in the EG 11751 δ-endotoxin was moved 75 base pairs 3' compared to the EGl 1063 δ-endotoxin and results in improved insecticidal activity. Although no significant improvement in S. exigua activity is observed between EGl 1063 and EGl 1751, a significant improvement in H zea activity of almost 4-fold is observed for EGl 1751. It is important to note that improvements in hybrid δ-endotoxin bioactivity by altering exchange sites is unpredictable. In the case of EGl 1062, moving the exchange site 63 base pairs 5' of the EGl 1063 exchange site abolishes insecticidal activity as shown in Table 8. TABLE 9 BIOACTIVITY OF EG11063 AND EG11751 B. thuringiensis Strain LC 50 Values for Washed Sporulated Cultures S. exigua H. zea EGl 1063 106 38 EGl 1751 90 10 To further examine the effect of changes in the exchange site for hybrid δ-endotoxins, the hybrid δ-endotoxin encoded by pEG381 was compared to those encoded by pEG378 and pEG1068. In this example, the 3' exchange site for the pEG381 encoded hybrid δ-endotoxin was moved 340 base pairs 5' compared to the pEG378 hybrid δ-endotoxin. The data in Table 9 show that this change results in an increase in S. frugiperda activity compared to the pEG378 and pEG1066 encoded δ-endotoxins while maintaining the increased activity that was observed for the pEG378 encoded δ-endotoxin over the pEG1068 encoded δ-endotoxin (see Table 8). This result is unexpected since the activated toxin resulting from the proteo lysis ofthe encoded δ-endotoxins from pEG378 and pEG381 should be identical. This example further demonstrates that exchange sites within the protoxin fragment of δ-endotoxins can have a profound effect on insecticidal activity. TABLE 10 BIOACTIVITY OF TOXINS ENCODED BY PEG378, PEG381 AND PEG1068 Plasmid LC 5( , Values for Purified Crystals S. frugiperda T. ni H. zea P. xylostella pEG378 464 57.7 37.5 3.02 pEG381 274 56.0 36.6 2.03 pEG1068 476 66.7 72.7 3.83 6.5 EXAMPLE 5 - ACTIVITY OF THE HYBRID TOXINS ON ADDITIONAL PESTS The toxins ofthe present invention were also assayed against additional pests, including the southwestern corn borer and two pests active against soybean. Toxin proteins were solubilized, added to diet and bioassayed against target pests. The hybrid toxins showed very effective control of all three pests. TABLE 11 LC 50 AND EC 50 RANGES OF HYBRID TOXINS ON SOUTHWESTERN CORN BORER 1 ' 2 EG11063 EG11074 EG11091 EG11751 LC 50 20 10-20 10-20 10-20 EC 50 0.2-2 0.2-2 0.2-2 0.2-2 All values are expressed in μg/ml of diet. SWCB data ranges represent LC 50 and EC 50 ranges (as determined by % >lst instar), respectively. TABLE 12 LC 50 VALUES OF CHIMERIC CRYSTAL PROTEINS ON SOYBEAN PESTS 1 Pest EG11063 EG11074 EG11091 EG11751 EG11768 Velvetbean caterpillar 1 09 06 03 OΪ O06 Soybean looper 0.9 0.8 0.6 0.7 0.2 All values are expressed in μg/ml of diet. Velvetbean caterpillar (Anticarsia gemmatalis) and soybean looper (Psuedoplusi includens) are both members ofthe family Noctuidae. 6.6 EXAMPLE 6 ~ AMINO ACID SEQUENCES OF THE NOVEL CRYSTAL PROTEINS 6.6.1 AMINO ACID SEQUENCE OF THE EG11063 CRYSTAL PROTEIN (SEQ ID NO:10) MetAspAsnAsnProAsnlleAsnGluCysIleProTyrAsnCysLeuSerAsnProGluValGluVal eu GlyGlyGluArglleGluThrGlyTyrThrProIleAspIleSer euSerLeuThrGlnPheLeu euSer GluPheValProGlyAlaGlyPheVal euGlyLeuValAspIlelleTrpGlyllePheGlyProSerGln TrpAspAlaPheLeuValGlnlleGluGlnLeuIleAsnGlnArglleGluGluPheAlaArgAsnGlnAla IleSerArgLeuGluGly euSerAsn euTyrGlnlleTyrAlaGluSerPheArgGluTrpGluAlaAsp ProThrAsnProAlaLeuArgGluGluMetArglleGlnPheAsnAspMetAsnSerAlaLeuThrThr la IlePro euPheAlaValGlnAsnTyrGlnValPro euLeuSerValTyrValGlnAlaAlaAsnLeiiHis . euSerVal euArgAspValSerValPheGlyGlnArgTrpGlyPheAspAlaAlaThrlleAsnSerArg TyrAsnAspLeuThrArg euIleGlyAsnTyrThrAspTyrAlaValArgTrpTyrAsnThrGlyLeuGlu ArgValTrpGlyProAspSerArgAspTrpValArgTyrAsnGlnPheArgArgGlu euThrLeuThrVal LeuAspIleValAlaLeuPheProAsnTyrAspSerArgArgTyrProIleArgThrValSerGlnLeuThr ArgGluIleTyrThrAsnProValLeuGluAsnPheAspGlySerPheArgGlySerAlaGlnGlylleGlu ArgSerlleArgSerProHis euMetAspIleLeuAsnSerlleT rlleTyrThrAspAlaHisArgGly TyrTyrTyrTrpSerGlyHisGlnlleMetAlaSerProValGlyPheSerGlyProGluPheT rP ePro LeuTyrGlyThrMetGlyAsnAlaAlaProGlnGlnArglleValAlaGlnLeuGlyGlnGlyValTyrArg ThrLeuSerSerThr euTyrArgArgProPheAsnlleGlylleAsnAsnGlnGln euSerValLeuAsp GlyThrGluPheAlaTyrGlyThrSerSerAsnLeuProSerAlaValTyrArgLysSerGlyThrValAsp SerLeuAspGluIleProProGlnAsnAsnAsnValProProArgGlnGlyPheSerHisArgLeuSerHis ValSerMetPheArgSerGlyPheSerAsnSerSerValSerllelleArgAlaProMetPheSerTrpThr HisArgSerAlaThrProThrAsnThrlleAspProGlixArglleT rGlnllePro euVal ysAlaHis Thr euGlnSerGlyThrThrValValArgGlyProGlyPheThrGlyGlyAspIle euArgArgThrSer GlyGlyProPheAlaTyrThrlleValAsnlleAsnGlyGln euProGlnArgTyrArgAlaArglleArg TyrAlaSerThrThrAsnLeuArglleTyrValThrValAlaGlyGluArgllePheAlaGlyGlnPheAsn LysThrMetAspThrGlyAspPro euThrPheGlnSerPheSerTyrAlaThrlleAsnThrAlaPheThr PheProMetSerGlnSerSerPheThrValGlyAlaAspThrPheSerSerGlyAsnGluValTyrlleAsp ArgPheGl LeuIleProValThrAlaThrPheGluAlaGluTyrAspLeuGluArgAlaGlnLysAlaVal AsnAlaLeuPheThrSerlleAsnGlnlleGlylle ysThrAspValThrAspTyrHisIleAspGlnVal SerAsnLeuValAspCys euSerAspGluPheCysLeuAspGlu ysArgGlu euSerGluLysValLys HisAlaLysArgLeuSerAspGluArgAsnLeu euGlnAspProAsnPheLysGlylleAsnArgGlnLeu AspArgGlyTrpArgGlySerThrAspIleThrlleGlnArgGlyAspAspValPhe ysGluAsnTyrVal Thr euProGlyThrPheAspGluCysTyrProThrTyrLeuTyrGlnLysIleAspGluSerLys eu ys AlaPheThrArgTyrGlnLeuArgGlyTyrlleGliiAspSerGlnAspLeuGluIleTyrLeuIleArgTyr AsnAlaLysHisGluThrValAsnValProGlyThrGlySer euTrpProLeuSerAlaGlnSerProIle Gly ysCysGlyGluProAsnArgCysAlaProHisLeuGluTrpAsnProAsp euAspCysSerCysArg AspGlyGluLysCysAlaHisHisSerHisHisPheSerLeuAspIleAspValGlyCysThrAspLeuAsn GluAspLeuGlyValTrpValllePheLysIleLysThrGlnAspGlyHisAlaArgLeuGlyAsnLeuGlu Phe euGluGlu ysProLeuValGlyGluAlaLeuAlaArgVal ysArgAlaGluLys ysTrpArgAsp LysArgGluLysLeuGluTrpGluThrAsnlleValTyrLysGluAla ysGluSerValAspAlaLeuPhe ValAsnSerGlnTyrAspGln euGlnAlaAspT rAsnlleAlaMetlleHisAlaAlaAspLysArgVal HisSerlleArgGluAlaTyrLeuProGluLeuSerVallleProGlyValAsnAlaAlallePheGluGlu LeuGluGlyArgllePheThrAlaPheSerLeuTyrAspAlaArgAsnVallleLysAsnGlyAspPheAsn AsnGly euSerCysTrpAsnVal ysGlyHisValAspValGluGluGlnAsnAsnGlnArgSerValLeu ValValProGluTrpGluAlaGluValSerGlnGluValArgValCysProGlyArgGlyTyrlleLeuArg ValThrAlaTyrLysGluGlyTyrGlyGluGlyCysValThrlleHisGluIleGluAsnAsnThrAspGlu euLysPheSerAsnCysValGluGluGluIleTyrProAsnAsnThrValThrCysAsnAspTyrThrVal AsnGlnGluGluTyrGlyGlyAlaTyrThrSerArgAsnArgGlyTyrAsnGluAlaProSerValProAla AspTyrAlaSerValTyrGluGluLysSerTyrThrAspGlyArgArgGluAsnProCysGluPheAsnArg GlyTyrArgAspTyrThrProLeuProValGlyTyrValThrLysGluLeuGluTyrPheProGluThrAsp LysValTrpIleGluIleGlyGluThrGluGlyThrPhelleValAspSerValGlu euLeu euMetGlu Glu 6.6.2 AMINO ACID SEQUENCE OF THE EG11074 CRYSTAL PROTEIN (SEQ ID NO:12) MetAspAsnAsnProAsnlleAsnGluCysIleProTyrAsnCysLeuSerAsnProGluValGluVal eu GlyGlyGluArglleGluThrGlyTyrThrProIleAspIleSerLeuSerLeuThrGlnPheLeuLeuSer GluPheValProGlyAlaGlyPheValLeuGlyLeuValAspIlelleTrpGlyllePheGlyProSerGln TrpAspAlaPheLeuValGlnlleGluGlnLeuIleAsnGlnArglleGluGluPheAlaArgAsnGlnAla IleSerArg euGluGlyLeuSerAsn euTyrGlnlleTyrAlaGluSerPheArgGluTrpGluAlaAsp ProThrAsnProAlaLeuArgGluGlioMetArglleGlnPheAsnAspMetAsnSerAlaLeuThrThrAla IleProLeuPheAlaValGlnAsnTyrGlnValPro euLeuSerValTyrValGlnAlaAlaAsn euHis LeuSerVal euArgAspValSerValPheGlyGlnArgTrpGlyPheAspAlaAlaThrlleAsnSerArg TyrAsnAspLeuThrArg euIleGlyAsnTyrThrAspTyrAlaValArgTrpTyrAsnThrGlyLeuGlu ArgValTrpGlyProAspSerArgAspTrpValArgTyrAsnGlnPheArgArgGluLeuThrLeuThrVal LeuAspIleValAlaLeuPheProAsnTyrAspSerArgArgTyrProIleArgThrValSerGln euThr ArgGluIleTyrThrAsnProValLeuGluAsnPheAspGlySerPheArgGlySerAlaGlnGlylleGlu ArgSerlleArgSerProHisLeuMetAspIleLeuAsnSerlleThrlleTyrThrAspAlaHisArgGly TyrTyrTyrTrpSerGlyHisGlnlleMetAlaSerProValGlyPheSerGlyProGluPheThrPhePro LeuTyrGlyThr etGlyAsnAlaAlaProGlnGlnArglleValAlaGln euGlyGlnGlyValTyrArg Thr euSerSerThrLeuTyrArgArgProPheAsnIleGlyIleAsnAsnGlnGlnLeuSerValLe\ιAsp GlyThrGluPheAlaTyrGlyThrSerSerAsnLeuProSerAlaValTyrArgLysSerGlyThrValAsp SerLeuAspGluIleProProGlnAsnAsnAsnValProProArgGlnGlyPheSerHisArgLeuSerHis ValSerMetPheArgSerGlyPheSerAsnSerSerValSerllelleArgAlaProMetPheSerTrpThr HisArgSerAlaThrProThrAsnThrlleAspProGluArglleThrGlnllePro euValLysAlaHis ThrLeuGlnSerGlyThrThrValValArgGlyProGlyPheThrGlyGlyAspIle e\ιArgArgThrSer GlyGlyProPheAlaTyrThrlleValAsnlleAsnGlyGlnLeuProGlnArgTyrArgAlaArglleArg TyrAlaSerThrThrAsnLeuArglleTyrValThrValAlaGlyGluArgllePheAlaGlyGlnPheAsn LysThrMetAspThrGlyAspProLeuThrPheGlnSerPheSerTyrAlaThrlleAsnThrAlaPheThr PheProMetSerGlnSerSerPheThrValGlyAlaAspThrPheSerSerGlyAsnGluValTyrlleAsp ArgPheGlu euIleProValThrAlaThrLeuGl\ιAlaGluTyrAsnLeuGluArgAlaGlnLysAlaVal AsnAla euPheThrSerThrAsnGlnLeuGlyLeuLysThrAsnValThrAspTyrHisIleAspGlnVal SerAsnLeuValThrTyrLeuSerAspGluPheCysLeuAspGluLysArgGluLeuSerGluLysVal ys HisAla ysArgLeuSerAspGluArgAsnLeuLeuGlnAspSerAsnPheLysAspIleAsnArgGlnPro Gl\ιArgGlyTrpGlyGlySerThrGlyIleThrIleGlnGlyGlyAspAspValPheLysGluAsnTyrVal ThrLeuSerGlyThrPheAspGluCysTyrProThrTyrLeuTyrGln ysIleAspGluSerLysLeu ys AlaPheThrArgTyrGlnLeuArgGlyTyrlleGluAspSerGlnAsp euGluIleTyrLeuIleArgTyr AsnAla ysHisGluThrValAsnValProGlyThrGlySerLeuTrpProLeuSerAlaGlnSerProIle GlyLysCysGlyGluProAsnArgCysAlaProHisLeuGluTrpAsnProAspLeuAspCysSerCysArg AspGlyGluLysCysAlaHisHisSerHisHisPheSerLeuAspIleAspValGlyCysThrAspLeuAsn GluAsp euGlyValTrpValllePheLysIleLysThrGlnAspGlyHisAlaArgLeuGlyAsnLeuGlu PheLeuGluGluLysPro euValGlyGluAlaLeuAlaArgValLysArgAlaGlu ysLysTrpArgAsp ysArgGluLysLeuGluTrpGluThrAsnlleValTyrLysGluAlaLysGluSerValAspAlaLeuPhe ValAsnSerGlnTyrAspGlnLeuGlnAlaAspThrAsnlleAlaMetlleHisAlaAlaAspLysArgVal HisSerlleArgGluAlaTyrLeuProGluLeuSerVallleProGlyValAsnAlaAlallePheGluGlu LeuGluGlyArgllePheThrAlaPheSerLeuTyrAspAlaArgAsnVallleLysAsnGlyAspPheAsn AsnGlyLeuSerCysTrpAsnVal ysGlyHisValAspValGluGluGlnAsnAsnGlnArgSerVal eu ValValProGluTrpGluAlaGluValSerGlnGluValArgValCysProGlyArgGlyTyrlleLeuArg ValThrAlaTyrLysGluGlyTyrGlyGluGlyCysValThrlleHisGluIleGluAsnAsnThrAspGlu LeuLysPheSerAsnCysValGluGluGluIleTyrProAsnAsnThrValThrCysAsnAspTyrThrVal AsnGlnGluGluTyrGlyGlyAlaTyrThrSerArgAsnArgGlyTyrAsnGluAlaProSerValProAla AspTyrAlaSerValTyrGluGluLysSerTyrThrAspGlyArgArgGluAsnProCysGluPheAsnArg GlyTyrArgAspTyrThrProLeuProValGlyTyrValThrLysGluLeuGluTyrPheProGluThrAsp LysValTrpIleGluIleGlyGluThrGluGlyThrPhelleValAspSerValGluLeuLeuLeuMetGlu Glu 6.6.3 AMINO ACID SEQUENCE OF THE EGl 1735 CRYSTAL PROTEIN (SEQ ID NO: 14) MetAspAsnAsnProAsnlleAsnGluCysIleProTyrAsnCysLeuSerAsnProGluValGluValLeu GlyGlyGluArglleGluThrGlyTyrThrProIleAspIleSer euSerLeuThrGlnPheLeuLeuSer GluPheValProGlyAlaGlyPheValLeuGly euValAspIlelleTrpGlyllePheGlyProSerGln TrpAspAlaPheLeuValGlnlleGluGlnLeuIleAsnGlnArglleGluGluPheAlaArgAsnGlnAla IleSerArg euGluGlyLeuSerAsn euTyrGlnlleTyrAlaGluSerPheArgGluTrpGluAlaAsp ProThrAsnProAla euArgGluGluMetArglleGlnPheAsnAspMetAsnSerAlaLeuThrThrAla IleProLeuPheAlaValGlnAsnTyrGlnValProLeuLeuSerValTyrValGlnAlaAlaAsnLeuHis LeuSerValLeuArgAspValSerValPheGlyGlnArgTrpGlyPheAspAlaAlaThr leAsnSerArg TyrAsnAsp euThrArg euIleGlyAsnTyrThrAspHisAlaValArgTrpTyrAsnThrGlyLeuGlu ArgValTrpGlyProAspSerArgAspTrpIleArgTyrAsnGlnPheArgArgGluLeuThrLeuThrVal euAsp11eValSerLeuPheProAsnTyrAspSerArgThrTyrPro11eArgThrValSerGln euThr ArgGluIleTyrThrAsnProValLeuGluAsnPheAspGlySerPheArgGlySerAlaGlnGlylleGlu GlySerlleArgSerProHisLeuMetAspIle euAsnSerlleThrlleTyrThrAspAlaHisArgGly GluTyrTyrTrpSerGlyHisGlnlleMetAlaSerProValGlyPheSerGlyProGluPheThrPhePro LeuTyrGlyThrMetGlyAsnAlaAlaProGlnGlnArglleValAlaGln euGlyGlnGlyValTyrArg ThrLeuSerSerThrLeuTyrArgArgProPheAsnl1eGly11eAsnAsnGlnGlnLeuSerValLeuAsp GlyThrGluPheAlaTyrGlyThrSerSerAsnLeuProSerAlaValTyrArg ysSerGlyThrValAsp SerLeuAspGluIleProProGlnAsnAεsnAsnValProProArgGlnGlyPheSerHisArgLeuSerHis ValSerMetPheArgSerGlyPheSerAsnSerSerValSerllelleArgAlaProMetPheSerTrpThr HisArgSerAlaThrProThrAsnThrlleAspProGluArglleThrGlnlleProLeuVal ysAlaHis ThrLeuGlnSerGlyThrThrValValArgGlyProGlyPheThrGlyGlyAspIleLeuArgArgThrSer GlyGlyProPheAlaTyrThrlleValAsnlleAsnGlyGln euProGlnArgTyrArgAlaArglleArg TyrAlaSerThrThrAsnLeuArglleTyrValT rValAlaGlyGluArgllePheAlaGlyGlnPheAsn ysThrMetAspThrGlyAspPro euThrPheGlnSerPheSerTyrAlaThr leAsnThrAlaPheThr PheProMetSerGlnSerSerP eThrValGlyAlaAspThrPheSerSerGlyAsnGluValTyrlleAsp ArgPheGlu euIleProValThrAlaThrP eGluAlaGluTyrAsp euGluArgAlaGlnLysAlaVal AsnAlaLeuPheThrSerlleAsnGlnlleGlylleLysThrAspValThrAspTyrHisIleAspGlnVal SerAsnLeuValAspCysLeuSerAspGluPheCysLeuAspGluLysArgGluLeuSerGluLysVal ys HisAlaLysArg euSerAspGluArgAsnLeu euGlixAspProAsnPheLysGlylleAsnArgGln eu AspArgGlyTrpArgGlySerThrAspIleThrlleGlnArgGlyAspAspValPhe ysGluAsnTyrVal ThrLeuProGlyT rPheAspGluCysTyrProThrTyrLeuTyrGlnLysIleAspGluSerLysLeuLys AlaPheThrArgTyrGlnLeuArgGlyTyrlleGluAspSerGlnAspLeuGluIleTyrLeuIleArgTyr AsnAlaLysHisGluThrValAsnValProGlyThrGlySerLeuTrpPro euSerAlaGlnSerProIle Gly ysCysGlyGluProAsnArgCysAlaProHisLeuGluTrpAsnProAspLeuAspCysSerCysArg AspGlyGluLysCysAlaHisHisSerHisHisPheSer euAspIleAspValGlyCysThrAsp euAsn GluAsp euGlyValTrpValllePheLysIleLysThrGlnAspGlyHisAlaArgLeuGlyAsn euGlu PheLeuGluGlu ysProLeuValGlyGluAlaLeuAlaArgVal ysArgAlaGluLys ysTrpArgAsp LysArgGluLys euGluTrpGluThrAsnlleValTyrLysGluAla ysGluSerValAspAla euPhe ValAsnSerGlnTyrAspGlnLeuGlnAlaAspThrAsnlleAlaMetlleHisAlaAlaAspLysArgVal HisSerlleArgGluAlaTyrLeuProGlu euSerVallleProGlyValAsnAlaAlallePheGluGlu LeuGluGlyArgllePheThrAlaPheSerLeuTyrAspAlaArgAsnVallleLysAsnGlyAspPheAsn AsnGlyLeuSerCysTrpAsnValLysGlyHisValAspValGluGluGlnAsnAsnGlnArgSerValLeu ValValProGluTrpGluAlaGluValSerGlnGluValArgValCysProGlyArgGlyTyrlleLeuArg ValThrAlaTyrLysGluGlyTyrGlyGluGlyCysValThrlleHisGluIleGluAsnAsnThrAspGlu LeuLysPheSerAsnCysValGluGluGluIleTyrProAsnAsnThrValThrCysAsnAspTyrThrVal AsnGlnGluGluTyrGlyGlyAlaTyrThrSerArgAsnArgGlyTyrAsnGluAlaProSerValProAla AspTyrAlaSerValTyrGluGlu ysSerTyrThrAspGlyArgArgGluAsnProCysGluPheAsnArg GlyTyrArgAspTyrThrProLeuProValGlyTyrValThrLysGluLeuGluTyrPheProGluThrAsp LysValTrpIleGluIleGlyGluThrGluGlyThrPhelleValAspSerValGluLeuLeu eu etGlu Glu 6.6.4 AMINO ACID SEQUENCE OF THE EGl 1092 CRYSTAL PROTEIN (SEQ ID NO:26) MetAspAsnAsnProAsnlleAsnGluCysIleProTyrAsnCys euSerAsnProGluValGluVal eu GlyGlyGluArglleGluThrGlyTyrThrProIleAspIleSerLeuSerLeuThrGlnPheLeuLeuSer GluPheValProGlyAlaGlyPheValLeuGlyLeuValAspIlelleTrpGlyllePheGlyProSerGln TrpAspAlaPheLeuValGlnlleGluGlnLeuIleAsnGlnArglleGluGluPheAlaArgAsnGlnAla IleSerArg euGluGlyLeuSerAsnLeuTyrGlnlleTyrAlaGluSerPheArgGluTrpGluAlaAsp ProThrAsnProAlaLeuArgGluGluMetArglleGlnPheAsnAspMetAsnSerAla euThrThrAla IleProLeuPheAlaValGlnAsnTyrGlnValProLeu euSerValTyrValGlnAlaAlaAsn euHis LeuSerValLeuArgAspValSerValP eGlyGlnArgTrpGlyPheAspAlaAlaThrlleAsnSerArg TyrAsnAspLeuThrArg euIleGlyAsnTyrThrAspHisAlaValArgTrpTyrAsnThrGlyLeuGlu ArgValTrpGlyProAspSerArgAspTrpIleArgTyrAsnGlnPheArgArgGluLeuThrLeuThrVal euAspIleValSerLeuPheProAsnTyrAspSerArgThrTyrProIleArgThrValSerGln euThr ArgGluIleTyrThrAsnProValLeuGluAsnPheAspGlySerPheArgGlySerAlaGlnGlylleGlu ArgSerlleArgSerProHis euMetAspIle euAsnSerlleThrlleTyrThrAspAlaHisArgGly TyrTyrTyrTrpSerGlyHisGlnlleMetAlaSerProValGlyPheSerGlyProGluPheThrPhePro euTyrGlyThrMetGlyAsnAlaAlaProGlnGlnArglleValAlaGln euGlyGlnGlyValTyrArg ThrLeuSerSerThrLeuTyrArgArgProPheAsnlleGlylleAsnAsnGlnGln euSerValLeuAsp GlyThrGluPheAlaTyrGlyThrSerSerAsnLeuProSerAlaValTyrArgLysSerGlyThrValAsp SerLeuAspGluIleProProGlnAsnAsnAsnValProProArgGlnGlyPheSerHisArgLeuSerHis ValSerMetPheArgSerGlyPheSerAsnSerSerValSerllelleArgAlaProMetPheSerTrpThr HisArgSerAlaThrProThrAsnThrlleAspProGluArglleThrGlnlleProLeuValLysAlaHis ThrLeuGlnSerGlyThrThrValValArgGlyProGlyPheThrGlyGlyAspIleLeuArgArgThrSer GlyGlyProPheAlaTyrThrlleValAsnlleAsnGlyGln euProGlnArgTyrArgAlaArglleArg TyrAlaSerThrThrAsnLeuArglleTyrValThrValAlaGlyGluArgllePheAlaGlyGlnPheAsn LysThrMetAspThrGlyAspProLeuThrPheGlnSerPheSerTyrAlaThrlleAsnThrAlaPheThr PheProMetSerGlnSerSerPheThrValGlyAlaAspThrPheSerSerGlyAsnGluValTyrlleAsp ArgPheGluLeuIleProValThrAlaThrPheGluAlaGluTyrAspLeuGluArgAlaGlnLysAlaVal AsnAlaLeuPheThrSerlleAsnGlnlleGlylleLysThrAspValThrAspTyrHisIleAspGlnVal SerAsn euValAspCysLeuSerAspGluPheCys euAspGluLysArgGluLeuSerGluLysValLys HisAlaLysArgLeuSerAspGluArgAsnLeuLeuGlnAspProAsnPheLysGlylleAsnArgGlnLeu AspArgGlyTrpArgGlySerThrAspIleThrlleGlnArgGlyAspAspValPheLysGluAsnTyrVal ThrLeuProGlyThrPheAspGluCysTyrProThrTyrLeuTyrGln ysIleAspGluSerLysLeuLys AlaPheThrArgTyrGlnLeuArgGlyTyrlleGluAspSerGlnAsp euGluIleTyrLeuIleArgTyr AsnAlaLysHisGluThrValAsnValProGlyThrGlySerLeuTrpProLeuSerAlaGlnSerProIle GlyLysCysGlyGluProAsnArgCysAlaProHis euGluTrpAsnProAsp euAspCysSerCysArg AspGlyGluLysCysAlaHisHisSerHisHisPheSer euAspIleAspValGlyCysThrAspLeuAsn GluAspLeuGlyValTrpValllePheLysIle ysThrGlnAspGlyHisAlaArgLeuGlyAsn euGlu PheLeuGluGluLysPro euValGlyGluAlaLeuAlaArgValLysArgAlaGluLysLysTrpArgAsp LysArgGluLysLeuGluTrpGluThrAsnlleValTyrLysGluAla ysGluSerValAspAlaLeuPhe ValAsnSerGlnTyrAspGlnLeuGlnAlaAspThrAsnl1eAlaMetileHisAlaAlaAspLysArgVal HisSerlleArgGluAlaTyrLeuProGlu euSerVallleProGlyValAsnAlaAlallePheGluGlu LeuGluGlyArgllePheThrAlaPheSer euTyrAspAlaArgAsnVallleLysAsnGlyAspPheAsn AsnGlyLeuSerCysTrpAsnValLysGlyHisValAspValGluGluGlnAsnAsnGlnArgSerValLeu ValValProGluTrpGluAlaGluValSerGlnGluValArgValCysProGlyArgGlyTyrlleLeuArg ValThrAlaTyrLysGluGlyTyrGlyGluGlyCysValT rlleHisGluIleGluAsnAsnThrAspGlu eu ysP eSerAsnCysValGluGluGluIleTyrProAsnAsnThrValThrCysAsnAspTyrThrVal AsnGlnGluGluTyrGlyGlyAlaTyrThrSerArgAsriArgGlyTyrAsnGluAlaProSerValProAla AspTyrAlaSerValTyrGluGluLysSerTyrThrAspGlyArgArgGluAsnProCysGluPheAsnArg GlyTyrArgAspTyrThrProLeuProValGlyTyrValThrLysGluLeuGluTyrPheProGluThrAsp ysValTrpIleGluIleGlyGluThrGluGlyThrPhelleValAspSerValGluLeuLeuLeuMetGlu Glu 6.6.5 AMINO ACID SEQUENCE OF THE EGl 1751 CRYSTAL PROTEIN (SEQ ID NO:28) MetAspAsnAsnProAsnlleAsnGluCysIleProTyrAsnCysLeuSerAsnProGluValGluValLeu GlyGlyGluArglleGluThrGlyTyrThrProIleAspIleSer euSerLeuThrGlnPheLeuLeuSer GluPheValProGlyAlaGlyPheValLeuGly euValAspIlelleTrpGlyllePheGlyProSerGln TrpAspAlaPheLeuValGlnlleGluGlnLeuIleAsnGlnArglleGluGluPheAlaArgAsnGlnAla IleSerArg euGluGly euSerAsnLeuTyrGlnlleTyrAlaGluSerPheArgGluTrpGluAlaAsp ProThrAsnProAlaLeuArgGluGluMetArglleGlnPheAsnAspMetAsnSerAla euThrThr la IleProLeuPheAlaValGlnAsnTyrGlnValPro euLeuSerValTyrValGlnAlaAlaAsn euHis LeuSerValLeuArgAspValSerValPheGlyGlnArgTrpGlyPheAspAlaAlaThrlleAsnSerArg TyrAsnAspLeuThrArg euIleGlyAsnTyrThrAspTyrAlaValArgTrpTyrAsnThrGly euGlu ArgValTrpGlyProAspSerArgAspTrpValArgTyrAsnGlnPheArgArgGluLeuThrLeuThrVal euAspIleValAlaLeuPheProAsnTyrAspSerArgArgTyrProIleArgThrValSerGln euThr ArgGluIleTyrThrAsnProValLeuGluAsnPheAspGlySerPheArgGlySerAlaGlnGlylleGlu ArgSerlleArgSerProHisLeuMetAspIleLeuAsnSerlleThrlleTyrThrAspAlaHisArgGly TyrTyrTyrTrpSerGlyHisGlnlleMetAlaSerProValGlyPheSerGlyProGluPheThrPhePro euTyrGlyThrMetGlyAsnAlaAlaProGlnGlnArglleValAlaGlnLeuGlyGlnGlyValTyrArg ThrLeuSerSerThr euTyrArgArgProPheAsnlleGlylleAsnAsnGlnGlnLeuSerValLeuAsp GlyThrGluPheAlaTyrGlyThrSerSerAsnLeuProSerAlaValTyrArgLysSerGlyThrValAsp Ser euAspGluIleProProGlnAsnAsnAsnValProProArgGlnGlyPheSerHisArgLeuSerHis ValSerMetPheArgSerGlyPheSerAsnSerSerValSerllelleArgAlaProMetPheSerTrpIle HisArgSerAlaGluPheAsnAsnllelleAlaSerAspSerlleThrGlnlleProLeuValLysAlaHis ThrLeuGlnSerGlyThrThrValValArgGlyProGlyPheThrGlyGlyAspIle euArgArgThrSer GlyGlyProPheAlaTyrThrlleValAsnlleAsnGlyGlnLeuProGlnArgTyrArgAlaArglleArg TyrAlaSerThrThrAsnLeuArglleTyrValThrValAlaGlyGluArgllePheAlaGlyGlnPheAsn LysThr etAspThrGlyAspProLeuThrPheGlnSerPheSerTyrAlaThrlleAsnThrAlaPheThr PheProMetSerGlnSerSerPheThrValGlyAlaAspThrPheSerSerGlyAsnGluValTyrlleAsp ArgPheGluLeuIleProValThrAlaThrPheGluAlaGluTyrAspLeuGluArgAlaGln ysAlaVal AsnAlaLeuPheThrSerlleAsnGlnlleGlylleLysThrAspValThrAspTyrHisIleAspGlnVal SerAsnLeuValAspCysLeuSerAspGluPheCysLeuAspGlu ysArgGlu euSerGluLysValLys HisAlaLysArg euSerAspGluArgAsnLeuLeuGlnAspProAsnPheLysGlylleAsnArgGlnLeu AspArgGlyTrpArgGlySerThrAspIleThrlleGlnArgGlyAspAspValPheLysGluAsnTyrVal ThrLeuProGlyThrPheAspGluCysTyrProThrTyr euTyrGln ysIleAspGluSerLys eu ys AlaPheThrArgTyrGln euArgGlyTyrlleGluAspSerGlnAspLeuGluIleTyr euIleArgTyr AsnAlaLysHisGluThrValAsnValProGlyThrGlySerLeuTrpPro euSerAlaGlnSerProIle GlyLysCysGlyGluProAsnArgCysAlaProHisLeuGluTrpAsnProAsp euAspCysSerCysArg AspGlyGlu ysCysAlaHisHisSerHisHisPheSer euAspIleAspValGlyCysThrAspLeuAsn GluAsp euGlyValTrpValllePheLysIleLysThrGlnAspGlyHisAlaArg euGlyAsnLeuGlu PheLeuGluGlu ysProLeuValGlyGluAlaLeuAlaArgValLysArgAlaGluLysLysTrpArgAsp LysArgGluLys euGluTrpGluThrAsn leValTyrLysGluAla ysGluSerValAspAlaLeuPhe ValAsnSerGlnTyrAspGlnLeuGlnAlaAspThrAsnlleAlaMetlleHisAlaAlaAspLysArgVal HisSerlleArgGluAlaTyrLeuProGluLeuSerVallleProGlyValAsnAlaAlallePheGluGlu LeuGluGlyArgllePheThrAlaPheSerLeuTyrAspAlaArgAsnVallleLysAsnGlyAspPheAsn AsnGly euSerCysTrpAsnValLysGlyHisValAspValGluGluGlnAsnAsnGlnArgSerVal eu ValValProGluTrpGluAlaGluValSerGlnGluValArgValCysProGlyArgGlyTyrlle euArg ValThrAlaTyrLysGluGlyTyrGlyGluGlyCysValThrlleHisGluIleGluAsnAsnThrAspGlu LeuLysPheSerAsnCysValGluGluGluIleTyrProA-snAsnThrValThrCysAsnAspTyrThrVal AsnGlnGluGluTyrGlyGlyAlaTyrThrSerArgAsnArgGlyTyrAsnGluAlaProSerValProAla AspTyrAlaSerValTyrGluGlu ysSerTyrThrAspGlyArgArgGluAsnProCysGluPheAsnArg GlyTyrArgAspTyrThrProLeuProValGlyTyrValThr ysGluLeuGluTyrPheProGluThrAsp ysValTrpIleGluIleGlyGluT rGluGlyThrPhelleValAspSerValGluLeuLeuLeuMetGlu Glu 6.6.6 AMINO ACID SEQUENCE OF THE EG11091 CRYSTAL PROTEIN (SEQ ID NO:30) MetAspAsnAsnProAsnlleAsnGluCysIleProTyrAsnCysLeuSerAsnProGluValGluValLeu GlyGlyGluArglleGluThrGlyTyrThrProIleAspIleSerLeuSerLeuThrGlnPheLeu euSer GluPheValProGlyAlaGlyPheValLeuGly euValAspIlelleTrpGlyllePheGlyProSerGln TrpAspAlaPheLeuValGlnlleGluGlnLeuIleAsnGlnArglleGluGluPheAlaArgAsnGlnAla IleSerArgLeuGluGlyLeuSerAsnLeuTyrGlnlleTyrAlaGluSerPheArgGluTrpGluAlaAsp ProThrAsnProAla euArgGluGluMetArglleGlnPheAsnAspMetAsnSerAla euThrThrAla IleProLeuPheAlaValGlnAsnTyrGlnValPro euLeuSerValTyrValGlnAlaAlaAsnLeuHis LeuSerValLeuArgAspValSerValPheGlyGlnArgTrpGlyPheAspAlaAlaThrlleAsnSerArg TyrAsnAspLeuThrArgLeuIleGlyAsriTyrThrAspTyrAlaValArgTrpTyrAsnThrGlyLeuGlu ArgValTrpGlyProAspSerArgAspTrpValArgTyrAsnGlnPheArgArgGluLeuThrLeuThrVal LeuAspIleValAlaLeuPheProAsnTyrAspSerArgArgTyrProIleArgThrValSerGlnLeuThr ArgGluIleTyrThrAsnProValLeuGluAsnPheAspGlySerPheArgGlySerAlaGlnGlylleGlu ArgSerlleArgSerProHisLeuMetAspIleLeuAsnSerlleThrlleTyrThrAspAlaHisArgGly TyrTyrTyrTrpSerGlyHisGlnlleMetAlaSerProValGlyPheSerGlyProGluPheThrPhePro euTyrGlyThrMetGlyAsnAlaAlaProGlnGlnArglleValAlaGlnLeuGlyGlnGlyValTyrArg ThrLeuSerSerThrLeuTyrArgArgProPheAsn leGlylleAsnAsnGlnGln euSerValLeuAsp GlyThrGluPheAlaTyrGlyThrSerSerAsnLeuProSerAlaValTyrArgLysSerGlyThrValAsp SerLeuAspGluIleProProGlnAsnAsnAsnValProProArgGlnGlyPheSerHisArgLeuSerHis ValSerMetPheArgSerGlyPheSerAsnSerSerValSerllelleArgAlaProMetPheSerTrpIle HisArgSerAlaThr euThrAsnThrlleAspProGluArglleAsnGln leProLeuValLysGlyPhe ArgValTrpGlyGlyThrSerVallleThrGlyProGlyPheThrGlyGlyAspIle euArgArgAsnThr PheGlyAspPheValSerLeuGlnValAsnlleAsnSerProIleThrGlnArgTyrArgLeuArgPheArg TyrAlaSerSerArgAspAlaArgVallleVal euThrGlyAlaAlaSerThrGlyValGlyGlyGlnVal SerValAsnMetPro euGlnLysThrMetGluIleGlyGluAsnLeuThrSerArgThrPheArgTyrThr AspPheSerAsnProPheSerPheArgAlaAsnProAspIlelleGlylleSerGluGlnPro euPheGly AlaGlySerlleSerSerGlyGluLeuTyrlleAspLysIleGluIlelleLeuAlaAspAlaThrPheGlu AlaGluSerAspLeuGluArgAlaGlnLysAlaValAsnAlaLeuPheThrSerSerAsnGlnlleGlyLeu ysThrAspValThrAspTyrHisIleAspGlnValSerAsnLeuValAspCysLeuSerAspGluPheCys LeuAspGluLysArgGluLeuSerGlu ysVal ysHisAlaLysArgLeuSerAspGluArgAsn euLeu GlnAspProAsnPheArgGlylleAsnArgGlnProAspArgGlyTrpArgGlySerThrAspIleThrlle GlnGlyGlyAspAspValPhe ysGluAsnTyrValThr euProGlyThrValAspGluCysTyrProThr TyrLeuTyrGlnLysIleAspGluSer ysLeuLysAlaTyrThrArgTyrGlu euArgGlyTyrlleGlu AspSerGlnAsp euGluIleTyrLeuIleArgTyrAsnAlaLysHisGluIleValAsnValProGlyThr GlySerLeuTrpPro euSerAlaGlnSerProIleGlyLysCysGlyGluProAsnArgCysAlaProHis euGluTrpAsnProAspLeuAspCysSerCysArgAspGlyGluLysCysAlaHisHisSerHisHisPhe Thr euAspIleAspValGlyCysThrAspLeuAsnGluAspLeuGlyValTrpValllePheLysIleLys ThrGlnAspGlyHisAlaArg euGlyAsn euGluPheLeuGluGluLysProLeuLeuGlyGluAlaLeu AlaArgValLysArgAlaGluLysLysTrpArgAsp ysArgGlu ysLeuGlnLeuGluThrAsnlleVal TyrLysGluAla ysGluSerValAspAlaLeuPheValAsnSerGlnTyrAspArg euGlnValAspThr AsnlleAlaMetlleHisAlaAlaAsp ysArgValHisArglleArgGluAlaTyrLeuProGlu euSer VallleProGlyValAsnAlaAlallePheGluGluLeuGluGlyArgllePheThrAlaTyrSerLeuTyr AspAlaArgAsnVallleLysAsnGlyAspPheAsnAsnGlyLeuLeuCysTrpAsnValLysGlyHisVal AspValGluGluGlnAsnAsnHisArgSerVal euVallleProGluTrpGluAlaGluValSerGlnGlu ValArgValCysProGlyArgGly yrlleLeuArgValThrAlaTyrLysGluGly yrGlyGluGlyCys ValThrlleHisGluIleGluAspAsnThrAspGlu eu ysPheSerAsnCysValGluGluGluValTyr ProAsnAsnThrValThrCysAsnAsnTyrThrGlyThrGlnGluGluTyrGluGlyThrTyrThrSerArg AsnGlnGlyTyrAspGluAlaTyrGlyAsnAsnProSerValProAlaAspTyrAlaSerValTyrGluGlu ysSerTyrThrAspGlyArgArgGluAsnProCysGluSerAsnArgGlyTyrGlyAspTyrThrPro eu ProAlaGlyTyrValThrLysAsp euGluTyrPheProGluThrAspLysValTrpIleGluIleGlyGlu ThrGluGlyThrPhelleValAspSerValGlu eu euLeuMetGluGlu 6.6.7 AMINO ACID SEQUENCE OF THE EG11768 CRYSTAL PROTEIN (SEQ ID NO:34) MetAspAsnAsnProAsnlleAsnGluCysIleProTyrAsnCysLeuSerAsnProGluValGluValLeuGlyG lyGluArglleGluThrGlyTyrThrProIleAspIleSer euSer euThrGlnPheLeuLeuSerGluPheVa lProGlyAlaGlyPheValLeuGlyLeuValAspIlelleTrpGlyllePheGlyProSerGlnTrpAspAlaPhe euValGlnlleGluGlnLeuIleAsnGlnArglleGluGluPheAlaArgAsnGlnAlalleSerArgLeuGluG lyLeuSerAsnLeuTyrGlnlleTyrAlaGluSerPheArgGluTrpGluAlaAspProThrAsnProAlaLeuAr gGluGluMetArglleGlnPheAsnAspMetAsnSerAlaLeuThrThrAlalleProLeuPheAlaValGlnAsn TyrGlnValProLeuLeuSerValTyrValGlnAlaAlaAsnLeuHisLeuSerVal euArgAspValSerValP heGlyGlnArgTrpGlyPheAspAlaAlaThrlleAsnSerArgTyrAsnAspLeuThrArgLeuIleGlyAsnTy rThrAspTyrAlaValArgTrpTyrAsnThrGlyLeuGluArgValTrpGlyProAspSerArgAspTrpValArg TyrAsnGlnPheArgArgGluLeuThrLeuThrVal euAspIleValAlaLeuPheProAsnTyrAspSerArgA rgTyrProIleArgThrValSerGlnLeuThrArgGluIleTyrThrAsnProValLeuGluAsnPheAspGlySe rPheArgGlySerAlaGlnGlylleGluArgSerlleArgSerProHis euMetAspIleLeuAsnSerlleThr IleTyrThrAspAlaHisArgGlyTyrTyrTyrTrpSerGlyHisGlnlleMetAlaSerProValGlyPheSerG lyProGluPheThrPheProLeuTyrGlyThrMetGlyAsnAlaAlaProGlnGlnArglleValAlaGlnLeuGl yGlnGlyValTyrArgThr euSerSerThr euTyrArgArgProPheAsnlleGlylleAsnAsnGlnGlnLeu SerVal euAspGlyThrGluPheAlaTyrGlyThrSerSerAsn euProSerAlaValTyrArg ysSerGlyT hrValAspSerLeuAspGluIleProProGlnAsnAsnAsnValProProArgGlnGlyPheSerHisArgLeuSe rHisValSerMetPheArgSerGlyPheSerAsnSerSerValSerllelleArgAlaProMetPheSerTrpIle HisArgSerAlaGluPheAsnAsnllelleAlaSerAspSerlleThrGlnlleProLeuVal ysAlaHisThrL euGlnSerGlyThrThrValValArgGlyProGlyPheThrGlyGlyAspIleLeuArgArgThrSerGlyGlyPr oPheAlaTyrThrlleValAsnlleAsnGlyGlnLeuProGlnArgTyrArgAlaArglleArgTyrAlaSerThr ThrAsn euArglleTyrValThrValAlaGlyGluArgllePheAlaGlyGlnPheAsnLysThrMetAspThrG lyAspProLeuThrPheGlnSerPheSerTyrAlaThrlleAsnThrAlaPheThrPhePro etSerGlnSerSe rPheThrValGlyAlaAspThrPheSerSerGlyAsnGluValTyrlleAspArgPheGlu euIleProValThr AlaThrLeuGluAlaGluTyrAsn euGluArgAlaGln ysAlaValAsnAlaLeuPheThrSerThrAsnGlnL euGlyLeuLysThrAsnValThrAspTyrHisIleAspGlnValSerAsnLeuValThrTyrLeuSerAspGluPh eCysLeuAspGluLysArgGluLeuSerGluLysValLysHisAla ysArgLeuSerAspGluArgAsnLeuLeu GlnAspSerAsnPhe ysAspIleAsnArgGlnProGluArgGlyTrpGlyGlySerThrGlylleThrlleGlnG lyGlyAspAspValPheLysGluAsnTyrValThr euSerGlyThrPheAspGluCysTyrProThrTyrLeuTy rGlnLysIleAspGluSer ysLeu ysAlaPheThrArgTyrGln euArgGlyTyrlleGluAspSerGlnAsp LeuGluIleTyrLeuIleArgTyrAsnAla ysHisGluThrValAsnValProGlyThrGlySerLeuTrpProL euSerAlaGlnSerProIleGlyLysCysGlyGluProAsnArgCysAlaProHisLeuGluTrpAsnProAsp e uAspCysSerCysArgAspGlyGlu ysCysAlaHisHisSerHisHisPheSerLeuAspIleAspValGlyCys ThrAspLeuAsnGluAspLeuGlyValTrpValllePheLysIle ysThrGlnAspGlyHisAlaArgLeuGlyA sn euGluPheLeuGluGluLysPro euValGlyGluAlaLeuAlaArgValLysArgAlaGluLysLysTrpAr gAsp ysArgGluLys euGluTrpGluThrAsnlleValTyrLysGluAlaLysGluSerValAspAlaLeuPhe ValAsnSerGlnTyrAspGln euGlnAlaAspThrAsnlleAlaMetlleHisAlaAlaAspLysArgValHisS erlleArgGluAlaTyrLeuProGluLeuSerVallleProGlyValAsriAlaAlallePheGluGluLeuGluGl yArgllePheThrAlaPheSerLeuTyrAspAlaArgAsnVallleLysAsnGlyAspPheAsnAsnGlyLeuSer CysTrpAsnValLysGlyHisValAspValGluGluGlnAsnAsnGlnArgSerVal euValValProGluTrpG luAlaGluValSerGlnGluValArgValCysProGlyArgGlyTyrlleLeuArgValThrAlaTyrLysGluGl yTyrGlyGluGlyCysValThrlleHisGluIleGluAsnAsnThrAspGluLeu ysPheSerAsnCysValGlu GluGluIleTyrProAsnAsnThrValThrCysAsnAspTyrThrValAsnGlnGluGluTyrGlyGlyAlaTyrT hrSerArgAsnArgGlyTyrAsnGluAlaProSerValProAlaAspTyrAlaSerValTyrGluGluLysSerTy rThrAspGlyArgArgGluAsnProCysGluPheAsnArgGly yrArgAspTyrThrProLeuProValGlyTyr ValThrLysGluLeuGluTyrPheProGluThrAsp ysValTrpIleGluIleGlyGluThrGluGlyThrPhel leValAspSerValGluLeu euLeuMetGluGlu 6.7 EXAMPLE 7 ~ DNA SEQUENCES ENCODING THE NOVEL CRYSTAL PROTEINS 6.7.1 DNA SEQUENCE ENCODING THE EG11063 CRYSTAL PROTEIN (SEQ ID NO:9) ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3531 6.7,2 DNA SEQUENCE ENCODING THE EG11074 CRYSTAL PROTEIN (SEQ ID NO:ll) ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 GCA ACA CTC GAG GCT GAA TAT AAT CTG GAA AGA GCG CAG AAG GCG GTG 1872 AAT GCG CTG TTT ACG TCT ACA AAC CAA CTA GGG CTA AAA ACA AAT GTA 1920 ACG GAT TAT CAT ATT GAT CAA GTG TCC AAT TTA GTT ACG TAT TTA TCG 1968 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 CAT GCG AAG CGA CTC AGT GAT GAA CGC AAT TTA CTC CAA GAT TCA AAT 2064 TTC AAA GAC ATT AAT AGG CAA CCA GAA CGT GGG TGG GGC GGA AGT ACA 2112 GGG ATT ACC ATC CAA GGA GGG GAT GAC GTA TTT AAA GAA AAT TAC GTC 2160 ACA CTA TCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3531 6.7.3 DNA SEQUENCE ENCODING THE EGl 1735 CRYSTAL PROTEIN (SEQ ID NO: 13) ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT CAT GCT GTA 624 CGC TGG TAC AAT ACG GGA TTA GAG CGT GTA TGG GGA CCG GAT TCT AGA 672 GAT TGG ATA AGA TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 TTA GAT ATC GTT TCT CTA TTT CCG AAC TAT GAT AGT AGA ACG TAT CCA 768 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 GGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 ATC TAT ACG GAT GCT CAT AGA GGA GAA TAT TAT TGG TCA GGG CAT CAA 960 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3531 6.7.4 DNA SEQUENCE ENCODING THE EGl 1092 CRYSTAL PROTEIN (SEQ ID NO:25) ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT CAT GCT GTA 624 CGC TGG TAC AAT ACG GGA TTA GAG CGT GTA TGG GGA CCG GAT TCT AGA 672 GAT TGG ATA AGA TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 TTA GAT ATC GTT TCT CTA TTT CCG AAC TAT GAT AGT AGA ACG TAT CCA 768 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 AGC GTG GAA TTA CTC CTT ATG GAG GAA TAG 3534 6.7.5 DNA SEQUENCE ENCODING THE EG11751 CRYSTAL PROTEIN (SEQ ID NO:27) ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 AGA GCT CCT ATG TTC TCT TGG ATA CAT CGT AGT GCT GAA TTT AAT AAT 1392 ATA ATT GCA TCG GAT AGT ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 AGC GTG GAA TTA CTC CTT ATG GAG GAA TAG 3534 6.7.6 DNA SEQUENCE ENCODING THE EG11091 CRYSTAL PROTEIN (SEQ ID NO:29) ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 AGA GCT CCT ATG TTC TCT TGG ATA CAT CGT AGT GCA ACT CTT ACA AAT 1392 ACA ATT GAT CCA GAG AGA ATT AAT CAA ATA CCT TTA GTG AAA GGA TTT 1440 AGA GTT TGG GGG GGC ACC TCT GTC ATT ACA GGA CCA GGA TTT ACA GGA 1488 GGG GAT ATC CTT CGA AGA AAT ACC TTT GGT GAT TTT GTA TCT CTA CAA 1536 GTC AAT ATT AAT TCA CCA ATT ACC CAA AGA TAC CGT TTA AGA TTT CGT 1584 TAC GCT TCC AGT AGG GAT GCA CGA GTT ATA GTA TTA ACA GGA GCG GCA 1632 TCC ACA GGA GTG GGA GGC CAA GTT AGT GTA AAT ATG CCT CTT CAG AAA 1680 ACT ATG GAA ATA GGG GAG AAC TTA ACA TCT AGA ACA TTT AGA TAT ACC 1728 GAT TTT AGT AAT CCT TTT TCA TTT AGA GCT AAT CCA GAT ATA ATT GGG 1776 ATA AGT GAA CAA CCT CTA TTT GGT GCA GGT TCT ATT AGT AGC GGT GAA 1824 CTT TAT ATA GAT AAA ATT GAA ATT ATT CTA GCA GAT GCA ACA TTT GAA 1872 GCA GAA TCT GAT TTA GAA AGA GCA CAA AAG GCG GTG AAT GCC CTG TTT 1920 ACT TCT TCC AAT CAA ATC GGG TTA AAA ACC GAT GTG ACG GAT TAT CAT 1968 ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA GAT GAA TTT TGT 2016 CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA CAT GCG AAG CGA 2064 CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC TTC AGA GGG ATC 2112 AAT AGA CAA CCA GAC CGT GGC TGG AGA GGA AGT ACA GAT ATT ACC ATC 2160 CAA GGA GGA GAT GAC GTA TTC AAA GAG AAT TAC GTC ACA CTA CCG GGT 2208 ACC GTT GAT GAG TGC TAT CCA ACG TAT TTA TAT CAG AAA ATA GAT GAG 2256 TCG AAA TTA AAA GCT TAT ACC CGT TAT GAA TTA AGA GGG TAT ATC GAA 2304 GAT AGT CAA GAC TTA GAA ATC TAT TTG ATC CGT TAC AAT GCA AAA CAC 2352 GAA ATA GTA AAT GTG CCA GGC ACG GGT TCC TTA TGG CCG CTT TCA GCC 2400 CAA AGT CCA ATC GGA AAG TGT GGA GAA CCG AAT CGA TGC GCG CCA CAC 2448 CTT GAA TGG AAT CCT GAT CTA GAT TGT TCC TGC AGA GAC GGG GAA AAA 2496 TGT GCA CAT CAT TCC CAT CAT TTC ACC TTG GAT ATT GAT GTT GGA TGT 2544 ACA GAC TTA AAT GAG GAC TTA GGT GTA TGG GTG ATA TTC AAG ATT AAG 2592 ACG CAA GAT GGC CAT GCA AGA CTA GGG AAT CTA GAG TTT CTC GAA GAG 2640 AAA CCA TTA TTA GGG GAA GCA CTA GCT CGT GTG AAA AGA GCG GAG AAG 2688 AAG TGG AGA GAC AAA CGA GAG AAA CTG CAG TTG GAA ACA AAT ATT GTT 2736 TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT GTA AAC TCT CAA 2784 TAT GAT AGA TTA CAA GTG GAT ACG AAC ATC GCA ATG ATT CAT GCG GCA 2832 GAT AAA CGC GTT CAT AGA ATC CGG GAA GCG TAT CTG CCA GAG TTG TCT 2880 GTG ATT CCA GGT GTC AAT GCG GCC ATT TTC GAA GAA TTA GAG GGA CGT 2928 ATT TTT ACA GCG TAT TCC TTA TAT GAT GCG AGA AAT GTC ATT AAA AAT 2976 GGC GAT TTC AAT AAT GGC TTA TTA TGC TGG AAC GTG AAA GGT CAT GTA 3024 GAT GTA GAA GAG CAA AAC AAC CAC CGT TCG GTC CTT GTT ATC CCA GAA 3072 TGG GAG GCA GAA GTG TCA CAA GAG GTT CGT GTC TGT CCA GGT CGT GGC 3120 TAT ATC CTT CGT GTC ACA GCA TAT AAA GAG GGA TAT GGA GAG GGC TGC 3168 GTA ACG ATC CAT GAG ATC GAA GAC AAT ACA GAC GAA CTG AAA TTC AGC 3216 AAC TGT GTA GAA GAG GAA GTA TAT CCA AAC AAC ACA GTA ACG TGT AAT 3264 AAT TAT ACT GGG ACT CAA GAA GAA TAT GAG GGT ACG TAC ACT TCT CGT 3312 AAT CAA GGA TAT GAC GAA GCC TAT GGT AAT AAC CCT TCC GTA CCA GCT 3360 GAT TAC GCT TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3408 GAG AAT CCT TGT GAA TCT AAC AGA GGC TAT GGG GAT TAC ACA CCA CTA 3456 CCG GCT GGT TAT GTA ACA AAG GAT TTA GAG TAC TTC CCA GAG ACC GAT 3504 AAG GTA TGG ATT GAG ATC GGA GAA ACA GAA GGA ACA TTC ATC GTG GAT 3552 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3579 6.7.7 DNA SEQUENCE ENCODING THE EGl 1768 CRYSTAL PROTEIN (SEQ ID NO:33) ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 AGA GCT CCT ATG TTC TCT TGG ATA CAT CGT AGT GCT GAA TTT AAT AAT 1392 ATA ATT GCA TCG GAT AGT ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 GCA ACA CTC GAG GCT GAA TAT AAT CTG GAA AGA GCG CAG AAG GCG GTG 1872 AAT GCG CTG TTT ACG TCT ACA AAC CAA CTA GGG CTA AAA ACA AAT GTA 1920 ACG GAT TAT CAT ATT GAT CAA GTG TCC AAT TTA GTT ACG TAT TTA TCG 1968 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 CAT GCG AAG CGA CTC AGT GAT GAA CGC AAT TTA CTC CAA GAT TCA AAT 2064 TTC AAA GAC ATT AAT AGG CAA CCA GAA CGT GGG TGG GGC GGA AGT ACA 2112 GGG ATT ACC ATC CAA GGA GGG GAT GAC GTA TTT AAA GAA AAT TAC GTC 2160 ACA CTA TCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 AGC GTG GAA TTA CTC CTT ATG GAG GAA TAG 3534 6.8 EXAMPLE 8 - ISOLATION OF TRANSGENIC PLANTS RESISTANT TO CRY* VARIANTS 6.8.1 PLANT GENE CONSTRUCTION The expression of a plant gene which exists in double-stranded DNA form involves transcription of messenger RNA (mRNA) from one strand of the DNA by RNA polymerase enzyme, and the subsequent processing of the mRNA primary transcript inside the nucleus. This processing involves a 3' non-translated region which adds polyadenylate nucleotides to the 3' end of the RNA. Transcription of DNA into mRNA is regulated by a region of DNA usually referred to as the "promoter". The promoter region contains a sequence of bases that signals RNA polymerase to associate with the DNA and to initiate the transcription of mRNA using one ofthe DNA strands as a template to make a corresponding strand of RNA. A number of promoters which are active in plant cells have been described in the literature. Such promoters may be obtained from plants or plant vimses and include, but are not limited to, the nopaline synthase (NOS) and octopine synthase (OCS) promoters (which are carried on tumor-inducing plasmids of Agrobacterium tumefaciens), the cauliflower mosaic vims (CaMV) 19S and 35S promoters, the light-inducible promoter from the small subunit of ribulose 1,5-bisphosphate carboxylase (ssRUBISCO, a very abundant plant polypeptide), and the Figwort Mosaic Virus (FMV) 35S promoter. All of these promoters have been used to create various types of DNA constructs which have been expressed in plants (see e.g., U. S. Patent No. 5,463,175, specifically incorporated herein by reference). The particular promoter selected should be capable of causing sufficient expression of the enzyme coding sequence to result in the production of an effective amount of protein. One set of preferred promoters are constitutive promoters such as the CaMV35S or FMV35S promoters that yield high levels of expression in most plant organs (U. S. Patent No. 5,378,619, specifically incorporated herein by reference). Another set of preferred promoters are root enhanced or specific promoters such as the CaMV derived 4 as-1 promoter or the wheat POX1 promoter (U. S. Patent No. 5,023,179, specifically incorporated herein by reference; Hertig et al, 1991). The root enhanced or specific promoters would be particularly preferred for the control of com rootworm (Diabroticus spp.) in transgenic com plants. The promoters used in the DNA constmcts (i.e. chimeric plant genes) ofthe present invention may be modified, if desired, to affect their control characteristics. For example, the CaMV35S promoter may be ligated to the portion of the ssRUBISCO gene that represses the expression of ssRUBISCO in the absence of light, to create a promoter which is active in leaves but not in roots. The resulting chimeric promoter may be used as described herein. For purposes of this description, the phrase "CaMV35S" promoter thus includes variations of CaMV35S promoter, e.g., promoters derived by means of ligation with operator regions, random or controlled mutagenesis, etc. Furthermore, the promoters may be altered to contain multiple "enhancer sequences" to assist in elevating gene expression. The RNA produced by a DNA constmct of the present invention also contains a 5' non-translated leader sequence. This sequence can be derived from the promoter selected to express the gene, and can be specifically modified so as to increase translation of the mRNA. The 5' non-translated regions can also be obtained from viral RNA's, from suitable eucaryotic genes, or from a synthetic gene sequence. The present invention is not limited to constmcts wherein the non-translated region is derived from the 5' non-translated sequence that accompanies the promoter sequence. For optimized expression in monocotyledenous plants such as maize, an intron should also be included in the DNA expression constmct. This intron would typically be placed near the 5' end of the mRNA in untranslated sequence. This intron could be obtained from, but not limited to, a set of introns consisting of the maize hsp70 intron (U. S. Patent No. 5,424,412; specifically incoφorated herein by reference) or the rice Actl intron (McElroy et al, 1990). As shown below, the maize hsp70 intron is useful in the present invention. As noted above, the 3' non-translated region of the chimeric plant genes of the present invention contains a polyadenylation signal which functions in plants to cause the addition of adenylate nucleotides to the 3' end of the RNA. Examples of preferred 3' regions are (1) the 3' transcribed, non-translated regions containing the polyadenylate signal of Agrobacterium tumor-inducing (Ti) plasmid genes, such as the nopaline synthase (NOS) gene and (2) plant genes such as the pea ssRUBISCO E9 gene (Fischhoff et al. , 1987). 6.8.2 PLANT TRANSFORMATION AND EXPRESSION A chimeric transgene containing a structural coding sequence of the present invention can be inserted into the genome of a plant by any suitable method such as those detailed herein. Suitable plant transformation vectors include those derived from a Ti plasmid of Agrobacterium tumefaciens, as well as those disclosed, e.g., by Herrera-Estrella (1983), Bevan (1983), Klee (1985) and Eur. Pat. Appl. Publ. No. EP0120516. In addition to plant transformation vectors derived from the Ti or root-inducing (Ri) plasmids of Agrobacterium, alternative methods can be used to insert the DNA constmcts of this invention into plant cells. Such methods may involve, for example, the use of liposomes, electroporation, chemicals that increase free DNA uptake, free DNA delivery via microprojectile bombardment, and transformation using vimses or pollen (Fromm et al, 1986; Armstrong et al, 1990; Fromm et al, 1990). 6.8.3 CONSTRUCTION OF PLANT EXPRESSION VECTORS FOR CRY* TRANSGENES For efficient expression of the cry* variants disclosed herein in transgenic plants, the gene encoding the variants must have a suitable sequence composition (Diehn et al, 1996). To place a cry* gene in a vector suitable for expression in monocotyledonous plants (i.e. under control of the enhanced Cauliflower Mosaic Vims 35S promoter and link to the hsp70 intron followed by a nopaline synthase polyadenylation site as in U. S. Patent No. 5,424,412, specifically incorporated herein by reference), the vector is digested with appropriate enzymes such as vVcøl and EcoRI. The larger vector band of approximately 4.6 kb is then electrophoresed, purified, and ligated with T4 DNA ligase to the appropriate restriction fragment containing the plantized cry* gene. The ligation mix is then transformed into E. coli, carbenicillin resistant colonies recovered and plasmid DNA recovered by DNA miniprep procedures. The DNA may then be subjected to restriction endonuclease analysis with enzymes such as Ncol and EcoRI (together), Notl, and Pstl to identify clones containing the cry* gene coding sequence fused to the hsp70 intron under control of the enhanced CaMV35S promoter). To place the gene in a vector suitable for recovery of stably transformed and insect resistant plants, the restriction fragment from pMOΝ33708 containing the lysine oxidase coding sequence fused to the hsp70 intron under control of the enhanced CaMV35S promoter may be isolated by gel electrophoresis and purification. This fragment can then be ligated with a vector such as pMON30460 treated with Notl and calf intestinal alkaline phosphatase (pMOΝ30460 contains the neomycin phosphotransferase coding sequence under control of the CaMV35S promoter). Kanamycin resistant colonies may then be obtained by transformation of this ligation mix into E. coli and colonies containing the resulting plasmid can be identified by restriction endonuclease digestion of plasmid miniprep DNAs. Restriction enzymes such as Notl, EcoRV, H dIII, Ncol, EcoRI, and BgUl can be used to identify the appropriate clones containing the restriction fragment properly inserted in the corresponding site of pMOΝ30460, in the orientation such that both genes are in tandem (i.e. the 3' end ofthe cry* gene expression cassette is linked to the 5' end ofthe nptll expression cassette). Expression of the Cry* protein by the resulting vector is then confirmed in plant protoplasts by electroporation of the vector into protoplasts followed by protein blot and ELISA analysis. This vector can be introduced into the genomic DNA of plant embryos such as maize by particle gun bombardment followed by paromomycin selection to obtain com plants expressing the cry* gene essentially as described in U. S. Patent No. 5,424,412, specifically incoφorated herein by reference. In this example, the vector was introduced via cobombardment with a hygromycin resistance conferring plasmid into immature embryo scutella (ies) of maize, followed by hygromycin selection, and regeneration. transgenic com lines expressing the cry* protein are then identified by elisa analysis, progeny seed from these events are then subsequently tested for protection from susceptible insect feeding. 7.0 REFERENCES The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incoφorated herein by reference. U. S. Patent 4,196,265, issued April 1, 1980. U. S. Patent 4,554,101, issued Nov. 19, 1985. U. S. Patent 4,683,195, issued Jul. 28, 1987. U. S. Patent 4,683,202, issued Jul. 28, 1987. U. S. Patent 4,702,914, issued Oct. 27, 1987. U. S. Patent 4,757,011 , issued Jul. 12, 1988. U. S. Patent 4,769,061, issued Sept. 6, 1988. U. S. Patent 4,940,835, issued Jul 10, 1990. U. S. Patent 4,965,188, issued Oct. 23, 1990. U. S. Patent 4,971,908, issued Nov. 20, 1990. U. S. Patent 4,987,071, issued January 22, 1991. U. S. Patent 5,004,863, issued Apr. 2, 1991. U. S. Patent 5,015,580, issued May 14, 1991. U. S. Patent 5,023,179, issued June 11, 1991. U. S. Patent 5,055,294, issued Oct. 8, 1991. U. S. Patent 5,128,130, issued Jul. 7, 1992. U. S. Patent 5,176,995, issued Jan. 5, 1993. U. S. Patent 5,349,124, issued Sept. 20, 1994. U. S. Patent 5,378,619, issued January 3, 1995. U. S. Patent 5,380,831, issued Jan. 10, 1995. U. S. Patent 5,384,253, issued Jan. 24, 1995. U. S. Patent 5,416,102, issued May 16, 1995. U. S. Patent 5,424,412, issued June 13, 1995. U. S. Patent 5,441,884, issued Aug. 15, 1995. U. S. Patent 5,449,681, issued Sept. 12, 1995. U. S. Patent 5,463,175, issued October 31, 1995. U. S. Patent 5,500,365, issued Mar. 19, 1996. U. S. Patent 5,631,359, issued May 20, 1997. U. S. Patent 5,659,123, issued Aug. 19, 1997. Eur. Pat. EP 0120516, issued October 3, 1984. Eur. Pat. EP 0360257, issued March 28, 1990. Intl. Pat. Appl. Publ. No. WO 91/10725, published Jul. 25, 1991. Intl. Pat. Appl. Publ. No. WO 93/07278, published Apr. 15, 1993. Intl. Pat. Appl. Publ. No. WO 95/02058, published Jan. 19, 1995. Intl. Pat. Appl. Publ. No. WO 95/06730, published Mar. 9, 1995. Intl. Pat. Appl. Publ. No. WO 95/30752, published Nov. 16, 1995. Intl. Pat. Appl. Publ. No. WO 95/30753, published Nov. 16, 1995. Intl. Pat. WO 92/07065, issued April 30, 1992, Intl. Pat. WO 93/15187, issued August 5, 1993. Intl. Pat. WO 93/23569, issued November 25, 1993. Intl. Pat. WO 94/02595, issued February 3, 1994. Intl. Pat. WO 94/13688, issued June 23, 1994. Intl. Pat. WO 91/03162, issued March 21, 1991. Abdullah et al, Biotechnology, 4:1087, 1986. Adami and Nevins, In: RNA Processing, Cold Spring Harbor Laboratory, p. 26, 1988. Adang et al, In: Molecular Strategies for Crop Protection, Alan R. Liss, Inc., pp. 345-353, 1987. Adelman et al, DNA, 2/3:183-193, 1983. Allen and Choun, "Large unilamellar liposomes with low uptake into the reticuloendothelial system," FEBS Lett., 223:42-46, 1987. Altschul, et al, "Basic local alignment search tool," J. Mol. Biol, 215:403-410, 1990. Arvidson et α/., o/. Biol, 3:1533-1534, 1989. Barton et al, Plant Physiol., 85:1103-1109, 1987. Baum et al, Appl. Environ. Microbiol, 56:3420-3428, 1990. Benbrook et al, In: Proceedings Bio Expo 1986, Butterworth, Stoneham, MA, pp. 27-54, 1986. Bevan et al, Nature, 304:184, 1983. Bolivar et al., Gene, 2:95, 1977. Bosch et al, " Recombinant Bacillus thuringiensis Crystal Proteins with New Properties: Possibilities for Resistance Management," Bio/Technology, 12:915-918, 1994. Brady and Wold, In: RNA Processing, Cold Spring Harbor Laboratory, p. 224, 1988. Brown, Nucl. Acids Res., 14(24):9549, 1986. Bytebier et al, Proc. Natl. Acad. Sci. USA, 84:5345, 1987. Callis et al. , Genes Develop. 1 : 1183, 1987. Callis, Fromm, Walbot, Genes and Develop., 1 :1183-1200, 1987. Campbell, In: Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 13, Burden and Von Knippenberg, Eds. pp. 75-83, Elsevier, Amsterdam, 1984. Capecchi, "High efficiency transformation by direct microinjection of DNA into cultured mammalian cells," Cell, 22(2):479-488, 1980. Cashmore et al, Gen. Eng. of Plants, Plenum Press, New York, 29-38, 1983. Chambers et al, J. Bacteriol, 173:3966-3976, 1991. Chang et al, Nature, 375:615, 1978. Chau et al. , Science, 244: 174-181 , 1989. Chen et al, Nucl Acids Res., 20:4581-9, 1992. Clapp, "Somatic gene theraphy into hematopoietic cells. Current status and future implications," Clin. Perinatol 20(1):155-168, 1993. Collins and Olive, Biochem., 32:2795-2799, 1993. Conway and Wickens, In: RNA Processing, Cold Spring Harbor Laboratory, p. 40, 1988. Cornellssen et al, EMBO J., 5(l):37-40, 1986. Couvreur et al, "Nanocapsules, a new lysosomotropic carrier," FEBS Lett., 84:323-326, 1977. Couvreur, "Polyalkyleyanoacrylates as colloidal dmg carriers," Crit. Rev. Ther. Drug Carrier Syst., 5:1-20, 1988. Crickmore et al, Abstr. 28th Annu. Meet. Soc. Invert. Pathol, Cornell University, Ithaca, NY, 1995. Cristou et al, Plant Physiol, 87:671-674, 1988. Curiel, Agarwal, Wagner, Cotten, "Adenovirus enhancement of transferrin-polylysine- mediated gene delivery," Proc. Natl. Acad. Sci. USA, 88(19):8850-8854, 1991. Curiel, Wagner, Cotten, Birnstiel, Agarwal, Li, Loechel, Hu, "High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes," Hum. Gen. Ther., 3(2):147-154, 1992. Daar et al, In: RNA Processing, Cold Spring Harbor Laboratory, p. 45, 1988. Dean et al., Nucl Acids Res., 14(5):2229, 1986. Dedrick et a/., J Biol Chem., 262(19):9098-l 106, 1987. Dhir et al. , Plant Cell Reports, 10:97, 1991. Diehn, De Rocher, Green., "Problems that can limit the expression of foreign genes in plants: Lessons to be learned from B.t. toxin genes," In: Genetic Engineering, Vol. 18, Edited by J.K. Setlow, Plenum Press, N.Y., 1996. Donovan et α/., J. Biol. Chem., 263(l):561-567, 1988. Doyle et al, J. Biol Chem., 261(20):9228-9236, 1986. Dropulic et α/., J. Virol, 66:1432-41, 1992. Eglitis and Anderson, "Retroviral vectors for introduction of genes into mammalian cells," Biotechniques, 6(7):608-614, 1988. Eglitis, Kantoff, Kohn, Karson, Moen, Lothrop, Blaese, Anderson, "Retroviral-mediated gene transfer into hemopoietic cells," Adv. Exp. Med. Biol, 241 :19-27, 1988. Eichenlaub, J. Bacteriol, 138(2):559-566, 1979. Elionor et al, Mol. Gen. Genet., 218:78-86, 1989. Elroy-Stein and Moss, Proc. Natl. Acad. Sci. USA, 87:6743-7, 1990. Fiers et al., Nature, 273:113, 1978. Fischhoff et al, Bio/Technology, 5:807, 1987. Fraley et al, Proc. Natl. Acad. Sci. USA, 80:4803, 1983. Fraley et al, Bio/Technology, 3:629-635, 1985. Fromm, Taylor, Walbot, Nature, 319:791-793, 1986. Fromm, Taylor, Walbot, "Expression of genes transferred into monocot and dicot plant cells by electroporation," Proc. Natl. Acad. Sci. USA, 82(17):5824-5828, 1985. Fromm et al, "Inheritance and expression of chimeric genes in the progeny of transgenic maize plants," Biotechnology (NY), 8(9):833-839, 1990. Fujimura et al, Plant Tissue Culture Letters, 2:74, 1985. Futterer and Hohn, "Translation in plants - rules and exceptions." Plant Mol. Biol, 32:159-189, 1996. Fynan, Webster, Fuller, Haynes, Santoro, Robinson, "DNA vaccines: protective immunizations by parenteral, mucosal, and gene gun inoculations," Proc. Natl. Acad. Sci. USA, 90(24): 11478-1 1482, 1993. Gallego and Nadal-Ginard, In: RNA Processing, Cold Spring Harbor Laboratory, p. 61, 1988. Gao and Huang, Nucl. Acids Res. , 21 :2867-72, 1993. Gawron-Burke and Baum, Genet. Engineer., 13:237-263, 1991. Gefter et al, Somat. Cell Genet., 3:231-236, 1977. Genovese and Milcarek, In: RNA Processing, Cold Spring Harbor Laboratory, p. 62, 1988. Gil and Proudfoot, Nature, 312:473, 1984. Gill et al, J. Biol. Chem., 270:27277-27282, 1995. Goding, "Monoclonal Antibodies: Principles and Practice," pp. 60-74. 2nd Edition, Academic Press, Orlando, FL, 1986. Goeddel et al, Nature, 281:544, 1979. Goeddel et al., Nucl. Acids Res., 8:4057, 1980. Goodall et al, In: RNA Processing, Cold Spring Harbor Laboratory, p. 63, 1988. Graham and van der Eb, "Transformation of rat cells by DNA of human adenovims 5," Virology, 54(2):536-539, 1973. Green, Nucl. Acids Res. 16(1):369. 1988. Grochulski et al., . Mol. Biol, 254:447-464, 1995. Gross et al, In: RNA Processing, Cold Spring Harbor Laboratory, p. 128, 1988. Guerrier-Takada et al, Cell, 35:849, 1983. Hampel and Tritz, Biochem., 28:4929, 1989. Hampel et al, Nucl Acids Res., 18:299, 1990 Hampson and Rottman, In: RNA Processing, Cold Spring Harbor Laboratory, p. 68, 1988. Hanley and Schuler, Nucl. Acids Res., 16(14):7159, 1988. Harlow and Lane, In: Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988. Helfman and Ricci, In: RNA Processing, Cold Spring Harbor Laboratory, p. 219, 1988. Henry-Michelland et al. , "Attachment of antibiotics to nanoparticles; Preparation, drug-release and antimicrobial activity in vitro, Int. J. Pharm., 35:121-127, 1987. Herrera-Estrella et al, Nature, 303:209, 1983. Hess et al, J. Adv. Enzyme Reg., 7:149, 1968. Hertig et al, "Sequence and tissue-specific expression of a putative peroxidase gene from wheat (Triticum aestivum L.)," Plant Mol. Biol, 16(1): 171-174, 1991. Hilber, Bodmer, Smith, Koller, "Biolistic transformation of conidia of Botryotinia fuckeliana," Curr. Genet., 25(2):124-127, 1994. Hitzeman et al, J. Biol. Chem., 255:2073, 1980. Hoekema et al, Molecular and Cellular Biology, 7:2914-2924, 1987. Hδfte and Whiteley, Microbiol. Rev., 53:242-255, 1989. Holland et al, Biochemistry, 17:4900, 1978. Honee et al, Mol Microbiol, 5:2799-2806, 1991. Honee et al., Nucl Acids Res., 16(13), 1988. Hoover et al, (Eds.), In: Remington 's Pharmaceutical Sciences, 15th Edition, Mack Publishing Co., Easton, PA, 1975. Horsch et al, Science, 227:1229-1231, 1985. Horsch et al, Science, 227:1229, 1985. Horton et al, Gene, 77:61-68, 1989. Humason, "Animal Tissue Techniques," W. H. Freeman & Company, New York, 1967. lannacone, Pasquale, Grieco, Francesco, Cellini, "Specific sequence modifications of a cr 3B endotoxin gene results in high levels of expression and insect resistance," Plant, Mol. Biol, 34:485-496, 1997. Itakura et al., Science, 198:1056, 1977. Jaeger et al, Proc. Natl. Acad. Sci. USA, 86: 7706-7710, 1989. Jameson and Wolf, "The Antigenic Index: A Novel Algorithm for Predicting Antigenic Determinants," Compu. Appl. Biosci., 4(l):181-6, 1988. Jarret et al. n Vitro, 17:825, 1981. Jarret et al, Physiol. Plant, 49:177, 1980. Johnston and Tang, "Gene gun transfection of animal cells and genetic immunization," Methods Cell. Biol, 43(A):353-365, 1994. Jones, Genetics, 85:12 1977. Jorgensen et al, Mol Gen. Genet., 207:471, 1987. Kaiser et al, "Amphiphilic secondary stmcture: design of peptide hormones," Science, 223(4633):249-255, 1984. Kashani-Saber et al, Antisense Res. Dev., 2:3-15, 1992. Kay et al, Science, 236:1299-1302, 1987. Keller et al, EMBO J., 8:1309-14, 1989. Kessler et al, In: RNA Processing, Cold Spring Harbor Laboratory, p. 85, 1988. Kingsman et α/., Gene, 7:141, 1979. Klee et al, Bio/Technology, 3:637, 1985. Klee et al, Bio/Technology, 3:637-642, 1985. Klein et al, Nature, 327:70, 1987. Klein et al, Proc. Natl. Acad. Sci. USA, 85:8502-8505, 1988. Knight et al, J. Biol. Chem., 270:17765-17770, 1995. Kohler and Milstein, Eur. J. Immunol, 6:511-519, 1976. Kohler and Milstein, Nature, 256:495-497, 1975. Kozak, Nature, 308:241-246, 1984. Krebbers et al. , Plant Molecular Biology, 11 :745-759, 1988. Kuby, Immunology 2nd Edition, W. H. Freeman & Company, New York, 1994. Kunkel, "Rapid and efficient site-specific mutagenesis without phenotypic selection," Proc. Natl Acad. Sci. U.S.A., 82(2):488-492, 1985. Kunkel et al. , "Rapid and efficient site-specific mutagenesis without phenotypic selection," Methods Enzymol, 154:367-382, 1987. Kyte and Doolittle, "A simple method for displaying the hydropathic character of a protein," J. Mol. Biol, 157(1):105-132, 1982. Langridge et al, Proc. Natl. Acad. Sci. USA, 86:3219-3223, 1989. Lee et al, Biochem. Biophys. Res. Comm., 216:306-312, 1995. LΗuillier et α/., E δO J., 11 :4411-8, 1992. Lieber et al, Methods Enzymol . 217:47-66, 1993. Lisziewicz et al, Proc. Natl. Acad. Sci. U.S.A., 90:8000-4, 1993. Lim et al. , "Human beta-globin mRNAs that harbor a nonsense codon are degraded in murine erythroid tissues to intermediates lacking regions of exon I or exons I and II that have a cap-like structure at the 5' termini," EMBO J., 1 1(9):3271-3278, 1992. Lindstrom et al, Develop. Genet., 11 :160, 1990. Lorz et α/., o/. Gen. Genet., 199: 178, 1985. Lu, Xiao, Clapp, Li, Broxmeyer, "High efficiency retroviral mediated gene transduction into single isolated immature and replatable CD34(3+) hematopoietic stem/progenitor cells from human umbilical cord blood," J. Exp. Med. 178(6):2089-2096, 1993. Luo et al, Plant Mol Biol. Report, 6:165, 1988. Maddock et al, Third Intl. Congr. Plant Mol Biol, Abstr. No. 372, 1991. Maloy et al, In: Microbiol Genetics, 2nd Ed., Jones & Bartlett Publishers, Boston, MA, 1994. Maniatis et al. , In: Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982. Marcotte et al, Nature, 335:454, 1988. Marrone et α/., J. Econ. Entomol, 78-290-293, 1985. Marzluff and Pandey, In: RNA Processing, Cold Spring Harbor Laboratory, p. 244, 1988. Masson et α/., J. Biol. Chem., 270:20309-20315, 1995. McCabe et al, Biotechnology, 6:923, 1988. McCormick et al, Plant Cell Reports, 5:81-84, 1986. McDevitt et al, Cell, 37:993-999, 1984. McElroy et al, "Characterization ofthe rice (Oryza sativa) actin gene family," Plant Mol Biol, 15(2):257-268, 1990. Mettus and Macaluso, Appl Environ. Microbiol. , 56:1128-1134, 1990. Murashige and Skoog, Physiol. Plant, 15:473, 1962. Murray, Lotzer, Eberle, "Codon usage in plant genes," Nucleic Acids Research, 17:(2)477-498, 1989. Neuhaus et al, Theor. Appl. Genet., 75:30, 1987. Odell et al, Nature, 313:810, 1985. Odell et al, Nature, 313:810, 1985. Ojwang et al., Proc. Natl. Acad. Sci. USA, 89: 10802-6, 1992. Ohkawa et al, Nucl. Acids Symp. Ser., 27: 15-6, 1992. Omirulleh et al, Plant Mol Biol, 21 :415-428, 1993. Pandey and Marzluff, In: RNA Processing, Cold Spring Harbor Laboratory, p. 133, 1987. Pieken et α/., 5c e«ce, 253:314, 1991. Pena et al, Nature, 325:274, 1987. Perrault et al, Nature, 344:565, 1990. Poszkowski et al, EMBO J., 3:2719, 1989. Potrykus et β/., Mol. Gen. Genet., 199:183, 1985. Poulsen et al. , Mol. Gen. Genet. , 205:193-200, 1986. Prokop and Bajpai, "Recombinant DNA Technology I" Ann. N. Y. Acad. Sci., Vol. 646, 1991. Proudfoot et al, In: RNA Processing, Cold Spring Harbor Laboratory, p. 17, 1987. Reines et α/., J. Mol. Biol, 196:299-312, 1987. Rogers et al, In: Methods For Plant Molecular Biology, A. Weissbach and H. Weissbach, eds., Academic Press Inc., San Diego, CA 1988. Rogers et al, Methods Enzymol, 153:253-277, 1987. Rossi et al, Aids Res. Hum. Retrovir., 8:183, 1992. Rouwendal, Odette Mendes, Wolbert Douwe de Boer, "Enhanced expression in tobaccoo of the gene encoding green fluorescent protein by modification of its codon usage," Plant Mol. Biol, 33:989-999, 1997. Ruud et al. , "Different Domains of Bacillus thuringiensis δ-Endotoxins Can Bind to Insect Midgut Membrane Proteins on Ligand Blots," Appl. Environ. Microbiol, 62(8):2753- 2757, 1996. Ruud et al., "Domain III Substitution in Bacillus thuringiensis Delta-Endotoxin CryΙA(b) Results in Superior Toxicity for Spodoptera exigua and Altered Membrane Protein Recognition," Appl. Environ. Microbiol, 62(5):1537-1543, 1996. Sadofsky and Alwine, Molecular and Cellular Biology, 4(8):1460-1468, 1984. Sambrook et al, In: Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989. Sanders et al, Nucl. Acids Res., 15(4): 1543, 1987. Saville and Collins, Cell, 61 :685-696, 1990. Saville and Collins, Proc. Natl Acad. Sci. USA, 88:8826-8830, 1991. Scanlon et al, Proc. Natl. Acad. Sci. USA, 88:10591-5, 1991. Scaringe et al., Nucl Acids Res. , 18:5433-5441, 1990. Schnepf et al, J. Biol. Chem., 265:20923-20930, 1990. Schuler et al, Nucl. Acids Res., 10(24):8225-8244, 1982. Segal, In: Biochemical Calculations, 2nd Ed., John Wiley & Sons, New York, 1976. Shaw and Kamen, Cell, 46:659-667, 1986. Shaw and Kamen, In: RNA Processing, Cold Spring Harbor Laboratory, p. 220, 1987. Simpson, Science, 233:34, 1986. Spielmann et al, Mol. Gen. Genet., 205:34, 1986. Spoerel, Methods Enzymol, 152:588-597, 1987. Stemmer, "DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution," Proc. Natl. Acad. Sci. U. S. A., 91(22):10747-10751, 1994. Stinchcomb et al, Nature, 282:39, 1979. Taira et α/., Nwc/. Acids Res., 19:5125-30, 1991. Thompson et al. , Genet. Engineer., 17:99-117, 1995. Toriyama et al. , Theor. Appl. Genet., 73: 16, 1986. Trolinder and Goodin, Plant Cell Reports, 6:231-234, 1987. Tschemper et al, Gene, 10:157, 1980 Tsumshita and Kom, In: RNA Processing, Cold Spring Harbor Laboratory, p. 215, 1987. Turner et al, Nucl Acids Reg., 14:8, 3325, 1986. Uchimiya et α/., Mol. Gen. Genet, 204:204, 1986. Usman and Cedergren, Trends in Biochem. Sci., 17:334, 1992. Vaeck et al, Nature, 328:33, 1987. Van Tunm et al, EMBO J., 7:1257, 1988. Vasil et al, "Herbicide-resistant fertile transgenic wheat plants obtained by microprojectile bombardment of regenerable embryogenic callus," Biotechnology, 10:667-674, 1992. Vasil, Biotechnology, 6:397, 1988. Velten and Schell, Nucl. Acids Res., 13:6981-6998, 1985. Velten et al, EMBO J., 3:2723-2730, 1984. Ventura et al, Nucl Acids Res., 21 :3249-55, 1993. Visser et al, Mol. Gen. Genet.. 212:219-224, 1988. Vodkin et al, Cell, 34:1023, 1983. Vogel et α/., J. Cell Biochem. , (Suppl.) 13D:312, 1989. Wagner, Zatloukal, Cotten, Kirlappos, Mechtler, Curiel, Birnstiel. "Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," Proc. Natl. Acad. Sci., USA 89(13):6099- 6103, 1992. Webb et al, Plant Sci. Letters, 30:1, 1983. Weerasinghe et α/., J Virol, 65:5531-4, 1991. Weissbach and Weissbach, Methods for Plant Molecular Biology, (eds.). Academic Press, Inc., San Diego, CA, 1988. Wenzler et al, Plant Mol. Biol, 12:41-50, 1989. Wickens and Stephenson, Science, 226: 1045, 1984. Wickens et al, In: RNA Processing, Cold Spring Harbor Laboratory, p. 9, 1987. Wiebauer et al. , Molecular and Cellular Biology, 8(5):2042-2051. 1988. Woolf et al, Proc. Natl. Acad. Sci. USA, 89:7305-7309, 1992. Wolf et al, "An Integrated Family of Amino Acid Sequence Analysis Programs." Compu. Appl. Biosci., 4(l):187-91, 1988. Wong and Neumann, "Electric field mediated gene transfer," Biochim. Biophys. Res. Commun., 107(2):584-587, 1982. Yamada et al, Plant Cell Rep., 4:85, 1986. Yamamoto and Iizuka, Archives of Biochemistry and Biophysics, 227(1):233-241, 1983. Yang et al, Proc. Natl. Acad. Sci., USA, 87:4144-48, 1990. Zhou et al, Methods Enzymol, 101 :433, 1983. Zhou et al. , Mol. Cell Biol. , 10:4529-37, 1990. All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. .0 SEQUENCE LISTING (1) GENERAL INFORMATION : (i) APPLICANT: (A) NAME: Ecogen, Inc. (B) STREET: 2005 Cabot Boulevard West (C) CITY: Langhorne (D) STATE: Pennsylvania (E) COUNTRY: USA (F) POSTAL CODE (ZIP) : 19047-3023 (ii) TITLE OF INVENTION: BROAD-SPECTRUM δ-ENDOTOXINS (iii) NUMBER OF SEQUENCES: 35 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/922,505 (B) FILING DATE: 03-SEP-1997 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/757,536 (B) FILING DATE: 27-NOV-1996 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/754,490 (B) FILING DATE: 20-NOV-1996 (2) INFORMATION FOR SEQ ID NO : 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1: GGATAGCACT CATCAAAGGT ACC 23 (2) INFORMATION FOR SEQ ID NO : 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 GAAGATATCC AATTCGAACA GTTTCCC 27 (2) INFORMATION FOR SEQ ID NO : 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3 CATATTCTGC CTCGAGTGTT GCAGTAAC 28 (2) INFORMATION FOR SEQ ID NO : 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: CCCGATCGGC CGCATGC 17 (2) INFORMATION FOR SEQ ID NO : 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5 CATTGGAGCT CTCCATG 17 (2) INFORMATION FOR SEQ ID NO : 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6 GCACTACGAT GTATCC 16 (2) INFORMATION FOR SEQ ID NO : 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CATCGTAGTG CAACTCTTAC 20 (2) INFORMATION FOR SEQ ID NO : 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : i CCAAGAAAAT ACTAGAGCTC TTGTTAAAAA AGGTGTTCC 39 (2) INFORMATION FOR SEQ ID NO : 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3531 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:!..3531 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 9: ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 Met Asp Asn Asn Pro Asn lie Asn Glu Cys lie Pro Tyr Asn Cys Leu 1 5 10 15 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg lie Glu Thr Gly 20 25 30 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3531 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1177 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 10: Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3531 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:!..3531 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 GCA ACA CTC GAG GCT GAA TAT AAT CTG GAA AGA GCG CAG AAG GCG GTG 1872 Ala Thr Leu Glu Ala Glu Tyr Asn Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 AAT GCG CTG TTT ACG TCT ACA AAC CAA CTA GGG CTA AAA ACA AAT GTA 1920 Asn Ala Leu Phe Thr Ser Thr Asn Gin Leu Gly Leu Lys Thr Asn Val 625 630 635 640 ACG GAT TAT CAT ATT GAT CAA GTG TCC AAT TTA GTT ACG TAT TTA TCG 1968 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Thr Tyr Leu Ser 645 650 655 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 CAT GCG AAG CGA CTC AGT GAT GAA CGC AAT TTA CTC CAA GAT TCA AAT 2064 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Ser Asn 675 680 685 TTC AAA GAC ATT AAT AGG CAA CCA GAA CGT GGG TGG GGC GGA AGT ACA 2112 Phe Lys Asp He Asn Arg Gin Pro Glu Arg Gly Trp Gly Gly Ser Thr 690 695 700 GGG ATT ACC ATC CAA GGA GGG GAT GAC GTA TTT AAA GAA AAT TAC GTC 2160 Gly He Thr He Gin Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 ACA CTA TCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 Thr Leu Ser Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3531 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1177 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 Ala Thr Leu Glu Ala Glu Tyr Asn Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 Asn Ala Leu Phe Thr Ser Thr Asn Gin Leu Gly Leu Lys Thr Asn Val 625 630 635 640 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Thr Tyr Leu Ser 645 650 655 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Ser Asn 675 680 685 Phe Lys Asp He Asn Arg Gin Pro Glu Arg Gly Trp Gly Gly Ser Thr 690 695 700 Gly He Thr He Gin Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 Thr Leu Ser Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3531 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:1..3531 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT CAT GCT GTA 624 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp His Ala Val 195 200 205 CGC TGG TAC AAT ACG GGA TTA GAG CGT GTA TGG GGA CCG GAT TCT AGA 672 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 GAT TGG ATA AGA TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 Asp Trp He Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 TTA GAT ATC GTT TCT CTA TTT CCG AAC TAT GAT AGT AGA ACG TAT CCA 768 Leu Asp He Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro 245 250 255 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 GGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 Gly Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 ATC TAT ACG GAT GCT CAT AGA GGA GAA TAT TAT TGG TCA GGG CAT CAA 960 He Tyr Thr Asp Ala His Arg Gly Glu Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 AGC GTG GAA TTA CTC CTT ATG GAG GAA 3531 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1177 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp His Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp He Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Gly Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Glu Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 ( 2 ) INFORMATION FOR SEQ ID NO : 15 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: TATCCAATTC GAACGTCATC 20 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: TTTAGTCATC GATTAAATCA 20 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ATAATAAGAG CTCCAATGTT 20 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: TACATCGTAG TGCAACTCTT 20 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19; TCATGGAGAG CTCCTATGTT 20 (2) INFORMATION FOR SEQ ID NO : 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: TTAACAAGAG CTCCTATGTT 20 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: ACTACCAGGT ACCTTTGATG 20 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: ACTACCGGGT ACCTTTGATA 20 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23 ATTTGAGTAA TACTATCC (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: ATTACTCAAA TACCATTGG 19 (2) INFORMATION FOR SEQ ID NO : 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3534 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:!..3531 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT CAT GCT GTA 624 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp His Ala Val 195 200 205 CGC TGG TAC AAT ACG GGA TTA GAG CGT GTA TGG GGA CCG GAT TCT AGA 672 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 GAT TGG ATA AGA TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 Asp Trp He Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 TTA GAT ATC GTT TCT CTA TTT CCG AAC TAT GAT AGT AGA ACG TAT CCA 768 Leu Asp He Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro 245 250 255 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 AGA GCT CCA ATG TTT TCT TGG ACG CAC CGT AGT GCA ACC CCT ACA AAT 1392 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 ACA ATT GAT CCG GAG AGG ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 2304 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT ' 2928 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 AGC GTG GAA TTA CTC CTT ATG GAG GAA TAG 3534 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO : 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1177 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26 Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp His Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp He Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ser Leu Phe Pro Asn Tyr Asp Ser Arg Thr Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp Thr His Arg Ser Ala Thr Pro Thr Asn 450 455 460 Thr He Asp Pro Glu Arg He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO : 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3534 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION :1..3531 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 27: ATG GAT AAC AAT CCG AAC ATC AAT GAA TGC ATT CCT TAT AAT TGT TTA 48 Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 AGT AAC CCT GAA GTA GAA GTA TTA GGT GGA GAA AGA ATA GAA ACT GGT 96 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 TAC ACC CCA ATC GAT ATT TCC TTG TCG CTA ACG CAA TTT CTT TTG AGT 144 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 GAA TTT GTT CCC GGT GCT GGA TTT GTG TTA GGA CTA GTT GAT ATA ATA 192 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 TGG GGA ATT TTT GGT CCC TCT CAA TGG GAC GCA TTT CTT GTA CAA ATT 240 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 GAA CAG TTA ATT AAC CAA AGA ATA GAA GAA TTC GCT AGG AAC CAA GCC 288 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 ATT TCT AGA TTA GAA GGA CTA AGC AAT CTT TAT CAA ATT TAC GCA GAA 336 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 TCT TTT AGA GAG TGG GAA GCA GAT CCT ACT AAT CCA GCA TTA AGA GAA 384 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 GAG ATG CGT ATT CAA TTC AAT GAC ATG AAC AGT GCC CTT ACA ACC GCT 432 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 ATT CCT CTT TTT GCA GTT CAA AAT TAT CAA GTT CCT CTT TTA TCA GTA 480 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 TAT GTT CAA GCT GCA AAT TTA CAT TTA TCA GTT TTG AGA GAT GTT TCA 528 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 GTG TTT GGA CAA AGG TGG GGA TTT GAT GCC GCG ACT ATC AAT AGT CGT 576 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 TAT AAT GAT TTA ACT AGG CTT ATT GGC AAC TAT ACA GAT TAT GCT GTA 624 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 CGC TGG TAC AAT ACG GGA TTA GAA CGT GTA TGG GGA CCG GAT TCT AGA 672 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 GAT TGG GTA AGG TAT AAT CAA TTT AGA AGA GAA TTA ACA CTA ACT GTA 720 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 TTA GAT ATC GTT GCT CTG TTC CCG AAT TAT GAT AGT AGA AGA TAT CCA 768 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 ATT CGA ACA GTT TCC CAA TTA ACA AGA GAA ATT TAT ACA AAC CCA GTA 816 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 TTA GAA AAT TTT GAT GGT AGT TTT CGA GGC TCG GCT CAG GGC ATA GAA 864 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 AGA AGT ATT AGG AGT CCA CAT TTG ATG GAT ATA CTT AAC AGT ATA ACC 912 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 ATC TAT ACG GAT GCT CAT AGG GGT TAT TAT TAT TGG TCA GGG CAT CAA 960 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 ATA ATG GCT TCT CCT GTA GGG TTT TCG GGG CCA GAA TTC ACT TTT CCG 1008 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 CTA TAT GGA ACT ATG GGA AAT GCA GCT CCA CAA CAA CGT ATT GTT GCT 1056 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 CAA CTA GGT CAG GGC GTG TAT AGA ACA TTA TCG TCC ACT TTA TAT AGA 1104 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 AGA CCT TTT AAT ATA GGG ATA AAT AAT CAA CAA CTA TCT GTT CTT GAC 1152 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 GGG ACA GAA TTT GCT TAT GGA ACC TCC TCA AAT TTG CCA TCC GCT GTA 1200 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 TAC AGA AAA AGC GGA ACG GTA GAT TCG CTG GAT GAA ATA CCG CCA CAG 1248 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 AAT AAC AAC GTG CCA CCT AGG CAA GGA TTT AGT CAT CGA TTA AGC CAT 1296 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 GTT TCA ATG TTT CGT TCA GGC TTT AGT AAT AGT AGT GTA AGT ATA ATA 1344 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 AGA GCT CCT ATG TTC TCT TGG ATA CAT CGT AGT GCT GAA TTT AAT AAT 1392 Arg Ala Pro Met Phe Ser Trp He His Arg Ser Ala Glu Phe Asn Asn 450 455 460 ATA ATT GCA TCG GAT AGT ATT ACT CAA ATA CCA TTG GTA AAA GCA CAT 1440 He He Ala Ser Asp Ser He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 ACA CTT CAG TCA GGT ACT ACT GTT GTA AGA GGG CCC GGG TTT ACG GGA 1488 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 GGA GAT ATT CTT CGA CGA ACA AGT GGA GGA CCA TTT GCT TAT ACT ATT 1536 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 GTT AAT ATA AAT GGG CAA TTA CCC CAA AGG TAT CGT GCA AGA ATA CGC 1584 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 TAT GCC TCT ACT ACA AAT CTA AGA ATT TAC GTA ACG GTT GCA GGT GAA 1632 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 CGG ATT TTT GCT GGT CAA TTT AAC AAA ACA ATG GAT ACC GGT GAC CCA 1680 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 TTA ACA TTC CAA TCT TTT AGT TAC GCA ACT ATT AAT ACA GCT TTT ACA 1728 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 TTC CCA ATG AGC CAG AGT AGT TTC ACA GTA GGT GCT GAT ACT TTT AGT 1776 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 TCA GGG AAT GAA GTT TAT ATA GAC AGA TTT GAA TTG ATT CCA GTT ACT 1824 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 GCA ACA TTT GAA GCA GAA TAT GAT TTA GAA AGA GCA CAA AAG GCG GTG 1872 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 510 615 620 AAT GCG CTG TTT ACT TCT ATA AAC CAA ATA GGG ATA AAA ACA GAT GTG 1920 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 ACG GAT TAT CAT ATT GAT CAA GTA TCC AAT TTA GTG GAT TGT TTA TCA 1968 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 GAT GAA TTT TGT CTG GAT GAA AAG CGA GAA TTG TCC GAG AAA GTC AAA 2016 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 CAT GCG AAG CGA CTC AGT GAT GAG CGG AAT TTA CTT CAA GAT CCA AAC 2064 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 TTC AAA GGC ATC AAT AGG CAA CTA GAC CGT GGT TGG AGA GGA AGT ACG 2112 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 GAT ATT ACC ATC CAA AGA GGA GAT GAC GTA TTC AAA GAA AAT TAT GTC 2160 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 ACA CTA CCA GGT ACC TTT GAT GAG TGC TAT CCA ACA TAT TTG TAT CAA 2208 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 AAA ATC GAT GAA TCA AAA TTA AAA GCC TTT ACC CGT TAT CAA TTA AGA 2256 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 GGG TAT ATC GAA GAT AGT CAA GAC TTA GAA ATC TAT TTA ATT CGC TAC 230 4 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 AAT GCA AAA CAT GAA ACA GTA AAT GTG CCA GGT ACG GGT TCC TTA TGG 2352 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 CCG CTT TCA GCC CAA AGT CCA ATC GGA AAG TGT GGA GAG CCG AAT CGA 2400 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 TGC GCG CCA CAC CTT GAA TGG AAT CCT GAC TTA GAT TGT TCG TGT AGG 2448 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 GAT GGA GAA AAG TGT GCC CAT CAT TCG CAT CAT TTC TCC TTA GAC ATT 2496 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 GAT GTA GGA TGT ACA GAC TTA AAT GAG GAC CTA GGT GTA TGG GTG ATC 2544 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 TTT AAG ATT AAG ACG CAA GAT GGG CAC GCA AGA CTA GGG AAT CTA GAG 2592 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 TTT CTC GAA GAG AAA CCA TTA GTA GGA GAA GCG CTA GCT CGT GTG AAA 2640 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 AGA GCG GAG AAA AAA TGG AGA GAC AAA CGT GAA AAA TTG GAA TGG GAA 2688 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 ACA AAT ATC GTT TAT AAA GAG GCA AAA GAA TCT GTA GAT GCT TTA TTT 2736 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 GTA AAC TCT CAA TAT GAT CAA TTA CAA GCG GAT ACG AAT ATT GCC ATG 2784 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 ATT CAT GCG GCA GAT AAA CGT GTT CAT AGC ATT CGA GAA GCT TAT CTG 2832 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 CCT GAG CTG TCT GTG ATT CCG GGT GTC AAT GCG GCT ATT TTT GAA GAA 2880 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 TTA GAA GGG CGT ATT TTC ACT GCA TTC TCC CTA TAT GAT GCG AGA AAT 2928 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 GTC ATT AAA AAT GGT GAT TTT AAT AAT GGC TTA TCC TGC TGG AAC GTG 2976 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 AAA GGG CAT GTA GAT GTA GAA GAA CAA AAC AAC CAA CGT TCG GTC CTT 3024 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 GTT GTT CCG GAA TGG GAA GCA GAA GTG TCA CAA GAA GTT CGT GTC TGT 3072 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 CCG GGT CGT GGC TAT ATC CTT CGT GTC ACA GCG TAC AAG GAG GGA TAT 3120 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 GGA GAA GGT TGC GTA ACC ATT CAT GAG ATC GAG AAC AAT ACA GAC GAA 3168 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 CTG AAG TTT AGC AAC TGC GTA GAA GAG GAA ATC TAT CCA AAT AAC ACG 3216 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 GTA ACG TGT AAT GAT TAT ACT GTA AAT CAA GAA GAA TAC GGA GGT GCG 3264 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 TAC ACT TCT CGT AAT CGA GGA TAT AAC GAA GCT CCT TCC GTA CCA GCT 3312 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 GAT TAT GCG TCA GTC TAT GAA GAA AAA TCG TAT ACA GAT GGA CGA AGA 3360 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 GAG AAT CCT TGT GAA TTT AAC AGA GGG TAT AGG GAT TAC ACG CCA CTA 3408 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 CCA GTT GGT TAT GTG ACA AAA GAA TTA GAA TAC TTC CCA GAA ACC GAT 3456 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 AAG GTA TGG ATT GAG ATT GGA GAA ACG GAA GGA ACA TTT ATC GTG GAC 3504 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 AGC GTG GAA TTA CTC CTT ATG GAG GAA TAG 3534 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO : 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1177 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 28: Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Arg Ser He Arg Ser Pro H s Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp He His Arg Ser Ala Glu Phe Asn Asn 450 455 460 He He Ala Ser Asp Ser He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 Phe Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 Ala Thr Phe Glu Ala Glu Tyr Asp Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 Asn Ala Leu Phe Thr Ser He Asn Gin He Gly He Lys Thr Asp Val 625 630 635 640 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser 645 650 655 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn 675 680 685 Phe Lys Gly He Asn Arg Gin Leu Asp Arg Gly Trp Arg Gly Ser Thr 690 695 700 Asp He Thr He Gin Arg Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 Thr Leu Pro Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg H05 1110 1115 1120 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO : 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3579 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 29: ATGGATAACA ATCCGAACAT CAATGAATGC ATTCCTTATA ATTGTTTAAG TAACCCTGAA 60 GTAGAAGTAT TAGGTGGAGA AAGAATAGAA ACTGGTTACA CCCCAATCGA TATTTCCTTG 120 TCGCTAACGC AATTTCTTTT GAGTGAATTT GTTCCCGGTG CTGGATTTGT GTTAGGACTA 180 GTTGATATAA TATGGGGAAT TTTTGGTCCC TCTCAATGGG ACGCATTTCT TGTACAAATT 240 GAACAGTTAA TTAACCAAAG AATAGAAGAA TTCGCTAGGA ACCAAGCCAT TTCTAGATTA 300 GAAGGACTAA GCAATCTTTA TCAAATTTAC GCAGAATCTT TTAGAGAGTG GGAAGCAGAT 360 CCTACTAATC CAGCATTAAG AGAAGAGATG CGTATTCAAT TCAATGACAT GAACAGTGCC 420 CTTACAACCG CTATTCCTCT TTTTGCAGTT CAAAATTATC AAGTTCCTCT TTTATCAGTA 480 TATGTTCAAG CTGCAAATTT ACATTTATCA GTTTTGAGAG ATGTTTCAGT GTTTGGACAA 540 AGGTGGGGAT TTGATGCCGC GACTATCAAT AGTCGTTATA ATGATTTAAC TAGGCTTATT 600 GGCAACTATA CAGATTATGC TGTACGCTGG TACAATACGG GATTAGAACG TGTATGGGGA 660 CCGGATTCTA GAGATTGGGT AAGGTATAAT CAATTTAGAA GAGAATTAAC ACTAACTGTA 720 TTAGATATCG TTGCTCTGTT CCCGAATTAT GATAGTAGAA GATATCCAAT TCGAACAGTT 780 TCCCAATTAA CAAGAGAAAT TTATACAAAC CCAGTATTAG AAAATTTTGA TGGTAGTTTT 840 CGAGGCTCGG CTCAGGGCAT AGAAAGAAGT ATTAGGAGTC CACATTTGAT GGATATACTT 900 AACAGTATAA CCATCTATAC GGATGCTCAT AGGGGTTATT ATTATTGGTC AGGGCATCAA 960 ATAATGGCTT CTCCTGTAGG GTTTTCGGGG CCAGAATTCA CTTTTCCGCT ATATGGAACT 1020 ATGGGAAATG CAGCTCCACA ACAACGTATT GTTGCTCAAC TAGGTCAGGG CGTGTATAGA 1080 ACATTATCGT CCACTTTATA TAGAAGACCT TTTAATATAG GGATAAATAA TCAACAACTA 1140 TCTGTTCTTG ACGGGACAGA ATTTGCTTAT GGAACCTCCT CAAATTTGCC ATCCGCTGTA 1200 TACAGAAAAA GCGGAACGGT AGATTCGCTG GATGAAATAC CGCCACAGAA TAACAACGTG 1260 CCACCTAGGC AAGGATTTAG TCATCGATTA AGCCATGTTT CAATGTTTCG TTCAGGCTTT 1320 AGTAATAGTA GTGTAAGTAT AATAAGAGCT CCTATGTTCT CTTGGATACA TCGTAGTGCA 1380 ACTCTTACAA ATACAATTGA TCCAGAGAGA ATTAATCAAA TACCTTTAGT GAAAGGATTT 1440 AGAGTTTGGG GGGGCACCTC TGTCATTACA GGACCAGGAT TTACAGGAGG GGATATCCTT 1500 CGAAGAAATA CCTTTGGTGA TTTTGTATCT CTACAAGTCA ATATTAATTC ACCAATTACC 1560 CAAAGATACC GTTTAAGATT TCGTTACGCT TCCAGTAGGG ATGCACGAGT TATAGTATTA 1620 ACAGGAGCGG CATCCACAGG AGTGGGAGGC CAAGTTAGTG TAAATATGCC TCTTCAGAAA 1680 ACTATGGAAA TAGGGGAGAA CTTAACATCT AGAACATTTA GATATACCGA TTTTAGTAAT 1740 CCTTTTTCAT TTAGAGCTAA TCCAGATATA ATTGGGATAA GTGAACAACC TCTATTTGGT 1800 GCAGGTTCTA TTAGTAGCGG TGAACTTTAT ATAGATAAAA TTGAAATTAT TCTAGCAGAT 1860 GCAACATTTG AAGCAGAATC TGATTTAGAA AGAGCACAAA AGGCGGTGAA TGCCCTGTTT 1920 ACTTCTTCCA ATCAAATCGG GTTAAAAACC GATGTGACGG ATTATCATAT TGATCAAGTA 1980 TCCAATTTAG TGGATTGTTT ATCAGATGAA TTTTGTCTGG ATGAAAAGCG AGAATTGTCC 2040 GAGAAAGTCA AACATGCGAA GCGACTCAGT GATGAGCGGA ATTTACTTCA AGATCCAAAC 2100 TTCAGAGGGA TCAATAGACA ACCAGACCGT GGCTGGAGAG GAAGTACAGA TATTACCATC 2160 CAAGGAGGAG ATGACGTATT CAAAGAGAAT TACGTCACAC TACCGGGTAC CGTTGATGAG 2220 TGCTATCCAA CGTATTTATA TCAGAAAATA GATGAGTCGA AATTAAAAGC TTATACCCGT 2280 TATGAATTAA GAGGGTATAT CGAAGATAGT CAAGACTTAG AAATCTATTT GATCCGTTAC 2340 AATGCAAAAC ACGAAATAGT AAATGTGCCA GGCACGGGTT CCTTATGGCC GCTTTCAGCC 2400 CAAAGTCCAA TCGGAAAGTG TGGAGAACCG AATCGATGCG CGCCACACCT TGAATGGAAT 2460 CCTGATCTAG ATTGTTCCTG CAGAGACGGG GAAAAATGTG CACATCATTC CCATCATTTC 2520 ACCTTGGATA TTGATGTTGG ATGTACAGAC TTAAATGAGG ACTTAGGTGT ATGGGTGATA 2580 TTCAAGATTA AGACGCAAGA TGGCCATGCA AGACTAGGGA ATCTAGAGTT TCTCGAAGAG 2640 AAACCATTAT TAGGGGAAGC ACTAGCTCGT GTGAAAAGAG CGGAGAAGAA GTGGAGAGAC 2700 AAACGAGAGA AACTGCAGTT GGAAACAAAT ATTGTTTATA AAGAGGCAAA AGAATCTGTA 2760 GATGCTTTAT TTGTAAACTC TCAATATGAT AGATTACAAG TGGATACGAA CATCGCAATG 2820 ATTCATGCGG CAGATAAACG CGTTCATAGA ATCCGGGAAG CGTATCTGCC AGAGTTGTCT 2880 GTGATTCCAG GTGTCAATGC GGCCATTTTC GAAGAATTAG AGGGACGTAT TTTTACAGCG 2940 TATTCCTTAT ATGATGCGAG AAATGTCATT AAAAATGGCG ATTTCAATAA TGGCTTATTA 3000 TGCTGGAACG TGAAAGGTCA TGTAGATGTA GAAGAGCAAA ACAACCACCG TTCGGTCCTT 3060 GTTATCCCAG AATGGGAGGC AGAAGTGTCA CAAGAGGTTC GTGTCTGTCC AGGTCGTGGC 3120 TATATCCTTC GTGTCACAGC ATATAAAGAG GGATATGGAG AGGGCTGCGT AACGATCCAT 3180 GAGATCGAAG ACAATACAGA CGAACTGAAA TTCAGCAACT GTGTAGAAGA GGAAGTATAT 3240 CCAAACAACA CAGTAACGTG TAATAATTAT ACTGGGACTC AAGAAGAATA TGAGGGTACG 3300 TACACTTCTC GTAATCAAGG ATATGACGAA GCCTATGGTA ATAACCCTTC CGTACCAGCT 3360 GATTACGCTT CAGTCTATGA AGAAAAATCG TATACAGATG GACGAAGAGA GAATCCTTGT 3420 GAATCTAACA GAGGCTATGG GGATTACACA CCACTACCGG CTGGTTATGT AACAAAGGAT 3480 TTAGAGTACT TCCCAGAGAC CGATAAGGTA TGGATTGAGA TCGGAGAAAC AGAAGGAACA 3540 TTCATCGTGG ATAGCGTGGA ATTACTCCTT ATGGAGGAA 3579 (2) INFORMATION FOR SEQ ID NO : 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1193 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 30: Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp He His Arg Ser Ala Thr Leu Thr Asn 450 455 460 Thr He Asp Pro Glu Arg He Asn Gin He Pro Leu Val Lys Gly Phe 465 470 475 480 Arg Val Trp Gly Gly Thr Ser Val He Thr Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Asn Thr Phe Gly Asp Phe Val Ser Leu Gin 500 505 510 Val Asn He Asn Ser Pro He Thr Gin Arg Tyr Arg Leu Arg Phe Arg 515 520 525 Tyr Ala Ser Ser Arg Asp Ala Arg Val He Val Leu Thr Gly Ala Ala 530 535 540 Ser Thr Gly Val Gly Gly Gin Val Ser Val Asn Met Pro Leu Gin Lys 545 550 555 560 Thr Met Glu He Gly Glu Asn Leu Thr Ser Arg Thr Phe Arg Tyr Thr 565 570 575 Asp Phe Ser Asn Pro Phe Ser Phe Arg Ala Asn Pro Asp He He Gly 580 585 590 He Ser Glu Gin Pro Leu Phe Gly Ala Gly Ser He Ser Ser Gly Glu 595 600 605 Leu Tyr He Asp Lys He Glu He He Leu Ala Asp Ala Thr Phe Glu 610 615 620 Ala Glu Ser Asp Leu Glu Arg Ala Gin Lys Ala Val Asn Ala Leu Phe 625 630 635 640 Thr Ser Ser Asn Gin He Gly Leu Lys Thr Asp Val Thr Asp Tyr His 645 650 655 He Asp Gin Val Ser Asn Leu Val Asp Cys Leu Ser Asp Glu Phe Cys 660 665 670 Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys His Ala Lys Arg 675 680 685 Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Pro Asn Phe Arg Gly He 690 695 700 Asn Arg Gin Pro Asp Arg Gly Trp Arg Gly Ser Thr Asp He Thr He 705 710 715 720 Gin Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val Thr Leu Pro Gly 725 730 735 Thr Val Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin Lys He Asp Glu 740 745 750 Ser Lys Leu Lys Ala Tyr Thr Arg Tyr Glu Leu Arg Gly Tyr He Glu 755 760 765 Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr Asn Ala Lys His 770 775 780 Glu He Val Asn Val Pro Gly Thr Gly Ser Leu Trp Pro Leu Ser Ala 785 790 795 800 Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg Cys Ala Pro His 805 810 815 Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg Asp Gly Glu Lys 820 825 830 Cys Ala His His Ser His His Phe Thr Leu Asp He Asp Val Gly Cys 835 840 845 Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He Phe Lys He Lys 850 855 860 Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu Phe Leu Glu Glu 865 870 875 880 Lys Pro Leu Leu Gly Glu Ala Leu Ala Arg Val Lys Arg Ala Glu Lys 885 890 895 Lys Trp Arg Asp Lys Arg Glu Lys Leu Gin Leu Glu Thr Asn He Val 900 905 910 Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe Val Asn Ser Gin 915 920 925 Tyr Asp Arg Leu Gin Val Asp Thr Asn He Ala Met He His Ala Ala 930 935 940 Asp Lys Arg Val His Arg He Arg Glu Ala Tyr Leu Pro Glu Leu Ser 945 950 955 960 Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu Leu Glu Gly Arg 965 970 975 He Phe Thr Ala Tyr Ser Leu Tyr Asp Ala Arg Asn Val He Lys Asn 980 985 990 Gly Asp Phe Asn Asn Gly Leu Leu Cys Trp Asn Val Lys Gly His Val 995 1000 1005 Asp Val Glu Glu Gin Asn Asn His Arg Ser Val Leu Val He Pro Glu 1010 1015 1020 Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys Pro Gly Arg Gly 1025 1030 1035 1040 Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr Gly Glu Gly Cys 1045 1050 1055 Val Thr He His Glu He Glu Asp Asn Thr Asp Glu Leu Lys Phe Ser 1060 1065 1070 Asn Cys Val Glu Glu Glu Val Tyr Pro Asn Asn Thr Val Thr Cys Asn 1075 1080 1085 Asn Tyr Thr Gly Thr Gin Glu Glu Tyr Glu Gly Thr Tyr Thr Ser Arg 1090 1095 1100 Asn Gin Gly Tyr Asp Glu Ala Tyr Gly Asn Asn Pro Ser Val Pro Ala 1105 1110 1115 1120 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1125 1130 1135 Glu Asn Pro Cys Glu Ser Asn Arg Gly Tyr Gly Asp Tyr Thr Pro Leu 1140 1145 1150 Pro Ala Gly Tyr Val Thr Lys Asp Leu Glu Tyr Phe Pro Glu Thr Asp 1155 1160 1165 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1170 1175 1180 Ser Val Glu Leu Leu Leu Met Glu Glu 1185 1190 (2) INFORMATION FOR SEQ ID NO : 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 31: CGTTGCTCTG TTCCCG 16 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: TCAAATACCA TTGGTAAAAG 20 (2) INFORMATION FOR SEQ ID NO : 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3534 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: ATGGATAACA ATCCGAACAT CAATGAATGC ATTCCTTATA ATTGTTTAAG TAACCCTGAA 60 GTAGAAGTAT TAGGTGGAGA AAGAATAGAA ACTGGTTACA CCCCAATCGA TATTTCCTTG 120 TCGCTAACGC AATTTCTTTT GAGTGAATTT GTTCCCGGTG CTGGATTTGT GTTAGGACTA 180 GTTGATATAA TATGGGGAAT TTTTGGTCCC TCTCAATGGG ACGCATTTCT TGTACAAATT 240 GAACAGTTAA TTAACCAAAG AATAGAAGAA TTCGCTAGGA ACCAAGCCAT TTCTAGATTA 300 GAAGGACTAA GCAATCTTTA TCAAATTTAC GCAGAATCTT TTAGAGAGTG GGAAGCAGAT 360 CCTACTAATC CAGCATTAAG AGAAGAGATG CGTATTCAAT TCAATGACAT GAACAGTGCC 420 CTTACAACCG CTATTCCTCT TTTTGCAGTT CAAAATTATC AAGTTCCTCT TTTATCAGTA 480 TATGTTCAAG CTGCAAATTT ACATTTATCA GTTTTGAGAG ATGTTTCAGT GTTTGGACAA 540 AGGTGGGGAT TTGATGCCGC GACTATCAAT AGTCGTTATA ATGATTTAAC TAGGCTTATT 600 GGCAACTATA CAGATTATGC TGTACGCTGG TACAATACGG GATTAGAACG TGTATGGGGA 660 CCGGATTCTA GAGATTGGGT AAGGTATAAT CAATTTAGAA GAGAATTAAC ACTAACTGTA 720 TTAGATATCG TTGCTCTGTT CCCGAATTAT GATAGTAGAA GATATCCAAT TCGAACAGTT 780 TCCCAATTAA CAAGAGAAAT TTATACAAAC CCAGTATTAG AAAATTTTGA TGGTAGTTTT 840 CGAGGCTCGG CTCAGGGCAT AGAAAGAAGT ATTAGGAGTC CACATTTGAT GGATATACTT 900 AACAGTATAA CCATCTATAC GGATGCTCAT AGGGGTTATT ATTATTGGTC AGGGCATCAA 960 ATAATGGCTT CTCCTGTAGG GTTTTCGGGG CCAGAATTCA CTTTTCCGCT ATATGGAACT 1020 ATGGGAAATG CAGCTCCACA ACAACGTATT GTTGCTCAAC TAGGTCAGGG CGTGTATAGA 1080 ACATTATCGT CCACTTTATA TAGAAGACCT TTTAATATAG GGATAAATAA TCAACAACTA 1140 TCTGTTCTTG ACGGGACAGA ATTTGCTTAT GGAACCTCCT CAAATTTGCC ATCCGCTGTA 1200 TACAGAAAAA GCGGAACGGT AGATTCGCTG GATGAAATAC CGCCACAGAA TAACAACGTG 1260 CCACCTAGGC AAGGATTTAG TCATCGATTA AGCCATGTTT CAATGTTTCG TTCAGGCTTT 1320 AGTAATAGTA GTGTAAGTAT AATAAGAGCT CCTATGTTCT CTTGGATACA TCGTAGTGCT 1380 GAATTTAATA ATATAATTGC ATCGGATAGT ATTACTCAAA TACCATTGGT AAAAGCACAT 1440 ACACTTCAGT CAGGTACTAC TGTTGTAAGA GGGCCCGGGT TTACGGGAGG AGATATTCTT 1500 CGACGAACAA GTGGAGGACC ATTTGCTTAT ACTATTGTTA ATATAAATGG GCAATTACCC 1560 CAAAGGTATC GTGCAAGAAT ACGCTATGCC TCTACTACAA ATCTAAGAAT TTACGTAACG 1620 GTTGCAGGTG AACGGATTTT TGCTGGTCAA TTTAACAAAA CAATGGATAC CGGTGACCCA 1680 TTAACATTCC AATCTTTTAG TTACGCAACT ATTAATACAG CTTTTACATT CCCAATGAGC 1740 CAGAGTAGTT TCACAGTAGG TGCTGATACT TTTAGTTCAG GGAATGAAGT TTATATAGAC 1800 AGATTTGAAT TGATTCCAGT TACTGCAACA CTCGAGGCTG AATATAATCT GGAAAGAGCG 1860 CAGAAGGCGG TGAATGCGCT GTTTACGTCT ACAAACCAAC TAGGGCTAAA AACAAATGTA 1920 ACGGATTATC ATATTGATCA AGTGTCCAAT TTAGTTACGT ATTTATCGGA TGAATTTTGT 1980 CTGGATGAAA AGCGAGAATT GTCCGAGAAA GTCAAACATG CGAAGCGACT CAGTGATGAA 2040 CGCAATTTAC TCCAAGATTC AAATTTCAAA GACATTAATA GGCAACCAGA ACGTGGGTGG 2100 GGCGGAAGTA CAGGGATTAC CATCCAAGGA GGGGATGACG TATTTAAAGA AAATTACGTC 2160 ACACTATCAG GTACCTTTGA TGAGTGCTAT CCAACATATT TGTATCAAAA AATCGATGAA 2220 TCAAAATTAA AAGCCTTTAC CCGTTATCAA TTAAGAGGGT ATATCGAAGA TAGTCAAGAC 2280 TTAGAAATCT ATTTAATTCG CTACAATGCA AAACATGAAA CAGTAAATGT GCCAGGTACG 2340 GGTTCCTTAT GGCCGCTTTC AGCCCAAAGT CCAATCGGAA AGTGTGGAGA GCCGAATCGA 2400 TGCGCGCCAC ACCTTGAATG GAATCCTGAC TTAGATTGTT CGTGTAGGGA TGGAGAAAAG 2460 TGTGCCCATC ATTCGCATCA TTTCTCCTTA GACATTGATG TAGGATGTAC AGACTTAAAT 2520 GAGGACCTAG GTGTATGGGT GATCTTTAAG ATTAAGACGC AAGATGGGCA CGCAAGACTA 2580 GGGAATCTAG AGTTTCTCGA AGAGAAACCA TTAGTAGGAG AAGCGCTAGC TCGTGTGAAA 2640 AGAGCGGAGA AAAAATGGAG AGACAAACGT GAAAAATTGG AATGGGAAAC AAATATCGTT 2700 TATAAAGAGG CAAAAGAATC TGTAGATGCT TTATTTGTAA ACTCTCAATA TGATCAATTA 2760 CAAGCGGATA CGAATATTGC CATGATTCAT GCGGCAGATA AACGTGTTCA TAGCATTCGA 2820 GAAGCTTATC TGCCTGAGCT GTCTGTGATT CCGGGTGTCA ATGCGGCTAT TTTTGAAGAA 2880 TTAGAAGGGC GTATTTTCAC TGCATTCTCC CTATATGATG CGAGAAATGT CATTAAAAAT 2940 GGTGATTTTA ATAATGGCTT ATCCTGCTGG AACGTGAAAG GGCATGTAGA TGTAGAAGAA 3000 CAAAACAACC AACGTTCGGT CCTTGTTGTT CCGGAATGGG AAGCAGAAGT GTCACAAGAA 3060 GTTCGTGTCT GTCCGGGTCG TGGCTATATC CTTCGTGTCA CAGCGTACAA GGAGGGATAT 3120 GGAGAAGGTT GCGTAACCAT TCATGAGATC GAGAACAATA CAGACGAACT GAAGTTTAGC 3180 AACTGCGTAG AAGAGGAAAT CTATCCAAAT AACACGGTAA CGTGTAATGA TTATACTGTA 3240 AATCAAGAAG AATACGGAGG TGCGTACACT TCTCGTAATC GAGGATATAA CGAAGCTCCT 3300 TCCGTACCAG CTGATTATGC GTCAGTCTAT GAAGAAAAAT CGTATACAGA TGGACGAAGA 3360 GAGAATCCTT GTGAATTTAA CAGAGGGTAT AGGGATTACA CGCCACTACC AGTTGGTTAT 3420 GTGACAAAAG AATTAGAATA CTTCCCAGAA ACCGATAAGG TATGGATTGA GATTGGAGAA 3480 ACGGAAGGAA CATTTATCGT GGACAGCGTG GAATTACTCC TTATGGAGGA ATAG 3534 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1177 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: Met Asp Asn Asn Pro Asn He Asn Glu Cys He Pro Tyr Asn Cys Leu 1 5 10 15 Ser Asn Pro Glu Val Glu Val Leu Gly Gly Glu Arg He Glu Thr Gly 20 25 30 Tyr Thr Pro He Asp He Ser Leu Ser Leu Thr Gin Phe Leu Leu Ser 35 40 45 Glu Phe Val Pro Gly Ala Gly Phe Val Leu Gly Leu Val Asp He He 50 55 60 Trp Gly He Phe Gly Pro Ser Gin Trp Asp Ala Phe Leu Val Gin He 65 70 75 80 Glu Gin Leu He Asn Gin Arg He Glu Glu Phe Ala Arg Asn Gin Ala 85 90 95 He Ser Arg Leu Glu Gly Leu Ser Asn Leu Tyr Gin He Tyr Ala Glu 100 105 110 Ser Phe Arg Glu Trp Glu Ala Asp Pro Thr Asn Pro Ala Leu Arg Glu 115 120 125 Glu Met Arg He Gin Phe Asn Asp Met Asn Ser Ala Leu Thr Thr Ala 130 135 140 He Pro Leu Phe Ala Val Gin Asn Tyr Gin Val Pro Leu Leu Ser Val 145 150 155 160 Tyr Val Gin Ala Ala Asn Leu His Leu Ser Val Leu Arg Asp Val Ser 165 170 175 Val Phe Gly Gin Arg Trp Gly Phe Asp Ala Ala Thr He Asn Ser Arg 180 185 190 Tyr Asn Asp Leu Thr Arg Leu He Gly Asn Tyr Thr Asp Tyr Ala Val 195 200 205 Arg Trp Tyr Asn Thr Gly Leu Glu Arg Val Trp Gly Pro Asp Ser Arg 210 215 220 Asp Trp Val Arg Tyr Asn Gin Phe Arg Arg Glu Leu Thr Leu Thr Val 225 230 235 240 Leu Asp He Val Ala Leu Phe Pro Asn Tyr Asp Ser Arg Arg Tyr Pro 245 250 255 He Arg Thr Val Ser Gin Leu Thr Arg Glu He Tyr Thr Asn Pro Val 260 265 270 Leu Glu Asn Phe Asp Gly Ser Phe Arg Gly Ser Ala Gin Gly He Glu 275 280 285 Arg Ser He Arg Ser Pro His Leu Met Asp He Leu Asn Ser He Thr 290 295 300 He Tyr Thr Asp Ala His Arg Gly Tyr Tyr Tyr Trp Ser Gly His Gin 305 310 315 320 He Met Ala Ser Pro Val Gly Phe Ser Gly Pro Glu Phe Thr Phe Pro 325 330 335 Leu Tyr Gly Thr Met Gly Asn Ala Ala Pro Gin Gin Arg He Val Ala 340 345 350 Gin Leu Gly Gin Gly Val Tyr Arg Thr Leu Ser Ser Thr Leu Tyr Arg 355 360 365 Arg Pro Phe Asn He Gly He Asn Asn Gin Gin Leu Ser Val Leu Asp 370 375 380 Gly Thr Glu Phe Ala Tyr Gly Thr Ser Ser Asn Leu Pro Ser Ala Val 385 390 395 400 Tyr Arg Lys Ser Gly Thr Val Asp Ser Leu Asp Glu He Pro Pro Gin 405 410 415 Asn Asn Asn Val Pro Pro Arg Gin Gly Phe Ser His Arg Leu Ser His 420 425 430 Val Ser Met Phe Arg Ser Gly Phe Ser Asn Ser Ser Val Ser He He 435 440 445 Arg Ala Pro Met Phe Ser Trp He His Arg Ser Ala Glu Phe Asn Asn 450 455 460 He He Ala Ser Asp Ser He Thr Gin He Pro Leu Val Lys Ala His 465 470 475 480 Thr Leu Gin Ser Gly Thr Thr Val Val Arg Gly Pro Gly Phe Thr Gly 485 490 495 Gly Asp He Leu Arg Arg Thr Ser Gly Gly Pro Phe Ala Tyr Thr He 500 505 510 Val Asn He Asn Gly Gin Leu Pro Gin Arg Tyr Arg Ala Arg He Arg 515 520 525 Tyr Ala Ser Thr Thr Asn Leu Arg He Tyr Val Thr Val Ala Gly Glu 530 535 540 Arg He Phe Ala Gly Gin Phe Asn Lys Thr Met Asp Thr Gly Asp Pro 545 550 555 560 Leu Thr Phe Gin Ser Phe Ser Tyr Ala Thr He Asn Thr Ala Phe Thr 565 570 575 he Pro Met Ser Gin Ser Ser Phe Thr Val Gly Ala Asp Thr Phe Ser 580 585 590 Ser Gly Asn Glu Val Tyr He Asp Arg Phe Glu Leu He Pro Val Thr 595 600 605 Ala Thr Leu Glu Ala Glu Tyr Asn Leu Glu Arg Ala Gin Lys Ala Val 610 615 620 Asn Ala Leu Phe Thr Ser Thr Asn Gin Leu Gly Leu Lys Thr Asn Val 625 630 635 640 Thr Asp Tyr His He Asp Gin Val Ser Asn Leu Val Thr Tyr Leu Ser 645 650 655 Asp Glu Phe Cys Leu Asp Glu Lys Arg Glu Leu Ser Glu Lys Val Lys 660 665 670 His Ala Lys Arg Leu Ser Asp Glu Arg Asn Leu Leu Gin Asp Ser Asn 675 680 685 Phe Lys Asp He Asn Arg Gin Pro Glu Arg Gly Trp Gly Gly Ser Thr 690 695 700 Gly He Thr He Gin Gly Gly Asp Asp Val Phe Lys Glu Asn Tyr Val 705 710 715 720 Thr Leu Ser Gly Thr Phe Asp Glu Cys Tyr Pro Thr Tyr Leu Tyr Gin 725 730 735 Lys He Asp Glu Ser Lys Leu Lys Ala Phe Thr Arg Tyr Gin Leu Arg 740 745 750 Gly Tyr He Glu Asp Ser Gin Asp Leu Glu He Tyr Leu He Arg Tyr 755 760 765 Asn Ala Lys His Glu Thr Val Asn Val Pro Gly Thr Gly Ser Leu Trp 770 775 780 Pro Leu Ser Ala Gin Ser Pro He Gly Lys Cys Gly Glu Pro Asn Arg 785 790 795 800 Cys Ala Pro His Leu Glu Trp Asn Pro Asp Leu Asp Cys Ser Cys Arg 805 810 815 Asp Gly Glu Lys Cys Ala His His Ser His His Phe Ser Leu Asp He 820 825 830 Asp Val Gly Cys Thr Asp Leu Asn Glu Asp Leu Gly Val Trp Val He 835 840 845 Phe Lys He Lys Thr Gin Asp Gly His Ala Arg Leu Gly Asn Leu Glu 850 855 860 Phe Leu Glu Glu Lys Pro Leu Val Gly Glu Ala Leu Ala Arg Val Lys 865 870 875 880 Arg Ala Glu Lys Lys Trp Arg Asp Lys Arg Glu Lys Leu Glu Trp Glu 885 890 895 Thr Asn He Val Tyr Lys Glu Ala Lys Glu Ser Val Asp Ala Leu Phe 900 905 910 Val Asn Ser Gin Tyr Asp Gin Leu Gin Ala Asp Thr Asn He Ala Met 915 920 925 He His Ala Ala Asp Lys Arg Val His Ser He Arg Glu Ala Tyr Leu 930 935 940 Pro Glu Leu Ser Val He Pro Gly Val Asn Ala Ala He Phe Glu Glu 945 950 955 960 Leu Glu Gly Arg He Phe Thr Ala Phe Ser Leu Tyr Asp Ala Arg Asn 965 970 975 Val He Lys Asn Gly Asp Phe Asn Asn Gly Leu Ser Cys Trp Asn Val 980 985 990 Lys Gly His Val Asp Val Glu Glu Gin Asn Asn Gin Arg Ser Val Leu 995 1000 1005 Val Val Pro Glu Trp Glu Ala Glu Val Ser Gin Glu Val Arg Val Cys 1010 1015 1020 Pro Gly Arg Gly Tyr He Leu Arg Val Thr Ala Tyr Lys Glu Gly Tyr 1025 1030 1035 1040 Gly Glu Gly Cys Val Thr He His Glu He Glu Asn Asn Thr Asp Glu 1045 1050 1055 Leu Lys Phe Ser Asn Cys Val Glu Glu Glu He Tyr Pro Asn Asn Thr 1060 1065 1070 Val Thr Cys Asn Asp Tyr Thr Val Asn Gin Glu Glu Tyr Gly Gly Ala 1075 1080 1085 Tyr Thr Ser Arg Asn Arg Gly Tyr Asn Glu Ala Pro Ser Val Pro Ala 1090 1095 1100 Asp Tyr Ala Ser Val Tyr Glu Glu Lys Ser Tyr Thr Asp Gly Arg Arg 1105 1110 1115 1120 Glu Asn Pro Cys Glu Phe Asn Arg Gly Tyr Arg Asp Tyr Thr Pro Leu 1125 1130 1135 Pro Val Gly Tyr Val Thr Lys Glu Leu Glu Tyr Phe Pro Glu Thr Asp 1140 1145 1150 Lys Val Trp He Glu He Gly Glu Thr Glu Gly Thr Phe He Val Asp 1155 1160 1165 Ser Val Glu Leu Leu Leu Met Glu Glu 1170 1175 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: TGCAACACTC GAGGCTGAAT 20

Claims: CLAIMS 1. An isolated nucleic acid segment comprising a gene which encodes a polypeptide having the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26 SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. 2. The nucleic acid segment of claim 1, wherein said gene encodes a polypeptide having insecticidal activity against Spodoptera frugiperda, Spodoptera exigua, Heliothis virescens, Helicoverpazea or Ostrinia nubilalis. 3. The nucleic acid segment of any preceding claim, wherein said nucleic acid segment is isolatable from Bacillus thuringiensis NRRL B-21579, NRRL B-21580, NRRL B-21581, NRRL B-21635, NRRL B-21636, NRRL B-21780, or NRRL B-21781. 4. The nucleic acid segment of any preceding claim, wherein said nucleic acid segment specifically hybridizes to a nucleic acid segment having the sequence of SEQ ID NO:9, SEQ ID NO:l l, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33, or a complement thereof. 5. The nucleic acid segment of any preceding claim, wherein said nucleic acid segment comprises the nucleic acid sequence of SEQ ID NO:9, SEQ ID NO:l 1, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33, or a complement thereof. The nucleic acid segment of any preceding claim, further defined as a DNA segment. WO 98/22595 , n Λ PCT/US97/21587 194 7. The nucleic acid segment of any preceding claim, wherein said gene is operably linked to a promoter that expresses said gene in a host cell. 8. The nucleic acid segment of any preceding claim, comprised within a recombinant vector. 9. The nucleic acid segment of any preceding claim, comprised within a plasmid, cosmid, phage, phagemid, viral, baculovirus, bacterial artificial chromosome, or yeast artificial chromsome recombinant vector. 10. The nucleic acid segment of any preceding claim, comprised within the plasmid vector pEG1068, pEG1077, pEGl 1092, pEG1093, pEG365, pEG378, or pEG381. 11. A nucleic acid segment in accordance with any preceding claim for use in a recombinant expression method to prepare a recombinant polypeptide. 12. A nucleic acid segment in accordance with any preceding claim for use in the preparation of an insect-resistant transgenic plant. 13. A method of using a nucleic acid segment in accordance with any preceding claim, comprising expressing said gene in a host cell and collecting the expressed polypeptide. 14. Use of a nucleic acid segment in accordance with any one of claims 1 to 12 in the preparation of a recombinant polypeptide composition. 15. Use of a nucleic acid segment in accordance with any one of claims 1 to 12 in the generation of a vector for use in producing an insect-resistanttransgenic plant. 16. Use of a nucleic acid segment in accordance with any one of claims 1 to 12 in the generation of an insect-resistanttransgenic plant. 17. A host cell comprising a nucleic acid segment in accordance with any one of claims 1 to 12. 18. The host cell of claim 17, wherein said host cell is a bacterial cell. 19. The host cell of claim 17 or 18, wherein said cell is an E. coli, B. thuringiensis, B. subtilis, B. megaterium, or a Pseudomonas spp. cell. 20. The host cell of any one of claims 17 to 19, wherein said cell is B. thuringiensis ΕG11063, EGl 1074, EGl 1090, EGl 1092, EGl 1735, EGl 1751, EGl 1768, NRRL B- 21579, NRRL B-21580, NRRL B-21581, NRRL B-21635, NRRL B-21636, NRRL B- 21780, or NRRL B-21781. 21. The host cell of claim 17, wherein said cell is an eukaryotic cell. 22. The host cell of claim 21 , wherein said host cell is a plant cell. 23. The host cell of claim 21 or 22, wherein said cell is a grain, tree, vegetable, fruit, berry, nut, grass, cactus, succulent, or ornamental plant cell. 24. The host cell of any of claims 21 to 23, wherein said cell is a com, rice, tobacco, potato, tomato, flax, canola, sunflower, cotton, wheat, oat, barley, or rye cell. 25. The host cell of any of claims 21 to 24, wherein said cell is comprised within a transgenic plant. 26. The host cell of any of claims 21 to 25 , wherein said cell produces a polypeptide having insecticidal activity against Spodoptera frugiperda, Spodoptera exigua, Heliothis virescens, Helicoverpazea or Ostrinia nubilalis. 27. A host cell in accordance with any one of claims 17 to 26 for use in the expression of a recombinant polypeptide. 28. A host cell in accordance with any one of claims 17 to 26 for use in the preparation of a transgenic plant. 29. Use of a host cell in accordance with any one of claims 17 to 26 in the generation of pluripotent plant cells. 30. Use of a host cell in accordance with any one of claims 1 to 26, in the preparation of an insecticidal polypeptide formulation. 31. A composition comprising an isolated polypeptide that comprises the amino acid sequence of SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. 32. The composition of claim 31 , wherein said polypeptide is insecticidally active against Spodoptera frugiperda, Spodoptera exigua, Heliothis virescens, Helicoverpa zea, or Ostrinia nubilalis. 33. The composition of claim 31 or 32, wherein said polypeptide is isolatable from Bacillus thuringiensis EGl 1060, EGl 1062, EGl 1063, EGl 1071, EGl 1073, EGl 1074, EGl 1090, EGl 1091, EGl 1092, EGl 1735, EGl 1751, EGl 1768, NRRL B-21579, NRRL B-21580, NRRL B-21581.NRRL B-21635,NRRL B-21636,NRRL B-21780, or NRRL B-21781. 34. The composition of any one of claims 31 to 33, wherein said polypeptide comprises from about 0.5% to about 99% by weight of said composition. 35. The composition of any one of claims 31 to 34, wherein said polypeptide comprises from about 50% to about 99% by weight of said composition. 36. A composition comprising a polypeptide preparable by a process comprising the steps of: (a) culturing a B. thuringiensis NRRL B-21579, NRRL B-21580, NRRL B-21581, NRRL B-21635, NRRL B-21636, NRRL B-21780, NRRL B-21781, EGl 1768, EGl 1090, EGl 1063, EGl 1074, EGl 1092, EGl 1735, or EGl 1751 cell under conditions effective to produce a composition comprising a B. thuringiensis polypeptide; and (b) obtaining said composition from said cell. 37. A composition in accordance with any one of claims 31 to 36 for use in killing an insect cell. 38. Use of a composition in accordance with any one of claims 31 to 37 in the preparation of an insecticidal formulation. 39. Use of a composition in accordance with any one of claims 31 to 37 in the preparation of a plant protective spray formulation. 40. A method of preparing a B. thuringiensis crystal protein comprising: (a) culturing a B. thuringiensis NRRL B-21579, NRRL B-21580, NRRL B-21581, NRRL B-21635, NRRL B-21636, NRRL B-21780, NRRL B-21781, EGl 1768, EGl 1090, EGl 1063, EGl 1074, EGl 1092, EGl 1735, or EGl 1751 cell under conditions effective to produce a B. thuringiensis crystal protein; and (b) obtaining said B. thuringiensis crystal protein from said cell. 41. A method of killing an insect cell, comprising providing to an insect cell an insecticidally- effective amount of a composition in accordance with any one of claims 31 to 37. 42. The method of claim 41 , wherein said insect cell is comprised within an insect. 43. The method of claim 42, wherein said insect ingests said composition by ingesting a plant coated with said composition. 44. The method of claim 42 or 43 , wherein said insect ingests said composition by ingesting a transgenic plant which expresses said composition. 45. A purified antibody that specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. 46. The antibody of claim 45, operatively attached to a detectable label. 47. An immunodetection kit comprising, in suitable container means, an antibody according to claim 45, and an immunodetection reagent. 48. A method for detecting an insecticidal polypeptide in a biological sample comprising contacting a biological sample suspected of containing said insecticidal polypeptide with an antibody in accordance with claim 45, under conditions effective to allow the formation of immunecomplexes, and detecting the immunecomplexes so formed. 49. A transgenic plant having incorporated into its genome a transgene that encodes a polypeptide comprising the amino sequence of SEQ ID NO: 10, SEQ ID NO:12, SEQ ID NO: 14, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, or SEQ ID NO:34. 50. The transgenic plant of claim 49, wherein said transgene comprises the nucleic acid sequence of SEQ ID NO:9, SEQ ID NO:l l, SEQ ID NO:13, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33. 51. Progeny ofthe plant of claim 49 or 50. 52. Seed from the plant or progeny of any of claims 49 to 51. 53. A plant from the seed of claim 52.

Inventors: GILMER AMY JELEN, MALVAR THOMAS, GILMER, AMY, JELEN, MALVAR, THOMAS
Applicants: ECOGEN INC, GILMER AMY JELEN, MALVAR THOMAS, ECOGEN, INC., GILMER, AMY, JELEN, MALVAR, THOMAS
Application year: 1997
Main classification: C12N15
IPC codes: A01H5, A01N63, C07K14, C07K16, C12N1, C12N5, C12N15, C12P21, C12R1, G01N33